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Burden of anastomotic leakage
Worldwide, intestinal resection and anastomosis is required for a few million patients 
annually. The greatest number of patients undergoing this procedure have colorectal 
cancer, followed by those suffering from morbid obesity, drug-resistant inflammatory bowel 
diseases (e.g. Crohn’s disease and ulcerative colitis) and diverticular disease (1–3). Intestinal 
resections and anastomosis are also made in cases of ischaemia, perforation and obstruction 
of the gastro-intestinal tract. Intestinal anastomoses are also constructed during urological 
procedures, in particular bladder reconstruction surgery (4).
Anastomotic leakage (AL) is the main cause of major morbidity and mortality after intestinal 
surgery (5). Leakage of intestinal content through a defect in the anastomosis and into the 
abdominal cavity can cause abscess, peritonitis, sepsis and death. It therefore requires 
rapid and appropriate intervention, such as percutaneous abscess drainage, reoperation, 
breakdown of the anastomosis, stoma construction and intensive care unit (ICU) 
admission (6–9). A stoma constructed after leakage is often permanent, and if it is 
reversed, the operation to do so is associated with a risk of complications and functional 
decline (10, 11). More readmissions, longer hospital and ICU stays, and additional interventions 
double the healthcare costs for patients with AL (12, 13). In spite of rigorous efforts to manage 
leakage in the past decade, mortality rates remain high, varying from 2%  to 37% (7, 8, 13). Quality 
of life following AL is significantly reduced and remains lower even after 10 years compared 
to patients without a leak (Daams et al., in press). Finally, leakage has been associated with 
an increase in local and distant cancer recurrence and lower survival, possibly as a result of 
a higher proportion of cancelled or delayed administration of adjuvant chemotherapy (14–17). 
Despite advances in surgical techniques and improvements in perioperative care, the AL rate 
has not declined over the past decades, and leakage still occurs in 3–14% of cases (5, 13, 18, 19). 
The incidence of leakage is relatively low after small-bowel anastomoses (0–6%), but high 
after both left and right hemicolectomies (6–11%), and highest for low rectal anastomoses 
(8–14%) (8, 20–22). Incidences may even be higher since substantial underreporting has 
been demonstrated, causing an underestimation of the true effects of leakage on patient 
outcomes (23). The protective loop ileostomy or transversostomy that is routinely constructed 
during low rectal surgery reduces the morbidity of leakage and possibly its incidence, but it 
is in turn associated with stoma-related morbidity (24–26). There is little evidence that surgical 
technique (i.e. single- or double-layer suturing; stapled or handsewn) significantly affects 
leak rates, though stapling may be beneficial in ileocolic anastomoses (27–29).
Combined with the devastating clinical consequences, prolonged hospital stay and doubled 
healthcare costs, the high incidence of AL imposes a huge burden upon the individual 
patient and society (13, 30). 
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Risk factors for anastomotic leakage
Multiple risk factors have been identified from a large number of studies (see Table 
1) (31–34). This knowledge, however, has not led to a satisfying reduction in leak rates, for 
several reasons. First, evidence about risk factors is often ambiguous or only of moderate 
strength, as data are primarily derived from retrospective analyses and experimental 
studies of questionable translational value (13, 35). Second, leakage also occurs in the absence 
of known risk factors (5). This indicates a gap in our knowledge of risk factors. The altered 
gut microbiome before and after surgery, for example, seems a factor which potentially 
constitutes a large risk but has seldom been investigated (36, 37). Third, many risk factors, such 
as male sex and low tumour site, cannot be altered prior to surgery (38, 39). An important 
factor is the lack of comprehensive knowledge of underlying pathophysiologic mechanisms, 
such as detailed knowledge of normal and disturbed anastomotic healing pathways. 
This hampers the translation from the phase of risk factor identification to the phase of 
appropriate (preventive) treatment recommendations. A good example of such a risk factor 
is the perioperative use of nonsteroidal anti-inflammatory drugs (NSAIDs). 
Table 1 Potential risk factors for anastomotic leakage.
Patient Perioperative care Surgery Other
 Factors not or difficult to modulate 
Male sex Blood transfusion Emergency surgery Low tumor site 
(High comorbidity) (Vasopressor use) (Intraoperative events) (Large tumor size)
(Diabetes) (Long operation time)
(Age – young and old) (High blood loss)
(IBD)
(Previous surgery)
(Ongoing anticoagulants)
Factors possible to modulate
Corticosteroid use NSAID use Multiple staple firings Radiotherapy
Nutritional status (Excessive fluid therapy) (Open surgery) (Chemotherapy)
(Alcohol) (Low body temperature) (Surgeon experience) (Hospital beds)
(Smoking) (Low blood pressure)
(Obesity) (Hyperglycemia)
Text in parentheses indicate that evidence is equivocal or of low quality. IBD, inflammatory bowel disease; 
NSAID, non-steroidal anti-inflammatory drugs.
Non-steroidal anti-inflammatory drugs and anastomotic leakage
NSAIDs are frequently used as perioperative analgesics and are recommended in guidelines 
on perioperative care and ‘fast-track’ surgery (40). In the past decade, several experimental 
studies have assessed their safety in visceral surgery (see Table 2) (41–44). In 2006, de Hingh 
5INTRODUCTION
Ch
ap
te
r 1
Ch
ap
te
r 2
Ch
ap
te
r 3
Ch
ap
te
r 4
Ch
ap
te
r 5
Ch
ap
te
r 6
Ch
ap
te
r 7
Ch
ap
te
r 8
Ch
ap
te
r 9
Ch
ap
te
r 1
0
Ch
ap
te
r 1
1
et al. demonstrated that celecoxib (a cyclooxygenase-2 [COX-2] inhibitor) causes leakage of 
ileal anastomoses in rats (43). In subsequent rat studies, both carprofen and diclofenac, and to 
a lesser extent naproxen, also caused leakage (45–47). The use of NSAIDs has been associated 
as a risk factor for AL in several clinical studies (see Table 2). Rosenberg et al. found an 
alarming increase in leak rates from 3.9% to 20.5% following introduction of diclofenac in 
protocols on perioperative care (48). Similar increases were seen after the introduction of 
celecoxib (15.1% leakage compared with 1.5–3.3% in non-celecoxib cohorts) (49). In 2012, 
two clinical series related diclofenac and ibuprofen use to increased leak rates (20, 50). Reviews 
of clinical and experimental studies similarly revealed higher leak rates in NSAID groups, 
although not all were statistically significant (51, 52). One study reported no evident risk of 
leakage after ketorolac use, but another found a higher risk of leakage specifically in the 
ketorolac group (53, 54). 
Altogether, evidence regarding perioperative NSAID use is worrisome and continues to 
increase (55). Nevertheless, further research is needed in this field because most evidence 
has been derived from experimental and retrospective clinical studies, and a few studies 
reported no adverse effects (56–58). In these studies selection bias may have affected outcomes; 
for example, those suffering from leakage are more likely to use analgesics. Furthermore, the 
relevance of NSAID subtype, dose, time of administration and the location of anastomosis 
at risk is still unclear. It is also not known to what extent NSAIDs increase the risk of leakage 
and whether this outweighs the clinical benefits of NSAIDs, such as reduced opioid use (59). 
Most fundamentally, it is not known through which mechanisms NSAIDs cause leakage. An 
understanding of the underlying pathophysiology is needed to support and specify clinical 
treatment recommendations. 
Table 2 Studies on the influence of NSAIDs on anastomotic healing.
Author, year Study type 
(number of 
animals/patients)
NSAID type Summary of results
Experimental
Mastboom, 1991
(60)
Rat ileum/colon model 
(n=100)
celecoxib, 
piroxicam, aspirine, 
indomethacin
Higher peritonitis + mortality rates in 
NSAID groups but no evident increase in 
AL.
De Sousa, 1991
(44)
Rabbit ileum model 
(n=48)
diclofenac AL ileum: 21% in diclofenac group vs 0% in 
controls, p<0.05
Cahill, 2004
(61)
Rat colon model 
(n=40)
rofecoxib AL: 5/20 in rofecoxib group vs 0/20 in 
controls, p=0.048.
De Hingh, 2006
(43)
Rat ileum/colon model 
(n=95)
celecoxib AL ileum: 6/12, 5/12, 7/12b in celecoxib 
groups; 0/12 in controls (p<0.05). No AL in 
distal colon.
Inan, 2006
(62)
Rat colon model 
(n=36)
diclofenac No AL. Bursting pressure lower after 
diclofenac.
Esen, 2008
(63)
Rat colon model 
(n=48)
diclofenac, 
metamizol, 
tenoxicam
No AL. Bursting pressure lower after 
diclofenac at day 7.
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Neuss, 2009
(64)
Rabbit colon model 
(n=80)
resveratrol, 
metamizol, 
valdecoxib
AL: valdecoxib 0/20, metamizol 3/20, 
resveratrol 1/20, Control 0/20 (p>0.05)
Benjamin, 2010
(65)
Rat colon model 
(n=48)
etodolac (with 
propanolol)
No leak occurred
Klein, 2010
(66)
Rat colon model 
(n=32)
diclofenac No AL data. No difference in breaking 
strength.
Klein, 2011
(67)
Rat colon model 
(n=60)
diclofenac No AL data. Lower collagen content after 
diclofenac
Van der Vijver, 
2012 (45)
Rat ileum/colon model carprofen AL ileum: 6/10, 8/10 and 12/15 in 
carprofena groups vs 0 in control groups 
(p<0.001). No AL in distal colon.
Van der Vijver, 
2013 (46)
Rat ileum/colon model diclofenac, 
naproxen
AL ileum: Ctrl 0/28; diclofenaca 19/28 
(p<0.001); Naproxen 4/28. No AL in distal 
colon.
Reisinger, 2017
(68)
Mouse colon model diclofenac AL: Ctrl 25%, diclofenac 100% p<0.001 
COX2 knockout 92%
Clinical
Rosenberg, 2007
(48)
Retrospective cohort, 
before/after design 
(n=230)
diclofenac AL: 20.5% in diclofenac group, 3.9% before 
diclofenac cohort, p<0.001.
Holte, 2009
(49)
Retrospective cohort 
(n=502)
celecoxib AL: 15.1% in period of celecoxib use vs 
3.3% before and 1.5% after this period 
(p<0.001)
Klein, 2009 Retrospective cohort 
(n=75)
diclofenac AL: 7/33 in diclofenac group, 1/42  in non-
diclofenac (p=0.018)
Klein, 2012
(50)
Retrospective cohort 
(n=2,756)
diclofenac, 
ibuprofen. At least 
2 days within 7 
days postopera-
tively
AL: diclofenac 12.8% vs Ibuprofen 8.2% 
vs controls 5.1% (p<0.001). OR after 
diclofenac 7.2(3.8-13.4; p<0.001).
Gorissen, 2012
(20)
Retrospective cohort 
(n=795)
non-selective 
(diclofenac and 
others) vs selective 
(meloxicam, 
celecoxib), any 
use within 5 days 
postoperatively
AL: any NSAIDs 13.2% vs no NSAIDs 7.6%, 
OR 1.86 (1.16-2.96) (p=0.010). Strongest 
effect in non-selective NSAID group. 
Longer duration of NSAID use associated 
with higher leak rate.
Burton, 2013
(51)
Review of RCT’s with 
AL as 2nd outcome 
(n=562)
celecoxib, 
diclofenac, 
flurbiprofen 
ketorolac, 
valdecoxib
AL: any NSAID 5.2% vs no NSAID 2.4%, OR 
2.16 (0.85-5.53; p=0.11)
Bhangu, 2014
(52)
Review of human 
(n=4464) + 12 animal 
studies
any OR for AL 2.14 (p<0.001) after any NSAID; 
2.37 (p<0.001) after non-selective, and 
2.32 (p=0.170) after selective NSAID
STARSurg coll, 
2014
Multicenter snapshot 
study (n=1503)
ibuprofen (>80%),  
diclofenac and 
other
AL (2nd outcome): NSAID 6.3%, no NSAID 
4.9% (p=0.384)
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Saleh, 2014
(53)
Restrospective cohort 
(n=731)
ketorolac AL: ketorolac 3.4%, no NSAID 3.2%, OR 
1.06 (0.43-2.62; p=0.886)
Subendran, 2014
(54)
Restrospective cohort 
(n=262)
ketorolac (>90%), 
ibuprofen, 
celecoxib, 
ketoprofen.
OR for AL: any NSAID OR 1.81 (0.98–3.37; 
p=0.06. ketorolac OR 2.09 (1.12-3.89; 
p=0.021)
Hakkarainen, 
2015 (55)
Restrospective cohort 
(n=9,864)
ibuprofen, 
naproxen, 
ketorolac, 
caldolor, celecoxib, 
diclofenac
Adjusted OR 1.24 (1.01-1.56; P = .04). 
In non-elective colorectal surgery, AL: 
12.3%in NSAID group vs 8.3%in non-NSAID 
group (OR 1.70 (1.11-2.68; P = .01).
Bakker, 2016
(69)
Restrospective cohort 
(n=856)
diclofenac, 
namebutone, 
ibuprofen
AL: NSAID 9.2 vs no NSAID 5.3%, p = 0.038. 
Diclofenac, for colonic resections, 11.8 vs. 
6.0%, p = 0.016; for rectal resections, 13.1 
vs. 0%, p = 0.017.
STARSurg coll, 
2017 (70)
Multicenter snapshot 
study (n=1951)
mainly ibuprofen AL (2nd outcome): NSAID 3.7%, no NSAID 
3.8% (p=0.877)
Kverneng, 2017
(71)
Retrospective database 
(n=1495)
ibuprofen (70%), 
namebutone, 
diclofenac 
AL NSAID 11%, no NSAID 14%. COX2-
selective 17% (NS)
Haddad, 2017
(72)
Posthoc analysis of 
prospective cohort 
(n=533)
AL NSAID 14%, no NSAID 11% (p=0.26). 
NSAIDs in colonic anastomosis 30%. 
(p=0.03)
AL – anastomotic leakage, NS – non-significant, NSAID – nonsteroidal anti-inflammatory drug, 
COX2 – cyclooxygenase-2. 
Colors represent the overall risk of 
anastomotic complications in NSAID 
groups:
green – no increased risk
orange – non significant risk or only in selective groups
purple – increased risk
Aim of this thesis
With the goal of reducing the burden of anastomotic leakage, this thesis aims to increase 
knowledge of both normal and disturbed bowel anastomotic healing, and more specifically 
to understand how the NSAID diclofenac disturbs this healing process. 
Outline of this thesis
In order to take measures to prevent anastomotic healing disturbances and leakage, it is 
important to understand normal healing physiology. Chapter 2 presents a comprehensive 
overview of the cellular and biochemical processes relevant during anastomotic healing, 
based on a literature review in which knowledge from anastomotic healing studies 
was combined with insights from gastrointestinal, immunological, oncological and 
pharmacological research. 
Most fundamental knowledge on anastomotic healing is derived from animal experiments. 
Thus far it has not been possible to adequately and sequentially study anastomoses in 
humans without the need for invasive or high-risk techniques. For this reason, prospective 
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clinical trials that study new techniques or risk factors are rare (73, 74). Other strategies to study 
anastomotic healing, such as cell culture and migration assays, are rarely used and are likely 
to have little translational value. The process of anastomotic healing involves a versatile and 
multilevel system and is considered too complicated to be mimicked in vitro. Consequently, 
increasing knowledge on anastomotic healing depends on retrospective analyses of clinical 
data and prospective investigations in animal models.
Despite numerous animal studies, the contribution of animal research to clinical knowledge 
and modulation of intestinal AL is unknown. To continue performing animal research on 
anastomotic healing, and in view of the current societal call to ‘replace, reduce and refine’ 
animal experiments (the 3R principle), it is relevant to critically evaluate the animal research 
on this topic. In Chapter 3 the quality of animal research on AL is systematically reviewed 
by checking items from the ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
guidelines. The chapter also provides an overview of the main topics studied regarding 
anastomotic healing, with the aim of guiding future animal experiments and helping other 
research groups avoid unnecessary repetition of studies. We evaluate the various animal 
models for their differences and address the question of what improvements in models are 
needed. 
In Chapters 4–8 we aim to increase the understanding of how NSAIDs affect anastomotic 
healing by conducting randomised controlled blinded animal experiments. In each chapter 
we use the same validated experimental model in male Wistar rats (46, 47). The model involves 
the creation of a complete small- and/or large-bowel anastomosis on day 0 and sacrifice 
on days 3–5 to assess anastomotic complications, the strength of the anastomosis and the 
anastomotic histopathology (46, 47). Further details of the model are described in each chapter. 
The effect of diclofenac is subjected to particular investigation because it is an NSAID used 
frequently in clinical practice and has been associated with leakage in previous human and 
rat studies. By choosing diclofenac we attempt to increase the translational value of the 
animal experiments. We study different routes of administration of diclofenac to understand 
the mechanisms by which the drug exerts its detrimental effects. More specifically, we study 
the pharmacologic action, the biliary excretion pattern, the degradation products of the 
drug within the gut and the potential of NSAIDs to alter gut microbiota composition.
Chapter 4 examines whether diclofenac affects anastomotic leak rate, leak severity and 
anastomotic strength differently depending on the location of the anastomosis in the colon. 
This may shed light on the relevance of faecal content (e.g. liquidity, microflora and bile 
acids) compared to the tissue morphology and the pharmacologic action of diclofenac in 
inducing leakage. 
In Chapter 5 we investigate whether the healing of an anastomosis can be improved by 
abrading the serosal surface of bowel ends that are invertedly anastomosed, based on the 
concept that serosal damage evokes an inflammatory response leading to scar tissue strongly 
connecting both bowel ends. We also study whether the expected increased inflammatory 
response can compensate for the anti-inflammatory effect of diclofenac. Outcome measures 
are anastomotic leak rate, leak severity, bursting pressure and breaking strength.
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In Chapter 6 the effects of bile and bile composition on intestinal anastomosis healing are 
determined. Diclofenac is largely excreted through bile and may thereby increase the toxicity 
of the bile and gut content. Based on reports showing the relevance of biliary metabolites 
in NSAID-associated enteropathy, the effects on anastomotic healing are studied by using a 
bile replacement technique involving the cannulation of bile duct and duodenum (75–78). The 
type, concentration and kinetics of diclofenac metabolites are measured in bile and plasma, 
and differences in anastomotic healing are determined.
Chapter 7 investigates the relevance of the biliary metabolite diclofenac-acyl-glucuronide. 
Reactivation of this metabolite has been shown to be toxic and to cause enteropathy in 
rodents (77). The relevance for intestinal anastomoses is studied by administration of Inh1 to 
inhibit the reactivation process by bacteria in the gut. Anastomotic leak rate, leak severity 
and anastomotic strength are compared between rats with and without Inh1, and the effect 
of Inh1 on diclofenac plasma levels is determined.
In Chapter 8 the microbiota composition of different bowel segments is analysed to 
determine the influence of both anastomotic surgery and NSAID treatment, and to explore 
whether alterations in microbiota can explain the differences in leak rates. Faecal samples 
collected from the anastomotic site are analysed by sequencing of the 16S rRNA V4 gene 
region. Taxonomic composition, alpha diversity, beta diversity and microbial taxa are 
compared between rats with and without NSAIDs, before and after surgery, and among 
intestinal segments.
Chapters 9 and 10 present a general discussion, with future perspectives and a summary.
10
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AD – adenosine diphosphate
ASA – acetylsalicylic acid
CAM – cell adhesion molecules
CC – chemokine of CC family
CCL – CC-ligand
CD40L – CD40 ligand
CD40R – CD40 receptor
CGRP – calcitonin gene related peptide
COX – cyclooxygenase
CSF – colony stimulating factor
CTAP – connective tissue activating peptide
CXC – cysteine-aminoacid-cysteine type 
chemokine
ECM – extracellular matrix
EGF – epidermal growth factor
ELAM - endothelial-leukocyte adhesion 
molecule
EPO – erythropoietin
FAK – focal adhesion kinase
FCS – fetal calve serum
FGF – fibroblast growth factor
GH – growth hormone
GM – granulocyte macrophage
GP – glycoprotein
HB – heparin binding
HGF – hepatocyte growth factor
HMG – high mobility group
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ROS – reactive oxygen species
SLPI – secretory leukocyte protease inhibitor
SMC – smooth muscle cells
SP – substance P
TER – transepithelial resistance
TGF – transforming growth factor
TF – tissue factor
TL – toll ligands
TLR – toll like receptor
TNF – tumor necrosis factor
TRAP – TNF related activation protein
TXA – thromboxane
VCAM - vascular cell adhesion molecule
VEGF – vascular endothelial growth factor
vWF – Von Willebrand factor
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2.1 Introduction
Cellular reactions are the essence of tissue repair. Understanding of these reactions is 
fundamental to improve anastomotic healing. Research has identified the cells most 
important in anastomotic healing. However, their exact role and the involved biochemical 
processes are complex and less understood. Cytokine studies on healing of intestinal 
anastomoses are relatively scarce. Related knowledge derives from studies on healing of 
skin, bone, peritoneum and intestinal mucosa.   Since the healing process of the intestinal 
wall follows the same basic phases as wound healing in other human tissues, main principles 
seem applicable to anastomotic healing, although differences are encountered on a cellular 
level(1, 2). Also specific cellular architecture and physiological factors, such as peristalsis and 
intraluminal microbiome, make the intestine a unique organ. 
The growing amount of knowledge on molecular mechanisms of cellular function has 
triggered physicians, pharmacists and scientists to modulate cellular processes in an 
attempt to enhance tissue repair. This is mainly done by using growth factors, such as 
‘transforming growth factor-β’ (TGF-β), ‘vascular endothelial growth factor’ (VEGF)-A, 
‘epidermal growth factor’ (EGF), ‘insuline like growth factor’ (IGF), ‘fibroblast growth 
factors’ (FGF)) and hormones (‘growth hormone’ (GH), erythropoietin (EPO)). Unfortunately 
many factors have not made their way into clinical practice, which may be due to the fact 
that each factor is part of a versatile and multi-level system in which simple and unilateral 
causality is rare.  In this chapter we review current insights in cellular function and tissue 
regeneration and the modulation hereof regarding the healing of an intestinal anastomosis. 
2.2 Phases in intestinal healing
As in other human tissues, intestinal anastomotic healing starts with the hemostatic and 
inflammatory phase. These precede the proliferative phase which in turn is followed by 
a long remodeling phase. All are descriptive names for overlapping activities, rather than 
confined time periods. Platelets, mast cells, granulocytes and macrophages are the main 
initiators of the inflammatory response and act primarily within this phase. They are the 
response of the body to deal with harmful stimuli, such as damaged cells and the pathogen 
rich content of the bowel lumen. Gradually proliferative activity increases as macrophages 
start to stimulate and assist smooth muscle cells and fibroblasts to restore local architecture 
of the intestinal wall. This requires the formation of a firm collagen network to connect 
the two bowel parts together and a functioning vascular and lymphatic system to provide 
nutrient transport. Mucosal repair is achieved by epithelial cells on the intraluminal side, 
and serosal sealing by mesothelial cells on the peritoneal side. Complete restoration of 
anatomical structures takes longer and is achieved in the remodeling phase. 
2.3 Inflammation
Inflammation is the response of the body to tissue damage and infection, in order to protect 
it from injurious agents and to facilitate healing. It includes a large range of integrated 
processes and involves the vascular, immunologic and neurologic systems. 
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2.3.1 Initiation of inflammatory response
The inflammatory response starts immediately after incision and entry in the abdominal 
cavity, thus even before the intestinal wall has been manipulated. Abdominal entry elicits 
a release of inflammatory mediators into the peritoneal fluid (3, 4). This response is the first 
to affect the subsequent healing process and an example of why tissue repair is not only a 
local or isolated process. 
Incision of the intestinal wall means a disruption of normal tissue and triggers inflammation 
by several simultaneous pathways, here divided into four groups (see Fig. 1). Tissue damage 
is inevitably associated with damage of capillaries. The following coagulation cascade 
is the first important initiator of subsequent inflammatory reactions. Second, damaged 
cells expose intracellular proteins (e.g. ‘heat-shock proteins’(HSP), and mitochondrial 
proteins(5, 6) and ‘high mobility group 1’(HMGB1)(7)).Third, stimulated nerve cells release 
a number of peptides (e.g. ‘calcitonin gene related protein’(CGRP) and substance P (SP)
(8)). Finally, disruption of the mucosal barrier results in exposure to microbes which trigger 
innate and adaptive immune responses. 
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Figure 1 Schematic overview of inflammatory stimuli and cellular response.
2.3.2 Platelets 
Vessel damage exposes the subendothelial collagen layer. Contact with exposed tissue 
factor (TF) protein in this layer causes adhesion and activation of passing platelets. Platelets 
are pivotal in primary hemostasis, but simultaneously also act as important initiators of the 
inflammatory process(9). They synthesize many different cytokines and release and modify 
signaling molecules (9, 10). By these actions platelets contribute to tissue repair.
Hemostasis and inflammatory signals
Primary hemostasis is achieved by adhesion of platelets to the different proteins of the 
vascular wall (e.g. collagen, fibronectin and laminin) and aggregation with other platelets 
by glycoprotein-1a (GP1a) and Von Willebrand Factor (vWF)(11). The release of ‘platelet 
activating factor’ (PAF), ‘adenosine diphosphate’ (ADP), serotonin and thromboxane 
A2 (TXA2) attracts and activates other platelets. Activated platelets secrete a number of 
coagulation factors (V, XI, and XIII) and fibrinogen, which contribute to the completion of 
the coagulation cascade.
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The release of PAF and TXA2 also contributes to the inflammatory activity of platelets, 
but more important is the release of the inflammatory cytokine Interleukin 1β 
(IL-1 β) (12-14). An example of the many effects of IL-1β is the upregulation of the pro-
inflammatory cyclo-oxygenase-2 (COX-2) expression in monocytes when these cells bind to 
activated platelets (15). Other inflammatory mediators of the platelet secretome include ‘TNF 
related activation protein’ (TRAP), CD40L, platelet factor 4 (PF4) and a number of other CXC 
and CC chemokines(10). All directly or indirectly attract and signal other cells, like neutrophil 
granulocytes, monocytes or lymphocytes (9, 16-18). 
Proliferative activity
The influence of platelets reaches beyond the ‘inflammatory phase’. Apart from the 
‘platelet derived growth factor’(PDGF), other growth factors like ‘fibroblast growth 
factor-2’(FGF2), ‘transforming growth factor α and β’(TGF-α/β), ‘vascular endothelial growth 
factor’ (VEGF), ‘epidermal growth factor’ (EGF), insulin-like growth factor (IGF-l) are found in 
the platelet secretome and contribute to proliferative actions like angiogenesis and collagen 
synthesis(13, 19-21).
Potential clinical relevance
Platelets contribute to tissue repair in many ways. Although unknown to what extent, 
intervening in platelet activity could influence the process of anastomotic healing. Many 
commonly used drugs in clinical practice influence platelet function such as platelet 
aggregation inhibitors and COX-inhibitors. Acetylsalicylic acid (ASA) is an inhibitor that 
primarily works via COX-1 inhibition. In platelets COX-1 is responsible for converting 
arachidonic acid to prostaglandin G2 and H2, which are precursors for TXA2. Thus, inhibition 
of COX-1 in platelets results in reduced TXA2 levels(11). Hereby aggregation and activation 
of other platelets are prevented which in turn reduces inflammatory response and may 
impair wound healing. Indeed many studies reported impaired healing of multiple tissues 
(skin, bone, intestinal mucosa) caused by ASA in animals, but this effect has not drawn 
sufficient attention in clinical practice. NSAIDs with selective COX-2 inhibitory effect have 
been associated with anastomotic leakage in animal experiments and retrospective human 
studies (22-26). From these experiments the relative contribution of disturbed platelet function 
on anastomotic healing, in comparison with other possible detrimental effects of COX-2 
inhibition, is not known. 
Paradoxically platelet inhibition has also been proposed as beneficial for wound healing, 
hypothesizing that decreased platelet aggregation and clotting improve capillary blood 
flow. Prostacyclin (also a product of COX-1 en 2) is secreted by endothelial cells and is a 
natural inhibitor of platelet aggregation. Analogs of prostacyclin (such as iloprost), have 
shown to improve anastomotic healing in rats that were subjected to ischemia, steroids 
or chemotherapy (27-30). No publication was found reporting on the effects of ASA on 
anastomotic healing.
In contrast to improving healing by platelet inhibition is the strategy to apply platelet rich 
plasma as a means to deliver a relatively balanced cocktail rich of growth factors to a site 
of tissue repair. Various tissues have been subjected to this seemingly safe treatment, with 
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success in some experimental rat and porcine intestinal anastomosis studies (31-34). No clinical 
studies have been started to confirm its beneficial effects.
2.3.3 Mast cells
Mast cells (MC’s) belong to the earliest actors in the inflammatory phase as most are 
already at the site in the peritoneal cavity(35). MC’s are known to play a role in cutaneous 
wound healing by generating inflammatory mediators that cause vasodilatation, vascular 
permeability and leukocyte infiltration (heparin, histamine, tryptase, chymase, serotonin, 
TNFα, C3a, C5a, leukotriene(LT)-B4, LTC4, PAF), and proliferative mediators that induce 
neoangiogenesis, fibrinogenesis and re-epitheliazation (VEGF, FGF2, PDGF, TGFβ, nerve 
growth factor(NGF), interleukin(IL)-4, IL8)(36). 
Potential clinical relevance
Mast cells have proved their importance in surviving bacterial peritonitis in a mast-cell-
deficient mouse model, but were rarely studied in the context of intestinal anastomoses (37, 
38). In one rat study, ketotifen, a suppressor of mast cell function, decreased the strength of 
both normal and ischemic colonic anastomoses (39). A promoter of mast cell degranulation 
(compound 48/80) increased anastomotic strength in this same study (39). In contrast, 
pentoxifylline, a suppressor of TNFα release from monocytes and mast cells, protected 
intestinal anastomoses in situations in which excessive inflammation occurs, such as 
ischemia reperfusion injury and obstructive jaundice(40, 41). Other actions of the drug, such as 
increasing capillary blood flow, may be responsible for this favorable finding. 
2.3.4 Neutrophil granulocytes
In the first 24-48 hours the cellular influx is dominated by neutrophil granulocytes (42). 
Their involvement in the healing process can be categorized into two major activities: the 
degradation and phagocytosis of cell fragments and microbes, and the signaling of other 
cells (e.g. other neutrophils, monocytes and lymphocytes). Several studies have shown 
the relevance of a balanced neutrophil action in healing. When neutrophil infiltration 
or activity is too abundant or prolonged, anastomotic strength appears to be decreased 
(43-46). Ischemia reperfusion injury resulting in decreased anastomotic strength was associated 
with an 18-fold increase of neutrophil infiltration(47). The same accounts for foreign body 
reactions in which neutrophil and lymphocyte activity persist(48). On the contrary, a reduced 
neutrophil number or activity due to cytostatic or immunosuppressive agents was also 
associated with impaired anastomotic healing(49).
Neutrophil activity, measured by myeloperoxidase (MPO) is very frequently used to assess 
anastomotic healing, or as general measure for inflammation during healing (50-55). However, 
it is not clear how to interpret MPO values or changes with respect to anastomotic healing 
(53).
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Extravasation and infiltration
Extravasation of neutrophil granulocytes is partly a matter of efflux from leaking capillaries. 
After hemostasis there is a coordinated cascade of events(56). Briefly, the capturing 
by and rolling along the endothelium are primarily facilitated by E-, L- and P-selectins 
found on activated endothelial cells and platelets(57).  Neutrophil activation is done by 
multiple chemokines, also deriving from platelets and resident inflammatory cells (e.g. 
CCL5, CXCL4+5). Next, a firm steady adhesion to the endothelium is achieved by integrin β 
1 and 2 , Intercellular Adhesion Molecules (ICAMs) and Vascular Cell Adhesion Molecule-1 
(VCAM-1)(58). Finally, transmigration through the vessel wall relies on the aforementioned 
integrins as well as ‘integrin α M’ (ITGAM), ‘platelet-endothelial cell adhesion molecule-1’ 
(PECAM-1), ICAM1 (59)(reviewed by ref(56, 60, 61). The inactivation of any of these adhesion 
molecules, such as in steroid treatment (reduction of ELAM and ICAM1), reduces neutrophil 
infiltration, thus impairing host defense and healing (56, 62-64). Also the interaction with 
platelets underlines how intervening in platelet function may alter subsequent steps in 
the healing process. ‘Connective tissue activating peptide-3’ (CTAP-3), which is secreted by 
platelets, is converted by neutrophils to ‘neutrophil activating peptide-2’(NAP-2) to attract 
other neutrophils  in an exponential increase(65). 
Other early attractors of neutrophils include a broad spectrum of cytokines, cellular proteins 
and bacterial components (see fig.1). Bacterial components for example, cause a short 
lasting upregulation of the complement receptor C5a on neutrophils, which also contributes 
to early neutrophil influx(65). The complexity of pathways allowing neutrophil infiltration is 
illustrative of the profoundness of the healing process on a biochemical level.
Phagocytosis and collagenolysis
When on site the neutrophil granulocyte’s primary objective is to defend the host against 
bacteria emerging from the gut lumen. Elimination of this threat is crucial to prevent 
abscesses, peritonitis and anastomotic failure. However, the same mechanisms by which 
neutrophils kill bacteria potentially threat healthy tissue and the healing anastomosis. 
Knowledge of this balance would be of great value, but mechanisms are still incompletely 
understood. 
It has long been thought reactive oxygen species (ROS), like peroxides and oxygen ions 
are the molecules that kill bacteria. The current supported theory states that bacteria are 
degraded by enzymes in the phagocytic vacuole, and the ROS are produced by intracellular 
NADPH oxidase only to induce and enhance the enzymatic process. ROS induce an electron 
and K+ transport across the vacuole membrane to achieve the specific potential, pH and 
tonicity needed for enzyme rich granules to enter the vacuole and for the enzymes (e.g. 
neutrophil elastase, cathepsin G) to function(66). Since ROS can also be harmful, it is not 
clear if ROS or neutrophil enzymes cause most tissue damage during excessive neutrophil 
infiltration. In the case of I-R injury when neutrophil infiltration abounds, ROS production 
was associated with a decrease in anastomotic strength. More precise, inhibition of ROS 
production by aprotinin (a protease inhibitor) reduced the negative effects of I-R on colonic 
anastomotic strength (47, 67). Also several other studies have demonstrated a beneficial effect 
of strategies to reduce oxidative stress (68, 69).
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A physiological mechanism to minimize tissue damage from proteolytic enzymes is the loss 
of enzymatic activity in the interstitial environment as a result of different extravacuolar pH 
and tonicity. However, not every proteolytic activity is ceased outside the cell. Neutrophils 
produce elastase, protease-3 and a number of matrix metalloproteinases (e.g. MMPs 8, 
9, 25) meant for extracellular activity. This initially enables them to migrate through the 
interstitial collagen network and later shapes the surrounding tissue in such a way that it 
traps microbes and prevents bacterial invasion of the lymphatics or bloodstream(70, 71). This 
collagenolytic activity results in a net decrease in collagen content during the first few days.
MMPs are produced by many different cells and can be categorized into different 
collagenases and gelatinases that cleave specific types of matrix structures (72-75). ‘Neutrophil 
collagenase’ (MMP-8) cleaves collagen types I, II and III but favors type I(70, 76). This matches 
with the findings that the collagen type I/III ratio in the anastomotic margins is decreased in 
first 3 days, when neutrophil infiltration is most prominent(77). Overall collagenolytic activity 
is at its most 12 hours after surgery, followed by a steady decline to normal levels(78). The 
anastomotic collagen content is lowest after 48 hours(42). Type I collagen is most prominent 
in unaffected intestine (68%) and is the main contributor to mechanical strength. It has been 
found that a decreased type I/III ratio is associated with anastomotic leakage (human:(79), 
diabetic rats:(80)). MMP-8 is the main MMP accounted for a significant decrease in collagen 
at the anastomotic wound margins  and is also elevated in the peritoneal fluid of patients 
who develop anastomotic leakage(3, 81). Other MMPs shown to be active during anastomotic 
healing are MMP 1, 2, 9 and 13(79). Activity of specific MMPs appears to vary depending on 
the location within the gut (i.e. ileum or colon)(82).
An example of beneficial MMP activity is that of MMP-7 in intestinal epithelial ulcer healing, 
which was delayed when MMP-7 was blocked (83). On the contrary, when over expressed 
under the influence of IL-1β, wound healing was also delayed. 
Many papers have described the influences of MMP’s on anastomotic healing and some 
investigators have successfully tried to improve healing by blocking MMP activity (84-86), 
but many questions remain. Which cytokines are primarily responsible for the stimulation 
of MMP synthesis, which MMPs contribute most and how are they stopped at the right 
moment? Blocking certain MMPs for example, might result in less collagenolysis, but 
inevitably means jeopardizing cellular tools in the process of moving around, killing bacteria 
and shaping the interstitial matrix.
Stopping neutrophil activity
To cease neutrophil activity and presence, several mechanisms come into action around the 
second day. Macrophages, endothelial cells, but also neutrophils produce mediators that 
suppress proteolytic activity, such as ‘secretory leukocyte protease inhibitor’ (SLPI) (87) and 
‘pro-epithelin’ (PEPI). Granulocytes also initiate a switch from prostaglandin production to 
lipoxin production. Both are formed by enzymatic transformation of  arachidonic acid, but 
lipoxin initiates the resolution of inflammation(88). Finally, neutrophils undergo a complex 
programmed cell death and attract macrophages that recognize and phagocytose aging 
neutrophils (71, 89).
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Conclusion
In conclusion, neutrophils are essential for host defense, modification of extracellular 
matrix and stimulation of numerous cellular processes during anastomotic repair. Excessive 
activity involves increased tissue destruction and jeopardizes healing. Current knowledge 
of neutrophil biochemical activity during anastomotic healing is insufficient to use MPO-
assays as measure for anastomotic inflammation and healing, let alone to use neutrophil 
modulation to enhance healing. 
2.3.5 Macrophages - Suppression of inflammation and transition to proliferative 
phase
The intestinal tract is the richest source of resident macrophages in the human body(90). 
Also in the process of intestinal repair these cells are key players (91). Supported by new 
monocytes coming from the bloodstream, macrophages will outnumber the neutrophils 
around the second to third day(42). They aid in host defense, cease inflammation and guide 
the process to the proliferative phase by stimulating angiogenesis and collagen synthesis. 
The macrophage is characterized by many executive and directive functions. Because 
macrophages play such a major role in tissue repair, several attempts have already been 
made to modify their function in order to promote wound healing (92, 93). 
Timely infiltration
Prior to definitive activation, monocytes have to be attracted from the bloodstream. The 
right combination of inflammatory mediators is needed to coordinate a cascade of events 
that allow for monocytes to arrive just after the neutrophils. This is partly achieved by 
neutrophils properties promoting monocyte extravasation. Neutrophils release numerous 
granule proteins when they leave the bloodstream (94). These proteins (e.g. azurocidin 
and proteinase-3) directly mediate activation and adhesion of monocytes, but also signal 
endothelial cells to express more adhesion molecules such as VCAM-1, ICAM-1CCL2 and 
IL-8(94). General inflammatory cytokines and agents, such as TNFα, IL-1β and LPS, are also 
considered important in the orderly process of monocyte extravasation by promoting the 
synthesis and expression of cell adhesion molecules(95, 96). 
Macrophage subtypes and activity
To understand macrophage function in wound healing, the heterogeneity of this cell type is 
explained. Macrophage properties and behavior are shown to be different in various parts of 
the body, where they are influenced by specific signals of surrounding tissue(review by ref(97)). 
Furthermore resident macrophages behave differently when compared to ‘inflammatory’ 
macrophages. For example, the resident macrophages in the lamina propria of the intestinal 
wall, being close to the ‘hostile’ environment of the gut lumen, are very potent regarding 
phagocytosis and bactericidal activity, but lack the capacity of large cytokine production(98). 
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By using a simplified categorization, infiltrating macrophages are divided into two 
subtypes. The macrophage M1 is ‘classically activated’ by mediators like LPS and IFNγ, and is an 
immune effector cell with strong microbicidal behavior and inflammatory cytokine 
production. The other ‘alternatively activated’ subtypes can be put under the name 
of M2 and include those involved in tissue repair and those halting inflammation(97). 
Polarization towards M2 is very important in the second stage of wound healing and is 
partly promoted by neutrophils (99). Without neutrophil activity, macrophages produce 
more pro-inflammatory TNFα and IL-6 and less TGFβ (99). The ‘tissue repair’ macrophage 
is ‘alternatively activated’ by IL-4 and IL-13 but also IL-6, and more anti-inflammatory 
macrophage behavior is stimulated by TGFβ, IL-10 or ligands for CD200r and CD172a(97). 
In a mouse skin wound model, macrophages produce more TNFα and IL-6 on day 1 
(primarily resident macrophages (98)), but more TGFβ on day 7(100). In turn the IL-6 
produced in the early phase enhances expression of the M-CSF-receptor on monocytes(101), 
which directs the macrophage towards an M2 subtype by autocrine mechanisms (102). 
Another example of macrophage polarization is that classically activated macrophages 
release relatively many antifibrinogenic or fibrinolytic factors (e.g. MMP-7), whereas 
alternatively activated macrophages enhance fibrinogenesis by factors like TGFβ, IGF-1, 
PDGF-AA and PDGF-BB (103, 104). The M2 subtype also upregulates arginase activity, which 
results in polyamine and proline biosynthesis and thereby in cell growth and collagen 
formation (105, 106). Other growth factors produced by the macrophage are TGFα(107), ‘heparin 
binding’(HB)-EGF(108) and FGF1,2,4 (109). Most of these proliferative mediators contribute to 
collagen synthesis. Another important proliferative feature of the macrophage is their role 
in angiogenesis, a crucial element for tissue repair. They produce a battery of pro-angiogenic 
factors of which most affect endothelial cell and fibroblast behavior(110, 111). In case of hypoxia 
and lactate acidosis, and stimulated by factors like PGE2, LPS, TGFβ and CD40L, macrophages 
produce IL-8(112), TNFα(113) and most important, different forms of VEGF(114-117),
Potential clinical relevance
Because macrophage activity appears mostly beneficial for wound healing, some investigators 
aimed at improving anastomotic healing by macrophage function enhancement. In 
animal experiments modulation of macrophages by glucan phosphate increased collagen 
production and anastomotic strength (92, 93). 
Another rather broad way of cellular modulation is achieved by the administration of 
‘granulocyte-macrophage colony stimulating factor’ (GM-CSF). GM-CSF is particularly 
found in states of inflammation and enhances the proliferation, differentiation and activity 
of all myeloid cells(118). Local or systemic administration of GM-CSF has shown to improve 
healing in experimental anastomoses that were subjected to radiation(119), intraperitoneal 
chemotherapy(120), peritonitis(121), corticosteroids(122), icterus(123) or ischemia(124). No beneficial 
effect was seen in non-compromised experimental anastomoses (125, 126). 
Conclusion
In conclusion, the inflammatory stage attracts the ‘alternatively activated macrophage’ to 
play a large role in halting neutrophil activity and stimulating the proliferative processes 
required for tissue reconstruction.
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2.3.6 Lymphocytes
Lymphocytes are relatively underexposed in literature when it comes to anastomotic 
healing. In cutaneous wounds T-lymphocyte concentrations start to rise from day 5 to 
peak for 1-4 weeks, after which B-lymphocytes emerge (127, 128). This implies that these 
immune cells primarily act in the remodeling phase of skin repair when contamination and 
inflammation are overcome and closure is already completed (129). Few have reported on 
lymphocyte concentrations during intestinal anastomotic healing. They are mostly related 
to foreign body reactions in novel stapling or sealing devices (e.g. (130)). In contrast to findings 
in skin wounds, a study in rats reported a normal to slight increased number of lymphocytes 
during the first 3 days, after which their number rapidly declined(131). 
Although their exact contribution is unknown, lymphocytes are found to be essential in 
general wound healing(132). One of the reasons for their importance could be the large amount 
of TGF-β released by activated T-lymphocytes(133). TGF- β helps in damping inflammatory 
activity and promotes collagen production (see also paragraph 2.2.5 and 2.3.2). 
Lymphocytes are also linked to the negative effects of blood transfusion on anastomotic 
healing(134). Transfusion suppresses cellular immunity and is considered a risk factor for 
anastomotic leakage (23, 135-139). 
2.4 Proliferation
When damaged cellular components have been removed and any associated microbial 
threat has been eliminated, the anastomotic wound is ready for tissue reconstruction. 
Proliferative activity increases exponentially over the first 3 days, is most prominent within 
the first week, but extends until the second week. It is in this short period where the barrier 
against the intraluminal content is restored and the new connection is strengthened to 
withstand peristaltic movement and passage of stools (140, 141). If not successful, it is also this 
period when most leaks occur(142), (143-145).
From inflammation to proliferation
Important for proper tissue repair is the timely and coordinated conversion from  to 
proliferative processes, from proteolytic to proteogenic(146). As mentioned earlier, a  presence 
of neutrophils or a delayed influx of fibroblasts are associated with anastomotic failure (44, 
45, 67). When the number of microbes and damaged cellular components declines, the level 
of pro-inflammatory stimuli will also diminish. Anti-inflammatory products released by 
macrophages and other cells (e.g. SLPI, PEPI, TGF-β1) will additionally decrease neutrophil 
activity and number(88).
A relevant phenomenon in the progress from inflammation to proliferation is the shifting 
effects of different cytokines. Because cytokines execute their function depending on 
molecules, some will switch from proinflammatory to anti-inflammatory signaling (such 
as TNFα, IFNγ, TGF-β, PGE2, ROS, ‘reactive nitrogen intermediates‘ (RNI))(146). For example, 
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when levels of the inflammatory cytokine PGE2 become high, COX2 and 5-lipoxygenase 
enzymes in neutrophils are inhibited and PGE2 and leukotriene B4 production (both from 
arachidonic acid) is consequently reduced (147). Another delayed effect of PGE2 is the 
induction of 15-lipoxygenase in neutrophils, which uses arachidonic acid to produce anti-
inflammatory lipoxins (147).
Tissue repair
The multilayer anatomy of the intestine makes perfect anatomical repair unachievable. 
Scarless healing is possible for isolated mucosal or peritoneal wounds, due to sufficient 
proliferative capacity of the involved cells. In the case of an anastomosis however, 
multiple layers of smooth muscle layers and connective tissue are involved. Moreover, 
the current standard in anastomotic technique, either sutured or staples, involves an 
inverting anastomosis in which intestinal layers are unlikely to precisely oppose each 
other. Thus anastomotic healing relies on proper scar formation. The creation of secure 
scar tissue in anastomotic healing can be categorized in three main elements essential 
for a firm new connection. Restoration of the interrupted mucosal barrier to protect the 
site from intraluminal threats, a new strong collagen network to provide strength and a 
vascular plexus to restore tissue oxygenation. For the intraperitoneal parts this also includes 
mesothelial sealing of the extraluminal side. The more specific reconstruction of lymphatics 
and a neuronal plexus across the anastomotic line are described as part of the remodeling 
phase.
2.4.1 The Mucosa – Intestinal Epithelial Cells (and lamina propria)
Mucosa related threats
With a mucosal surface area of up 300m2, the gut is an enormous and important 
immunological barrier preventing the translocation of commensal flora into the body(148). 
In comparison, this barrier is about 2m2 for the skin and 80m2 for the lungs. The construction 
of an anastomosis inevitably involves a circular defect in this mucosal barrier. Thereby the 
subepithelial layers are exposed to many possibly harmful agents, such as bowel content, 
bile, pancreatic juices, yeasts and bacteria(149). 
Aside from the surgical defect that is created, the mucosa is very sensitive to hypoxia. 
Macroscopically this may be seen by cyanotic appearance during suturing. When transient 
ischemia is induced and perianastomotic tissue has a vital appearance, the mucosa can 
still be affected(150). The ischemic effects include detachment of the epithelial layer from 
the lamina propria, decrease of villi height and occurrence of denuded areas, which 
consequently hampers submucosal healing(150). Moreover, hypoxic epithelial cells produces 
factors (like ‘hypoxia inducible factor’ (HIF)-1alpha) which can augment microbial virulence 
(e.g. that of Pseudomonas Aeruginosa) and thereby effectuate an additional threat (151-153). 
Because the mucosa consists of rapidly proliferating cells, it is also very sensitive to the 
(neo-) adjuvant cancer therapies often involved in intestinal anastomoses, such as radiation 
or cytostatics. Both have shown to significantly impair anastomotic healing, especially when 
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given too close in time to the operation (139, 142, 154-157). Both chemotherapy and radiation can 
cause severe mucositis (158, 159). By Nf-κB pathways increased apoptosis causes decreased 
villous height, a reduced number of goblet cells and a lowered mucus production(160). In 
turn, this means increased permeability and excessive inflammation which both threaten 
tissue repair. 
Mucosal defense
Normal mucosal defense consists of several elements. The lamina mucosa is covered with 
a single layer of epithelial cells which are sealed together with tight junctions regulating 
passive movement of fluids, proteins and lipids and preventing the passage of microbes. 
The epithelial cells express multiple receptors (Toll-like receptors (TLRs), mannose-binding 
receptor (MBR), scavenger receptors) that recognize microbes(161). TLRs are situated on the 
basolateral side, under the tight junction level, under normal conditions. When activated by 
microbial molecules TLRs induce the expression of multiple inflammatory, cytoprotective 
and angiogenic factors (e.g. COX2, keratinocyte growth factor(KGF)-1 and 2, hepatocyte 
growth factor(HGF), TGFb1 and VEGF), influencing processes in the underlying lamina 
propria mucosae(reviewed in(161)). 
Mucosal repair
When it comes to mucosal healing, most knowledge derives from research on inflammatory 
bowel diseases and gastric ulcer healing(162, 163). Isolated healing of superficial defects in the 
intestinal epithelial cell layer is relatively efficient and fast since these cells have strong 
proliferative and migratory capacity. However, in the case of an anastomosis the subepithelial 
layers part and the solid base for epithelial reunion is disturbed. Nevertheless, restitution 
of the epithelial barrier across the anastomotic line is rapidly achieved and almost scarless 
after two weeks(164). 
The process of epithelial healing in general can be divided in four steps (Figure 2). First, 
villous contraction (flattening) reduces the surface area for repair (this does not account 
for the colon where villi are not present). Second, intestinal epithelial cells (IEC) migrate 
and, third, proliferate to completely cover the defect. The final step is paracellular closure 
of mucosal cells.
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Figure 2 Schematic overview of mucosal healing.
A. Villous flattening. B. Migration by lamellipodal extensions, regulated by focal 
adhesion kinase (FAK or PTK2) and stimulated by numerous growth factors and 
cytokines, including (TGF-β, IGF1, HGF, PDGF, EGF, TGF-α, FGF, IL-1B + IFNγ)(148, 165, 166). 
Subepithelial myofibroblasts supply TGFβ1, which inhibits proliferation but enhances 
migration of IECs (167, 168). Nitric oxide (NO) permits numerous growth factors to stimulate 
migration(169-171), by preventing adhesive behavior of cells(172). Trefoil peptides, such as 
‘intestinal trefoil factor’ (ITF), are secreted by goblet cells throughout the intestine and 
act similarly by keeping adhesion molecules like E-Cadherin away from adherens junctions 
to allow migration (162, 173, 174). C. Proliferation of IECs through EGF-receptor pathway 
(175-177). TGFα and EGF are two of four factors activating the EGF-receptor to promote 
proliferation and to halt apoptosis (partly through COX2 expression) (178-180). Heparin 
deriving from subepithelial mast cells act with heparin-binding growth factors to induce 
epithelial crypt cell proliferation(181). D. Paracellular closure by formation of tight junctions. 
COX products PGE2 and PGI2 restore ‘transepithelial electrical resistance’ (TER), a measure 
for intestinal permeability (182-184). 
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Potential clinical relevance
The importance of the mucosal barrier is reflected in the many attempts that have been 
done, and are being done, to protect the anastomosis by intraluminal sealants or tubes(185). 
Also on a biochemical level people have aimed to improve anastomotic healing by 
enhancing mucosal repair. An increased anastomotic strength was observed when rats were 
treated with intraperitoneal administration of KGF (186). Later it was seen that intravenous 
KGF resulted in an increased number of Goblet cells and a thicker mucin layer around the 
anastomosis resulting in higher strength (187). 
2.4.2 The Submucosa
Since the 1887 study of Halstedt on intestinal anastomoses, the submucosal layer is 
considered to be the most important for providing  strength to the anastomoses(188). It 
primarily consists of collagen with a vascular, lymphatic and neurologic plexus running 
through it. 
Smooth muscle cells and fibroblasts
When it comes to submucosal reconstruction, the layer is very much depending on its 
surroundings. The submucosal layer of the intestinal wall is enclosed by the thin muscularis 
musocae on the inner and the muscularis propria on the outer side. Thus, the strength 
providing collagen layer is packed between intestinal smooth muscle cells (SMC) which 
are found to be most important in producing and maintaining the submucosa of uninjured 
intestine. In the case of anastomotic healing their involvement begins with landscaping the 
wounded area. In the early inflammatory phase, IL-1β stimulates proliferation of intestinal 
SMCs, it simultaneously down-regulates their collagen synthesis and augments collagenase 
expression(189). The collagenolytic activity is gradually replaced by collagen synthesis, 
marking the transition to the proliferation phase. Intestinal SMC’s synthesize type I, III and 
V collagen(190). This is different in other tissues (e.g. skin) where fibroblasts are accounted 
for most collagen production(190). Moreover, colonic fibroblasts behave quite differently 
from cutaneous fibroblasts. The latter show a considerable increase in collagen synthesis 
when stimulated with fetal calve serum (FCS) while their colonic relatives do not(191). Also, 
collagen production can be inhibited by IL-1β or corticosteroids in skin but not in colonic 
fibroblasts(191). 
TGF-β and other growth factors
Relatively few growth factors have been identified as direct stimulators of collagen 
formation. The best studied growth factor involving collagen synthesis is TGF-β, which is 
primarily produced by inflammatory cells like T-lymphocytes and macrophages(133). Both 
collagen synthesis and TGF-β levels in anastomotic tissue gradually increase from day 0 
to day 7(192, 193). In comparison, other growth factors like EGF and PDGF-B do not increase 
over the first week(192) and do not contribute to collagen formation(133). Moreover, EGF, 
which is considered more important within the mucosa, even antagonists collagen 
formation(133). TGF-β inhibits the proliferation of intestinal SMCs, but has shown to 
increase their collagen production(194). 
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In rats given postoperative chemotherapy, reduced levels of TGF-β were associated with 
decreased collagen synthesis and less anastomotic strength (91, 195). TGF-β is not solely a 
promoter of collagen production but, like the other cytokines, a dynamic player within the 
entire process. An example of its versatile role in extracellular matrix (ECM) formation is 
the promotion and prolongation of MMP-2 activity resulting in collagen breakdown (196). 
Furthermore, it is a major (indirect) contributor to angiogenesis(133). 
Another growth factor that is thought to be involved in submucosal healing is ‘insulin like 
growth factor’ (IGF) (50, 197). Intravenous administration has shown to increase collagen 
formation and anastomotic strength in rats (198). Other compounds known to be essential in 
collagen synthesis are Vitamin C and iron. If these are deficient wound healing is disturbed 
{Kumar, 2014 #859}.
Neovascularisation
New capillary growth is essential for proliferating cells and for the new anastomosis to 
survive as it provides the necessary nutrient and oxygen support and serves as the main 
infrastructure for cellular transportation. Insufficient vascularisation is the most notorious 
risk factor for a failing anastomosis and is often used as a method to compromise healing 
in animal experiments (153, 199, 200). Patterns and mechanisms of vascularisation have been 
investigated in several studies on intestinal anastomoses. Studies in mice, rats, dogs, pigs 
and horses have shown that the first new miniature vessels are visible starting from day 
2(201), the first vessels cross the anastomotic line from day 3(202), cross-anastomotic networks 
appear between day 7 and 14, and a mature plexus is formed after 3 to 6 weeks(203-206). 
The basic steps of angiogenesis include vasodilatation, increased vascular permeability, 
endothelial proliferation and migration, lumen formation and further maturation(207). Each 
step relies on a multitude of factors of which many derive from platelets, macrophages 
and fibroblasts(113). The VEGF-receptor pathways are the most  studied, but numerous 
other pathways are involved in angiogenesis(208). For example, proteolytic activity of 
multiple MMP’s is required to facilitate the migration of endothelial cells, whereas the 
recruitment, migration and proliferation of vascular smooth muscle cells also relies on 
other cytokines(angiopoietin 2(Ang2), PDGF-BB, FGF-1, TGF-β, IGF-1, IL-8, TNFα)(207). Many 
factors involved in the stimulation of collagen synthesis also cause pro-angiogenic action 
(e.g. IL-1A and B, TNFα, PDGF and FGFs) (209). Since many factors (e.g. TGF-β) can effectuate 
agonist and antagonist activities depending on cofactors present, it remains challenging to 
intervene in this process. Exogenous administration of angiogenic factors has evoked effects 
different from endogenous factors(207). Hence, VEGF-A and FGF-2 DNA-mediated gene therapy 
was claimed to improve both mechanical and histological healing parameters of ischemic 
anastomoses (210). The same was found for local injection of VEGF into the lamina propria of 
rabbit colon anastomoses. Surprisingly, anti-angiogenic therapy with the monoclonal VEGF-
antibody bevacizumab was considered to be safe for use when an anastomosis is made 
since no difference in histology, strength or clinical symptoms was noted between groups in 
both animal and human studies(211, 212). In contrast continuous treatment with angiostatin, 
a fragment of plasminogen and endogenous inhibitor of vascular growth, significantly 
impaired the healing of colonic anastomoses in mice(213). 
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Lymphangiogenesis
Relatively underexposed compared to vascular regeneration is the formation of a new 
lymphatic network. Functional lymph vessels provide an important route to transport cell 
debris from the anastomotic area. Incomplete or blocked lymph drainage causes insufficient 
interstitial transport and edema and has shown to increase leak rates in animal studies(214). 
Also, enlargement of lymph folliculae has been reported as a cause of anastomotic leakage 
(215). When inflammatory activity is high, the production of VEGF-C and VEGF-D, which are 
the main factors in lymphangiogenesis, is stimulated(216). One Japanese group has studied 
the lymphatic regeneration following intestinal anastomoses in the late 1970’s and was able 
to visualize the formation of lymph vessels along the muscularis mucosa and across the 
anastomosis starting from the 7th day until completion around the 21st(217). 
2.4.3 Mesothelial cells
The outermost layer of the intestinal wall, the serosa, consists of a squamous epithelium 
(mesothelial cells) and a thin layer of loose connective tissue underneath. There are two 
interesting aspects about the serosa. The first is that the extraperitoneal parts of the 
gut which do not have a serosal layer (e.g. the rectum or esophagus), tend to leak more 
often than the intraperitoneal parts. The second aspect is that in the case of inverting 
anastomoses, the serosal layers oppose each other. Ironically the original physiological 
purpose of a mesothelial cell layer is to provide a lubricious surface to allow intestinal 
movement and not to adhere. It is the field of research on adhesion formation that has 
provided a substantial amount of knowledge on peritoneal healing(218, 219). However, since 
most research concerns the healing of superficial serosal defects, it is hard to translate this 
to anastomotic healing. Additionally, no histological studies have yet assessed the serosal 
role in anastomotic healing.
Normal mesothelial healing
A remarkable aspect of mesothelial healing in general is that when a defect is made, the 
entire surface becomes epithelialized simultaneously and not just gradually from the border 
as in skin epidermalization. New mesothelial cells derive from differentiating fibroblasts or 
primitive mesenchymal cells from subserosal layers(220). Meanwhile migration from wound 
edges also contributes significantly to closure(221). Mesothelial defects are rapidly covered 
with macrophages and fibrin. Proliferating mesothelial cells use these fibrin strands and the 
serosal fluid when migrating to cover the defect(220). For small defects the covering process 
takes place within 3 days and, in optimal conditions, scarless healing can be achieved within 
a week(221).
The growth factors involved in mesothelial repair differ slightly from submucosal repair. 
Whereas EGF does not promote submucosal healing, it is a known contributor to proliferation 
of mesothelial cells and peritoneal fibroblasts (222, 223). Others include FGF2, PDGF and 
hepatocyte growth factor/scatter factor (HGF/SF). HGF/SF is produced by mesothelial cells 
and stimulates their own proliferation and motility(224). Similar to the submucosa, TGF-β and 
IL-1α again contribute to collagen synthesis(225). 
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Where the submucosa is mostly infiltrated with cells and growth factors from the blood 
stream, the serosa is relatively dependent on cells and cytokines deriving from the 
peritoneal fluid. Post-operative levels of inflammatory cytokines like TNFα, IL-6 and IL-10 
are higher within the peritoneal fluid than in peripheral blood(4). A relative lack of cytokines 
may account for impaired healing of extraperitoneal anastomoses. 
2.5 Remodeling phase
Since the first few days of anastomotic healing are most important and failure is most likely to 
occur within the first week, relatively few have looked at the later phases of healing. Longer 
follow-up periods have been used in studies on effects of radiotherapy, degradation profiles 
of absorbable material, and new anastomotic devices (e.g. staplers). In general, remodeling 
concerns all systems within anastomotic healing and thus cells from every system continue 
to optimize tissue structure. When mucosal defects are closed, new villi arise and a proper 
functioning mucosa is formed. The remaining inflammatory cells around sutures disappear 
from the fourth to the eighth week(226). Macrophages, lymphocytes, smooth muscle cells 
and fibroblasts strengthen collagen networks and the new vascular plexus turns into a more 
mature and efficient web of vessels (203-206, 227). Few have studied neuronal repair.  In dog 
anastomoses, new nerve fibers are seen within 3 weeks(228). It takes neurons about 6 months 
to cross the anastomotic line, but this is not required for adequate intestinal motility (229, 
230). Finally, within 6 to 10 months the multilayer anatomy is grossly restored though the 
orientation of muscular fibers remains disturbed (227, 231).
2.6 Conclusion
Wound healing is one of the most complicated processes within the human body. Anastomotic 
healing requires the collaboration of many different cell types to complete the course of an 
adequate inflammatory response combined with the reconstruction of specialized tissue. 
Biological influences and mechanical forces acting on an intestinal anastomosis greatly 
challenge the healing process, resulting in failure rates of 3-14%. 
In this chapter an overview is given of the main cellular and molecular processes that 
cooperate to achieve repair. Infiltrating platelets, mast cells, granulocytes, macrophages, 
dendritic cells, lymphocytes, fibroblasts work together with their resident relatives and 
others like mesenchymal stem cells, neurons, and endothelial, epithelial, mesothelial and 
smooth muscle cells. The intended full thickness intestinal repair requires an orderly, four 
dimensional system in which alternate cellular and balanced cytokine activity gradually 
reconstruct the mucosal barrier, the submucosal basis, the circulatory infrastructure and 
the serosal covering. 
The relevance of different steps and cellular interactions within the process becomes 
apparent when certain drugs or risk factors disturb one or more steps in the healing 
process. Cellular and molecular mechanisms might serve as potential therapeutic targets, 
but the complexity and interaction of the different systems impedes the development of 
such therapeutic strategies. Scarcity of studies on the molecular biology of anastomotic 
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healing makes one rely on knowledge extrapolated from related research fields. Though 
these have provided substantial insight into biochemical mechanisms of tissue repair, many 
fundamental elements of the system are still unknown.  The exact role of cells and cytokines 
concerning their amount, location and timing remains unsolved. Other topics relatively 
underexposed in anastomotic research include the essence of peritoneal cytokines and 
the influence of intraluminal factors such as bile, nutrients and microflora on the healing 
process. Complementation of our current knowledge of anastomotic healing by future 
research should improve our understanding of leakage etiology and also provide better 
suited therapies when it comes to cellular or molecular acting agents.
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Abstract
Background 
The contribution of animal research to a reduction in clinical intestinal anastomotic leakage 
is unknown, despite numerous experimental studies. In view of the current societal call to 
replace, reduce and refine animal experiments, this study examined the quality of animal 
research related to anastomotic healing and leakage.
Methods
Animal studies on intestinal anastomotic healing were retrieved systematically from PubMed 
and Embase. Study objective, conclusion and animal model were recorded. Reporting quality 
and internal validity (reporting of randomization and blinding) were assessed.
Results
A total of 1342 studies were identified, with a rising publication rate. The objectives of most 
studies were therapeutic interventions (64·8 per cent) and identification of risk factors 
(27·5 per cent). Of 350 articles studying experimental therapies, 298 (85·1  per cent) 
reported a positive effect on anastomotic healing. On average, 44·7 per cent of relevant 
study characteristics were not reported, in particular details on anastomotic complications 
(31·6 per cent), use of antibiotics (75·7 per cent), sterile surgery (83·4 per cent) and 
postoperative analgesia (91·4 per cent). The proportion of studies with randomization, 
blinding of surgery and blinding of primary outcome assessment has increased in the past 
two decades but remains insufficient, being included in only 62·4, 4·9 and 8·5 per cent 
of publications respectively. Animal models varied widely in terms of species, method to 
compromise healing, intestinal segment and outcome measures used.
Conclusion
Animal research on anastomotic leakage is of poor quality and still increasing, contrary to 
societal aims. Reporting and study quality must improve if results are to impact on patients.
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Introduction
Worldwide, intestinal resection and anastomosis are performed annually in over a million 
people with colorectal cancer, inflammatory bowel disease, complicated diverticulitis 
and morbid obesity1–3. Despite improvements in technique, anastomotic devices and 
perioperative care, an intestinal anastomosis has a 3–14 per cent risk of leakage4,5. This 
postoperative complication often results in severe morbidity, with a consequent mortality 
rate of up to 18 per cent6–8. Many risk factors have been identified from clinical studies4,9. 
Male sex, low colorectal anastomosis, preoperative chemoradiation, advanced tumour 
stage, immunosuppression, perioperative bleeding and multiple staple firings have all been 
associated with increased leak rates4,9,10.
Animal models have been used extensively to study causality and underlying 
pathophysiological mechanisms11,12, as well as the assessment of techniques and products 
that reinforce the anastomosis or improve healing13,14. The study of anastomotic failure 
in animals involves moderate to severe animal discomfort, dedicated human effort and 
considerable cost. This has led to a European directive that animal experiments need to be 
replaced, reduced and refined whenever possible15,16. Owing to its complex physiology, the 
process of anastomotic healing is presently considered too complicated to mimic in vitro. 
To reduce and refine animal experiments, it is necessary to perform a systematic review of 
the existing literature regarding methodology and quality, to see how experimental models 
and designs might be improved or standardized. The aim of the present systematic review 
was to investigate study characteristics and the quality of animal research on intestinal 
anastomotic healing.
Methods
 Search and study inclusion
This review is reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guideline17. A prespecified protocol was used for the 
study selection and extraction of study characteristics (available through https://www.
radboudumc.nl/syrcle). A systematic search was conducted in the PubMed version of 
MEDLINE and the OvidSP version of Embase on 4 April 2014, by using different synonyms, 
Medical subject headings (MesH) and Emtree terms (for PubMed and Embase respectively) 
to cover any study on intestinal anastomoses (Table S1, supporting information)18. To limit 
the results to animal studies, a specifically designed and validated filter was used for both 
databases (Table S1, supporting information)19,20. Selection was made by screening the title 
and abstract of all results. Every title or abstract was screened by two authors. Disagreement 
was resolved by discussion. Experimental studies in which the healing of an anastomosis of 
the small bowel or colon was investigated in an in vivo animal model were included. All 
duplicates, abstracts, posters and review articles, all studies in human, in vitro or ex vivo 
studies, all studies on other types of anastomosis (for example vascular, urological, biliary, 
gastrojejunal, oesophagojejunal), intestinal transplants, studies reporting outcomes not 
related to anastomotic healing (such as cancer recurrence) and those in which enterotomy 
was performed rather than anastomosis were excluded. Articles selected through title and 
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abstract screening were then subjected to full-text screening (using the same inclusion 
criteria) and simultaneous data extraction by one of the authors. Full-text retrieval was 
attempted through online searching, by consulting Dutch and German university libraries, 
and by e-mail to the corresponding author. Articles in all languages except Japanese were 
included.
Figure 1 PRISMA flow diagram of study selection
	
Excluded (duplicates) n = 3058 
Excluded n = 2784 
Duplicate data n = 4 
Abstract, poster or review n = 188 
Human study n = 253 
In vitro/ex vivo study n = 43 
Not a study of intestinal anastomosis n = 1212 
Study of intestinal transplants n = 152 
Not a prospective experiment n = 195 
Outcome unrelated to anastomotic patency n = 737 
	
Full text unretrievable n = 138 
No translation possible n = 16 
Duplicate data n = 48 
Abstract, poster or review n = 102 
Human study n = 2 
In vitro/ex vivo study n = 11 
Not a study of intestinal anastomosis n = 23 
Not a prospective experiment n = 5 
Outcome unrelated to anastomotic patency n = 39 
Use of enterotomy n = 17 
Full-text articles included 
n = 1342 
Records identified through 
PubMed 
n = 3412 
Records identified through 
Embase 
n = 4173 
Article title/abstract screened 
n = 4527 
Full-text articles assessed 
n = 1743 
Data extraction
Study objectives
The primary objective of each study was interpreted from the hypothesis or research 
question stated in the article. Study objectives were categorized as: therapeutic trial (for 
example ‘Does growth hormone improve anastomotic healing?’), risk factor identification 
(for example ‘Does chemotherapy cause leakage?’), study of physiology (for example ‘What 
is the role of neutrophils during healing?’) or animal model presentation (for example ‘a 
leakage model is developed in the pig’).
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Study conclusions
Study conclusions on experimental therapeutics and risk factors were categorized as having a 
positive (for example ‘growth hormone improves healing’), neutral (for example ‘hyaluronic 
acid does not affect leakage rate’) or negative (for example ‘chemotherapy impairs 
anastomotic strength’) effect on anastomotic healing according to the authors’ conclusions. 
Only studies on experimental therapeutics and risk factors were used to categorize study 
conclusions, because these involved control groups given placebo or no treatment. In 
comparison, studies on surgical technique often compared two existing techniques (such as 
single versus double-layer suturing), making any unilateral conclusion debatable. If multiple 
interventions were studied with different outcomes, they were scored separately. Reporting 
of study details.
The reporting quality of each article was scored according to a reporting score, which 
was designed specifically for this review according to items listed in the Animal Research: 
Reporting of In Vivo Experiments (ARRIVE) guidelines21 (such as animal species, strain and 
age) and items relevant to anastomosis studies (such as suture material and technique).
Assessment of internal validity
Three determinants of internal validity were evaluated. Risk of selection bias was addressed 
by scoring randomized treatment allocation in every controlled study. Randomization was 
scored when reported, even if the method of randomization or allocation concealment 
was not described. Risk of performance bias was determined by scoring the blinding of the 
surgical procedures. Risk of detection bias was estimated by assessing the use of blinded 
outcome assessment. This was categorized in blinding of the primary or secondary outcome 
(for example if only ‘histological analysis’ but not ‘macroscopic examination of leakage’ 
was blinded). If blinding was reported, this was scored accordingly, independent of further 
specification of the method used.
Description of animal models used
Details were recorded on animal species, method of compromising healing, intestinal 
segment and primary outcome measure used.
 Statistical analysis
Differences in mean values between groups were assessed using ANOVA and Tukey’s post 
hoc test. The χ2 test was used to compare proportional values between groups. Linear 
regression analysis was employed to determine changes over time in relation to the number 
of studies, animal species, reporting score, randomization and blinding. SPSS® version 20 
(IBM, Armonk, New York, USA) was used for statistical analysis. P < 0.050 was considered 
statistically significant.
52
Chapter 3
Results
After screening title, abstract and full text (as applicable) of 4527 citations, 1342 individual 
articles were included for data extraction and analysis (Fig. 1). There was considerable 
experimental repetition for some topics: 88 studies on adverse effects of chemotherapy, 
42 studies on fibrin glue and 18 studies on the use of growth hormone.
General characteristics and study objectives
The number of articles per year on intestinal anastomosis increased steadily over 60 years 
(P < 0.001). A mean of 36 articles were published each year from 2000 to 2009, and 53 
articles each year from 2010 to 2014 (Fig. 2a). A total of 73 304 animals were used with a 
mean(s.d.) of 55(49) animals per study. The mean number of animals per study remained 
constant over time (P = 0.455).
There were 68 studies (5.1 per cent) with multiple objectives, giving a total of 1410 objectives. 
Of all studies, 914 (64.8 per cent) were therapeutic trials, 388 (27.5 per cent) were risk factor 
identification studies, 89 (6.3 per cent) investigated anastomotic healing physiology, and 19 
(1.3 per cent) were on the presentation or evaluation of animal models. Over time there 
was a slight increase (P < 0.001) in the proportion of risk factor identification studies (Fig. 
2b). Most therapeutic trials studied experimental therapies designed to improve healing 
(Fig. 2c), and most risk factor identification studies focused on chemotherapy (Fig. 2d). The 
variety of therapies and risk factors studied is detailed in Tables S2 and S3.
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Figure 2 Number of studies, study objectives and study conclusions. a Number of studies per 
decade. The dashed line indicates the projected number of studies in the decade 2010–2019, 
based on the mean number of studies per month. b Study objective/character per decade. 
c Classification of studied strategies in the following therapeutic categories (with examples 
in parentheses): experimental therapy (growth factors, hormones, herbs, antioxidants), 
technique (comparing suture techniques or suture material), experimental technique 
(magnetic or glued anastomoses), external sealing (omental wrap, meshes, glue), internal 
sealing (tubes, glue), surgical approach (laparoscopy, natural-orifice surgery, single-incision 
surgery), other (nutritional management, ostomies, oximetry). d Classification of research 
topics of risk factor identification in the following categories (with examples in parentheses): 
chemotherapy (any pharmacological (neo)adjuvant therapy), radiotherapy, ischaemia 
(any form of ischaemia and/or reperfusion injury), antiadhesives, immunosuppressants 
(corticosteroids), infection (peritonitis, bacterial contamination, sepsis), analgesics, 
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co-morbidity (hypertension, diabetes, hypercholesterolaemia), other (blood transfusion, 
drains, malnutrition, trauma). NSAID, non-steroidal anti-inflammatory drug. e,f Effect of 
studied therapy (e) or risk factor (f) on anastomotic healing according to the conclusion 
stated in the article. c,d For further specification of therapeutic and risk factor categories, 
see Tables S2 and S3.
Study conclusions
Of 350 articles on experimental therapies, in 298 (85.1 per cent), the authors concluded that 
the treatment under investigation (approximately 200 different treatments) had a beneficial 
effect on anastomotic healing. Treatment was reported to have no effect in 41 studies (11.7 
per cent) and only 12 (3.4 per cent) reported a negative effect on healing (Fig. 2e). Of 388 
risk factor identification studies, it was concluded that the factor under investigation was 
a risk factor for anastomotic leakage in 235 (60.6 per cent) (Fig. 2f). The studied factor did 
not affect healing in 142 studies (36.6 per cent) and improved healing in 11 (2.8 per cent). 
A relatively large proportion of the latter two categories were articles studying the safety 
of antiadhesives: 28 (19.6 per cent) of 143 and four (36 per cent) of 11 articles respectively.
Quality of reporting study details.
A mean(s.d.) of 10.0(3.1) of 18 criteria (55 per cent) of the reporting score were met. The 
reporting score increased gradually, from 44 to 62 per cent, over six decades (P < 0.001) (Fig. 
3a). Items that were most frequently unreported were the use of postoperative analgesics 
(91.4 per cent), sterile surgery (83.4 per cent) and antibiotics (75.7 per cent). Important 
data specific to an experiment were frequently omitted, such as the number of sutures used 
in models investigating anastomotic strength, reported in only 110 (56.4 per cent) of 195 
studies. The occurrence of anastomotic complications, or their absence, was not reported 
in 424 studies (31.6 per cent) of the 1342. They were reported in 652 studies (48.6 per cent) 
and used for comparative outcome in 266 (19.8 per cent).
Assessment of internal validity
Measures to reduce selection bias increased over time, with randomization being reported 
in only 7.0 per cent of studies before 1970, compared with 62.4 per cent in the past decade 
(P = 0.001) (Fig. 3b). Measures to reduce performance bias were seldom used. Of 914 
studies in which blinding of surgery was considered possible, this was reported in only 21 
articles (2.3 per cent of the total; 4.9 per cent of studies since 2000), all published in the past 
three decades. With respect to detection bias, blinding of primary outcome assessment was 
reported in 4.9 per cent and blinding of secondary outcomes in 12.4 per cent. The reporting 
of blinding of primary outcome assessment has increased slowly since the 1990s (P = 0.035), 
but was still absent in 91.5 per cent of articles published since 2000 (Fig. 3c).
Animal models
Rats were used in most studies (792), followed by dogs (290), pigs (134), rabbits (100), mice 
(20), cats (11), horses (11), guinea-pigs (6), sheep (5), monkeys (3) and cows (1). Before 
1980, dogs were used in most experiments. Since the beginning of the 1990s there has been 
a marked increase in the use of rats (P = 0.002) (Fig. 4a). 
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A factor to compromise healing or induce leakage was used in 32.0 per cent of therapeutic 
studies. In the 1970s and 1980s, the most commonly employed compromising factor was 
intestinal ischaemia (respectively 24.2 and 20.5 per cent of studies using a compromising 
factor). The induction of peritonitis was most popular in the past two decades (27.9 and 
27.5 per cent) (Fig. 4b). The use of chemotherapeutic agents to impair healing varied 
between 15.1 and 28.4 per cent (mean 18.8 per cent) over time. The exact methods of 
inducing ischaemia, peritonitis, cytotoxic injury, radiation injury, obstruction, suture defects 
or immunosuppression varied greatly among studies, impeding further categorization. For 
example, the chemotherapeutic drug 5-fluorouracil was used regularly to compromise 
healing, but the route, timing and dose of administration varied greatly between studies, 
and different segments of the intestinal tract were used (Fig. 4c). Strength measurements 
were used most often, and increasingly, as the primary outcome (720 studies, 53.9 per cent 
of 1336 studies), followed by anastomotic complications (266, 19.9 per cent) and histological 
analyses (184, 13.8 per cent) (Fig. 4d).
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Figure 3 Reporting quality, randomization and blinding. a Mean(s.d.) reporting score 
(maximum 18 points). Points (in parentheses) scored for reporting animal characteristics: 
strain (1), sex (1), age or weight (1); perioperative management: any remark on housing 
(1), fasting/bowel preparation (1), type of anaesthesia (1), use of antibiotics (1) and 
postoperative analgesia (only if used, 1 point); surgery: reporting of strict aseptic techniques 
(2 points, 1 point for semisterile technique), method of bowel apposition (for example 
inverted or Gambee) (1), suture material (if type and thickness reported, 1 point), suture 
layers (1), suture pattern (1), suture distance (such as number of sutures or ‘every 3 mm’) 
(1); outcome assessment: anastomotic complications (as comparative outcome, 2 points; 
if only reported (for example if absent), 1 point), animal welfare (for example weight loss) 
(1). b Use of randomized treatment allocation if possible. c Blinding of primary or secondary 
outcome assessment.
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Figure 4 Animal models. a Animal species used. ‘Other’ included horses (11), cats (11), 
guinea-pigs (6), sheep (5), monkeys (3) and cows (1). b Categories of compromising 
methods (if used, with examples in parentheses): ischaemia (marginal artery clamping, 
mesenteric artery clamping, ischaemia and reperfusion protocols), chemotherapy 
(includes preoperative, intraoperative and postoperative regimens, and intravenous and 
intraperitoneal administrations), peritonitis (caecal ligation puncture, exogenous bacterial 
contamination), radiotherapy (various regimens), obstruction, immunosuppressants 
(corticosteroids) and suture defects. c Segments of the intestine in which the anastomosis 
was constructed. D Categories of primary outcome: anastomotic complications (leakage 
rate or anastomotic complications), strength (any form of bursting pressure or breaking 
strength testing), collagen (any form of collagen quantification or qualification other than 
histological, such as hydroxyproline assays), histology (any histological evaluation), other 
(microangiography, barium enema). If multiple outcomes were used and it was unclear which 
was used as primary outcome, the categorization was used in this order with ‘anastomotic 
complications’ first and ‘other’ last.
Discussion
The number of publications on animal research on intestinal anastomosis continues to 
increase. Reporting quality is poor and frequently insufficient. Internal validity was poor 
and external validity indicated wide variability in animal models. Although study quality 
has improved slightly over time, the use of important methodological strategies, such as 
blinding of primary outcome, is still inadequate.
The range of therapies and risk factors was diverse. The unnecessary repetition for some 
topics (adverse effects of chemotherapy, fibrin glue, growth hormone) highlights the 
importance of properly reviewing animal studies before commencing new projects22.
The true translational value of animal studies to clinical practice was not assessed in this 
review, but it seems very limited, bearing in mind that a high proportion of positively judged 
experimental treatments have no current application in patients. Reporting quality, internal 
validity and external validity of the model used are all contributing factors23,24.
This poor-quality reporting also makes it impossible to assess the internal validity of 
the studies and the reliability of the results25. For instance, breaking or tensile strength 
measurements determine the suture-holding capacity of the anastomosis by pulling it apart, 
and are highly dependent on the type and number of sutures used. Of 195 studies reporting 
breaking strength for sutured anastomosis, the number of sutures was not adequately 
reported in 110 (56.4 per cent). Anastomotic leakage is an outcome with infectious 
consequences. Consequently, signs of leakage such as abscess formation are influenced by 
antibiotic use and aseptic techniques, but these items were not reported in 75.7 and 83.4 
per cent respectively of relevant studies. Postoperative analgesia was not reported in 91.4 
per cent of studies. Apart from the fact that this raises concerns regarding animal welfare, 
there is increasing evidence that analgesia provided by non-steroidal anti-inflammatory 
drugs influences anastomotic healing and should therefore be reported26–29.
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A trend was seen in improved reporting of randomization measures to reduce selection 
bias, but even in the most recent decade this information was absent in nearly 40 per cent 
of studies. For example, the creation of an intestinal anastomosis in the rat is influenced 
by a technical learning curve, supporting the need for proper randomization. The influence 
of surgical technique also emphasizes the relevance of blinding the surgeon to reduce 
performance bias. Blinding of surgery was reported in only 2.3 per cent of studies. Although 
of considerable importance when assessing leakage by macroscopic inspection, blinding 
of primary outcomes assessment was reported only occasionally (4.9 per cent). As the 
definition of leakage is a frequent subject of debate, and the severity of leakage may vary, 
macroscopic assessment is a measure easily subject to detection bias. Overall, the internal 
validity of studies was poor.
External validity is highly dependent on the model used23. Animal models used for 
anastomotic healing varied widely in terms of the animal species, factors that compromised 
healing, the intestinal segment used and the outcome measures30. Although a narrative 
review31 in 2011 recommended mouse and porcine models, the present review shows that 
rat models have dominated the field since the 1990s.
The increase in porcine studies may reflect their use in minimally invasive surgery techniques 
and anastomotic devices, as porcine models were used heavily in articles on surgical 
approach, use of staplers, anastomotic rings and stents.
Concerning the choice of outcome measure, signs of anastomotic leakage would in theory 
be most valuable as primary outcome, because it is most relevant in clinical practice. 
Nevertheless, anastomotic complications were not reported in 424 articles (31.6 per cent) 
and were used to compare groups in only 266 papers (19.8 per cent). Although heterogeneity 
of animal models and experimental protocols may be useful to assess treatment efficacy 
under different circumstances, greater similarity between studies would allow for better 
assessment of external validity and better interpretation, comparison and meta-analysis32.
The present review has a number of limitations. Only full-text articles were included. The 
exclusion of abstracts, conference presentations and unpublished experiments leads to 
an underestimation of the number of animal studies on intestinal anastomosis actually 
undertaken. The scoring system to assess the quality of reporting of study methodology was 
designed specifically for anastomosis studies. Items such as details of housing, drug doses, 
sample size calculation and statistical analyses were not collected. The inclusion of such 
items might have revealed even more reporting deficiencies. The score should therefore be 
interpreted as a summary of included items, rather than a conclusive judgement. Reported 
randomization in less than half of articles and negligible reporting of blinding suggest a 
high overall risk of bias. True risk of bias assessment, however, was considered impossible 
because of insufficient reporting of study methodology. Complete descriptions of sequence 
generation, allocation concealment and blinding methods were hardly reported. The 
inclusion of such items in the present scoring system would only have suggested a greater 
risk of bias. The same is likely to be true for other items commonly included in risk of bias 
assessments, such as attrition bias and selective outcome reporting33.
To improve the quality and applicability of future studies on intestinal anastomosis, these 
experiments should be properly randomized and blinded whenever possible. Details on 
analgesia, anaesthesia, antibiotics, antiseptic measures, intestinal segment involved, 
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surgical technique and anastomotic complications should be essential data items. Choice 
of species and leakage model based on the research question is a prerequisite. Rats, for 
instance, are useful to study leakage, but not to study sealants or anastomotic technique, 
owing to small diameter.
Delphi consensus meetings and evidence appraisal of studies that might inform a clinical 
trial, as well as international platforms for multicentre preclinical studies, could all be used 
to maximize the likelihood of translating this work from bench to bedside34–36. Study of 
reproducibility and translational ability of different animal models is essential to select the 
strategies most likely to have an effect in patients, and to minimize unnecessary animal 
experimentation.
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Table S1 Search strategy 
Pubmed search command  (intestinal anastomosis + customized animal filter)
((anastomo*[tiab] OR surgical anastomosis[MeSH:noexp]) AND  (bowel[tiab] OR intestine[tiab] OR intestinal[tiab] 
OR intestines[tiab] OR enteral[tiab] OR ileum[tiab] OR colon[tiab] OR colonic[tiab] OR colorectal[tiab] 
OR rectum[tiab] OR rectal[tiab] OR "Colon"[Mesh] OR “Intestines"[Mesh:noexp] OR "Ileum"[Mesh] OR 
"Rectum"[Mesh]) OR (ileoileost*[tiab] OR ileo-ileost*[tiab] OR ileoascend*[tiab] OR ileo-ascend*[tiab] OR 
ileotransvers*[tiab] OR ileo-transvers*[tiab] OR ileo-colostom*[tiab] OR ileocolostom*[tiab] OR colocolost*[tiab] 
OR colo-colost*[tiab] OR colorectostom*[tiab] OR colo-rectostom*[tiab]) OR "anastomotic leak"[MeSH])
AND
((“animal experimentation”[MeSH Terms] OR “models, animal”[MeSH Terms] OR “invertebrates”[MeSH Terms] 
OR “Animals”[Mesh:noexp] OR “animal population groups”[MeSH Terms] OR “chordata”[MeSH Terms:noexp] 
OR “chordata, nonvertebrate”[MeSH Terms] OR “vertebrates”[MeSH Terms:noexp] OR “amphibians”[MeSH 
Terms] OR “birds”[MeSH Terms] OR “fishes”[MeSH Terms] OR “reptiles”[MeSH Terms] OR “mammals”[MeSH 
Terms:noexp] OR “primates”[MeSH Terms:noexp] OR “artiodactyla”[MeSH Terms] OR “carnivora”[MeSH Terms] 
OR “cetacea”[MeSH Terms] OR “chiroptera”[MeSH Terms] OR “elephants”[MeSH Terms] OR “hyraxes”[MeSH 
Terms] OR “insectivora”[MeSH Terms] OR “lagomorpha”[MeSH Terms] OR “marsupialia”[MeSH Terms] 
OR “monotremata”[MeSH Terms] OR “perissodactyla”[MeSH Terms] OR “rodentia”[MeSH Terms] OR 
“scandentia”[MeSH Terms] OR “sirenia”[MeSH Terms] OR “xenarthra”[MeSH Terms] OR “haplorhini”[MeSH 
Terms:noexp] OR “strepsirhini”[MeSH Terms] OR “platyrrhini”[MeSH Terms] OR “tarsii”[MeSH Terms] OR 
“catarrhini”[MeSH Terms:noexp] OR “cercopithecidae”[MeSH Terms] OR “hylobatidae”[MeSH Terms] OR 
“hominidae”[MeSH Terms:noexp] OR “gorilla gorilla”[MeSH Terms] OR “pan paniscus”[MeSH Terms] OR “pan 
troglodytes”[MeSH Terms] OR “pongo pygmaeus”[MeSH Terms]) OR OR ((animals[tiab] OR animal[tiab] OR 
mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR murine[Tiab] OR woodmouse[tiab] OR rats[Tiab] OR rat[Tiab] OR 
murinae[Tiab] OR muridae[Tiab] OR cottonrat[tiab] OR cottonrats[tiab] OR hamster[tiab] OR hamsters[tiab] 
OR cricetinae[tiab] OR rodentia[Tiab] OR rodent[Tiab] OR rodents[Tiab] OR pigs[Tiab] OR pig[Tiab] OR 
swine[tiab] OR swines[tiab] OR piglets[tiab] OR piglet[tiab] OR boar[tiab] OR boars[tiab] OR “sus scrofa”[tiab] 
OR ferrets[tiab] OR ferret[tiab] OR polecat[tiab] OR polecats[tiab] OR “mustela putorius”[tiab] OR “guinea 
pigs”[Tiab] OR “guinea pig”[Tiab] OR cavia[Tiab] OR callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR 
cebuella[Tiab] OR hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR gerbillinae[Tiab] 
OR gerbil[Tiab] OR gerbils[Tiab] OR jird[Tiab] OR jirds[Tiab] OR merione[Tiab] OR meriones[Tiab] OR 
rabbits[Tiab] OR rabbit[Tiab] OR hares[Tiab] OR hare[Tiab] OR diptera[Tiab] OR flies[Tiab] OR fly[Tiab] OR 
dipteral[Tiab] OR drosphila[Tiab] OR drosophilidae[Tiab] OR cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR felis[Tiab] 
OR nematoda[Tiab] OR nematode[Tiab] OR nematoda[Tiab] OR nematode[Tiab] OR nematodes[Tiab] OR 
sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] OR canine[Tiab] OR canines[Tiab] OR canis[Tiab] OR sheep[Tiab] 
OR sheeps[Tiab] OR mouflon[Tiab] OR mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] OR capra[Tiab] 
OR capras[Tiab] OR rupicapra[Tiab] OR chamois[Tiab] OR haplorhini[Tiab] OR monkey[Tiab] OR monkeys[Tiab] 
OR anthropoidea[Tiab] OR anthropoids[Tiab] OR saguinus[Tiab] OR tamarin[Tiab] OR tamarins[Tiab] OR 
leontopithecus[Tiab] OR hominidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR pan[Tiab] OR paniscus[Tiab] OR 
“pan paniscus”[Tiab] OR bonobo[Tiab] OR bonobos[Tiab] OR troglodytes[Tiab] OR “pan troglodytes”[Tiab] OR 
gibbon[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR siamangs[Tiab] OR nomascus[Tiab] OR symphalangus[Tiab] 
OR chimpanzee[Tiab] OR chimpanzees[Tiab] OR prosimians[Tiab] OR “bush baby”[Tiab] OR prosimian[Tiab] 
OR bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR pongidae[Tiab] OR gorilla[Tiab] OR gorillas[Tiab] 
OR pongo[Tiab] OR pygmaeus[Tiab] OR “pongo pygmaeus”[Tiab] OR orangutans[Tiab] OR pygmaeus[Tiab] OR 
lemur[Tiab] OR lemurs[Tiab] OR lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab] OR pongo[Tiab] OR equus[Tiab] 
OR cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR chicken[Tiab] OR chickens[Tiab] OR gallus[Tiab] OR quail[Tiab] OR 
bird[Tiab] OR birds[Tiab] OR quails[Tiab] OR poultry[Tiab] OR poultries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR 
reptile[Tiab] OR reptilia[Tiab] OR reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] 
OR alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] OR turtle[Tiab] OR turtles[Tiab] 
OR amphibian[Tiab] OR amphibians[Tiab] OR amphibia[Tiab] OR frog[Tiab] OR frogs[Tiab] OR bombina[Tiab] 
OR salientia[Tiab] OR toad[Tiab] OR toads[Tiab] OR “epidalea calamita”[Tiab] OR salamander[Tiab] OR 
salamanders[Tiab] OR eel[Tiab] OR eels[Tiab] OR fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR catfish[Tiab] OR 
catfishes[Tiab] OR siluriformes[Tiab] OR arius[Tiab] OR heteropneustes[Tiab] OR sheatfish[Tiab] OR perch[Tiab] 
OR perches[Tiab] OR percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR chars[Tiab] 
OR salvelinus[Tiab] OR “fathead minnow”[Tiab]
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OR minnow[Tiab] OR cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR zebrafish[Tiab] OR zebrafishes[Tiab] OR 
goldfish[Tiab] OR goldfishes[Tiab] OR guppy[Tiab] OR guppies[Tiab] OR chub[Tiab] OR chubs[Tiab] OR tinca[Tiab] 
OR barbels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] OR promelas[Tiab] OR “poecilia reticulata”[Tiab] OR 
mullet[Tiab] OR mullets[Tiab] OR seahorse[Tiab] OR seahorses[Tiab] OR mugil curema[Tiab] OR atlantic cod[Tiab] 
OR shark[Tiab] OR sharks[Tiab] OR catshark[Tiab] OR anguilla[Tiab] OR salmonid[Tiab] OR salmonids[Tiab] OR 
whitefish[Tiab] OR whitefishes[Tiab] OR salmon[Tiab] OR salmons[Tiab] OR sole[Tiab] OR solea[Tiab] OR “sea 
lamprey”[Tiab] OR lamprey[Tiab] OR lampreys[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] 
OR tilapia[Tiab] OR tilapias[Tiab] OR turbot[Tiab] OR turbots[Tiab] OR flatfish[Tiab] OR flatfishes[Tiab] OR 
sciuridae[Tiab] OR squirrel[Tiab] OR squirrels[Tiab] OR chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab] 
OR susliks[Tiab] OR vole[Tiab] OR voles[Tiab] OR lemming[Tiab] OR lemmings[Tiab] OR muskrat[Tiab] OR 
muskrats[Tiab] OR lemmus[Tiab] OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR 
martes[Tiab] OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR ermine[Tiab] OR mink[Tiab] OR minks[Tiab] 
OR sable[Tiab] OR sables[Tiab] OR gulo[Tiab] OR gulos[Tiab] OR wolverine[Tiab] OR wolverines[Tiab] OR 
minks[Tiab] OR mustela[Tiab] OR llama[Tiab] OR llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] 
OR camelids[Tiab] OR guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR chiropteras[Tiab] OR bat[Tiab] 
OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR 
parakeet[Tiab] OR parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR donkeys[Tiab] OR 
mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR shrew[Tiab] OR shrews[Tiab] OR bison[Tiab] OR 
bisons[Tiab] OR buffalo[Tiab] OR buffaloes[Tiab] OR deer[Tiab] OR deers[Tiab] OR bear[Tiab] OR bears[Tiab] 
OR panda[Tiab] OR pandas[Tiab] OR “wild hog”[Tiab] OR “wild boar”[Tiab] OR fitchew[Tiab] OR fitch[Tiab] OR 
beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR capybara[Tiab] OR capybaras[Tiab]) NOT 
medline[subset])
Ovid Embase search command (intestinal anastomosis + customized animal filter)
((anastomo*.ab,ti. AND ((bowel OR intestine OR intestinal OR intestines OR enteral OR ileum OR colon OR colonic 
OR colorectal OR rectum OR rectal).ab,ti. OR exp intestine/su)) OR (ileoileost* OR ileo-ileost* OR ileoascend* 
OR ileo-ascend* OR ileo-transvers* OR ileotransvers* OR ileocolostom* OR ileo-colostom* OR colo-colost* 
OR colocolostom* OR colo-rectostom* OR colorectostom*).ab,ti. OR exp Anastomosis leakage/ OR exp colon 
anastomosis/ OR exp colorectal anastomosis/ OR exp ileorectal anastomosis/) 
AND
anser OR harrier OR circus pygargus OR red knot OR great knot OR calidris OR canutus OR godwit OR limosa 
OR lapponica OR meleagris OR gallopavo OR jackdaw OR corvus OR monedula OR ruff OR philomachus OR 
pugnax OR lapwing OR peewit OR plover OR vanellus OR swan OR cygnus OR columbianus OR bewickii OR gull 
OR chroicocephalus OR ridibundus OR albifrons OR great tit OR parus OR aythya OR fuligula OR streptopelia OR 
risoria OR spoonbill OR platalea OR leucorodia OR blackbird OR turdus OR merula OR blue tit OR cyanistes OR 
pigeon OR pigeons OR columba OR pintail OR anas OR starling OR sturnus OR owl OR athene noctua OR pochard 
OR ferina OR cockatiel OR nymphicus OR hollandicus OR skylark OR alauda OR tern OR sterna OR teal OR crecca 
OR oystercatcher OR haematopus OR ostralegus OR shrew OR shrews OR sorex OR araneus OR crocidura OR 
russula OR european mole OR talpa OR chiroptera OR bat OR bats OR eptesicus OR serotinus OR myotis OR 
dasycneme OR daubentonii OR pipistrelle OR pipistrellus OR cat OR cats OR felis OR catus OR feline OR dog OR 
dogs OR canis OR canine OR canines OR otter OR otters OR lutra OR badger OR badgers OR meles OR fitchew OR 
fitch OR foumart or foulmart OR ferrets OR ferret OR polecat OR polecats OR mustela OR putorius OR weasel 
OR weasels OR fox OR foxes OR vulpes OR common seal OR phoca OR vitulina OR grey seal OR halichoerus OR 
horse OR horses OR equus OR equine OR equidae OR donkey OR donkeys OR mule OR mules OR pig OR pigs OR 
swine OR swines OR hog OR hogs OR boar OR boars OR porcine OR piglet OR piglets OR sus OR scrofa OR llama 
OR llamas OR lama OR glama OR deer OR deers OR cervus OR elaphus OR cow OR cows OR bos taurus OR bos 
indicus OR bovine OR bull OR bulls OR cattle OR bison OR bisons OR sheep OR sheeps OR ovis aries OR ovine OR 
lamb OR lambs OR mouflon OR mouflons OR goat OR goats OR capra OR caprine OR chamois OR rupicapra OR 
leporidae OR lagomorpha OR lagomorph OR rabbit OR rabbits OR oryctolagus OR cuniculus OR laprine OR hares 
OR lepus OR rodentia OR rodent OR rodents OR murinae OR mouse OR mice OR mus OR musculus OR murine 
OR woodmouse OR apodemus OR rat OR rats OR rattus OR norvegicus OR guinea pig OR guinea pigs OR cavia OR 
porcellus OR hamster OR hamsters OR mesocricetus OR cricetulus OR cricetus OR gerbil OR gerbils OR jird OR 
jirds OR meriones OR unguiculatus OR jerboa OR jerboas OR jaculus OR chinchilla OR chinchillas OR beaver OR 
beavers OR castor fiber OR castor canadensis OR sciuridae OR squirrel OR squirrels OR sciurus OR chipmunk OR 
chipmunks OR marmot OR marmots OR marmota OR suslik OR susliks OR spermophilus OR
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Table S2 Specification of research topics of therapeutic trials 
Therapeutic 
category
No. of 
articles*
Studied therapies (no. of studies addressing subject*)
Pharmacologically
active peptides, 
cytokines, etc.
61 Activated protein C (2), adenosine triphosphate (1), 
adrenomedulline (1), amelogenin (1), aminoguanidine (1), 
antithrombin III (2), β-aminopropionitrile intraperitoneally 
or orally (1), β-D-glucan (5), caffeic acid phenethyl ester (3), 
CGRP (2), carnitine (1), catalase (1), coagulation factor XIII (1), 
enterosan (2), flavonoids (1), glucagon-like peptides (1), MMP 
inhibitors (AG3340 (1), BB-94 (1), AZD3342 (1), BB-1101 (1), BB-
16627 (1), GM6001 (1), kallikrein–plasmin inhibitor S-2441 (1), 
nafamostat mesylate (2), soybean trypsin inhibitor (2), TIMP (2), 
tiopronin (1), trasylol (2)), neurokinin 1 receptor antagonist (1), 
neurotensin (1), pancreatic polypeptides (1), parthenolide (1), 
pentadecapeptide BPC 157 (3), poly-L-lysine and poly-L-glutamate 
(2), prostaglandin E1 (2) and E2 (1), RGTA11 (1), ribose–cysteine 
(1), S-methylisothiourea hemisulphate (2), substance P (1), 
taurolidine (1)
Antioxidants 17 Allopurinol (6), aprotinin (4), diosmine–hesperidine (1), N-(3-
(aminomethyl)benzyl)acetamidine (1400 W) (1), superoxide 
dismutase (6)
Vasodilators 18 Bosentan (2), nitroglycerine (1), papaverine (1), perflurane (1), 
prostacyclin analogues (iloprost, 6; other, 2), sildenafil (3), talafadil 
(1), trapidil (1)
Other drugs 32 Acetylcysteine (2), amifostine (1), famotidine (1), flurbiprofen (1), 
LMWH (1), ketotifen (1), lanreotide (1), lisinopril (1), mesalamine 
(1), montelukast (1), neostigmine (2), nifedipine (2), octreotide 
(2), pentoxifylline (6), phenytoin (1), piroxicam (2), propolis (2), 
ranitidine (2), simvastatin (2), tacrolimus (1), tranexamic acid (1), 
vinpocetine (1)
cynomys OR cottonrat OR cottonrats OR sigmodon OR vole OR voles OR microtus OR myodes OR glareolus OR 
primate OR primates OR prosimian OR prosimians OR lemur OR lemurs OR lemuridae OR loris OR bush baby OR 
bush babies OR bushbaby OR bushbabies OR galago OR galagos OR anthropoidea OR anthropoids OR simian OR 
simians OR monkey OR monkeys OR marmoset OR marmosets OR callithrix OR cebuella OR tamarin OR tamarins 
OR saguinus OR leontopithecus OR squirrel monkey OR squirrel monkeys OR saimiri OR night monkey OR night 
monkeys OR owl monkey OR owl monkeys OR douroucoulis OR aotus OR spider monkey OR spider monkeys OR 
ateles OR baboon OR baboons OR papio OR rhesus monkey OR macaque OR macaca OR mulatta OR cynomolgus 
OR fascicularis OR green monkey OR green monkeys OR chlorocebus OR vervet OR vervets OR pygerythrus OR 
hominoidea OR ape OR apes OR hylobatidae OR gibbon OR gibbons OR siamang OR siamangs OR nomascus OR 
symphalangus OR hominidae OR orangutan OR orangutans OR pongo OR chimpanzee OR chimpanzees OR pan 
troglodytes OR bonobo OR bonobos OR pan paniscus OR gorilla OR gorillas OR troglodytes).ti,ab.
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Growth factors 33 EGF (enterally, 1; in gelatine sponge, 1; topically, 1), FGF-2 
(1), ghrelin (1), G-CSF systemically (1), GM-CSF local (8), IGF-
1 systemically (2), IGF intraperitoneally (3), IGF coated sutures 
(2), KGF intraperitoneally (2), KGF systemically (1), leptin 
intraperitoneally (1), PDGF (1), platelet-rich plasma (4), TGF-β 
adenovirus-mediated gene transfer (1), VEGF locally (1), VEGF/
FGF-mediated gene therapy (1)
Hormones 33 Anabolic steroids (2), dopamine (1), erythropoietin (6), oestrogen 
(1), growth hormone (18), melatonin (3), placental lactogenic 
hormone (1), progesterone (1), somatomammogenic chorionic 
hormone (1), thyroid stimulating hormone (1)
Antibiotic 
strategies
36 Amikacin (1), antibacterial sutures (4), antibiotic lavage (3), 
cephalosporins intramuscularly (1) or intraperitoneally (1), 
chlorhexidine intraperitoneally (1), doxycycline (1), imipenem 
(1), iodine irrigation (4), iodine topically (1), gentamicin (sponge, 
1; topically/with fibrin glue, 4; systemically, 2), kanamycin + 
chloramphenicol (1), kanamycin + cephalotin intramuscularly 
(1), levamisole (2), metronidazole (2), neomycin orally (2), 
noxythiolin topically (2), penicillin/streptomycin/chlorostrep 
(chloramphenicol and dihydrostreptomycin) (1), penicillin orally 
(1)
Fatty acids 12 Short-chain fatty acids (mostly butyrate) (enema, 6; orally/
intravenously, 9)
Amino acids 19 Arginine (6), branched-chain amino acid mix (1), glutamine (orally, 
intravenously or lavage) (14), glycine (1), methionine (1), other (1)
Vitamins, minerals 15 Vitamin A/retinoic acid (6), vitamin B5 (1), vitamin C (5), zinc (4)
Nutrition 14 Glucose (1), kefir (1), lactulose (1), low-residue diet (2), probiotics 
(3), whey (1), hyperalimentation (4), ketone bodies (1)
Organics 21 Algae (1), aloe vera (1), Aroeira do sertӓo (timber tree) (2), 
Brazilian pepper tree extract (Schinus terebinthifolius Raddi) 
(1), castor oil (1), copaiba oil (1), ethyl pyruvaat (2), gingko 
bilboa extract Egb 761 (2), guar gum (2), honey (3), Jatropha 
gossypiifolia L. (bellyache bush) (1), Passiflora edulis extract (1), 
proanthocyanidins (Pycnogenol®; Horphag Research, Geneva, 
Switzerland) (1), reversatrol (2), shark cartilage orally (1), oxidized 
cellulose (1)
Non-solids 31 Electromagnetic field stimulation (8), extracorporeal shockwave 
therapy (1), hyperbaric oxygen (10), hyperoxygenated 
solution lavage (1), laser stimulation (7), positively charged 
diethylaminoethyl cross-linked dextran bead particles (1), other 
oxygen supplementation (2), ozone gas (1)
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Other 27 Adipose stem cells (local injection, 1; suture coating, 2), 
Ankaferd BloodStopper® (Ankaferd Drug Inc., Istanbul, Turkey) 
(1), bone marrow-derived mesenchymal stem cells (2), 
bupivacaine intraperitoneally (1), cartilage bone marrow extract 
intramuscularly (1), chitosan (1), cholera toxin (1), interleukin 2 
(1), intraoperative lavage (2), ischaemic preconditioning (locally, 3; 
remotely, 2), methylene blue (1), pancreatic islet transplantation 
(2), peritoneal lavage (1), pyrrolidine dithiocarbamate (2), 
taurocholate (1), TNF immunization (1), WR-2721 and RibCys 
radioprotective pretreatment (1)
Technique
Suture technique 88 Number of suture layers (e.g. single versus double) (52), suture 
distance (3), suture pattern (e.g. interrupted versus continuous) 
(8), suture tension (2), suture traject (e.g. Gambee versus 
Lembert) (19), other (7)
Staplers 69 Stapling devices and techniques (39), staples versus sutures (30)
Apposition 73 Inversion versus eversion (28), invagination (24), opposition (6), 
orientation (e.g. end–end versus side–side) (16)
Suture material 34 e.g. cotton, silk, (chromic) catgut, polyglactin, polyglycolic acid, 
polydioxanone, polypropylene, ophthalmic tendons, collagen, 
stainless steel, Teflon
Other 17 Cutting with knife versus diathermy (4), laser (6) or LigaSure™ 
(Covidien, Mansfield, Massachusetts, USA) (1), microsurgical 
techniques (3), early suture removal (2), donut technique (1)
Experimental technique
Anastomotic 
devices
41 Biofragmentable ring (14), compression ring (17), magnetic rings 
(8), other (2)
Glued anastomosis 35 Cyanoacrylate (17), fibrin glue (11), other (8)
Laser anastomosis 13 Carbon dioxide laser (5), KTP laser (1), Nd : YAG laser (7), other (3)
Other 7 Facilitated by prosthesis (e.g. sucrose) (2), jejunal interposition 
(1), radiofrequency welding (2), other sutureless technique (2)
External sealing
Biological sealant 35 Amniotic membrane (3), albumin sealant (2), pericardium (2), 
collagen fleece (6), dura mater (1), gastric seromuscular flap 
(1), ileal patch (1), intestinal seromuscular flap (1), omentum 
(10), peritoneum (8), small intestinal submucosa (3), pericardial/
collagen staple buttress (2)
Glue 65 Acrylates (13), cyanoacrylate-coated sutures (1), fibrin glue (42), 
formaldehyde (1), gelatine adhesive (2), glycerinaldehyde (1), 
glycolaldehyde (1), polyethylene glycol sealant (1), polyurethane 
adhesive(2), other (5)
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Other 21 Absorbable tape (e.g. Tissuepatch™; Tissuemed, Leeds, UK) (2), 
AlloDerm® buttress (LifeCell, Bridgewater, New Jersey, USA) (3), 
Dacron mesh (1), fibrin/thrombin patch (e.g. TachoSil®; Baxter, 
Deerfield, Illinois, USA) (6), photopolymerized hydrogel (1), 
polyglactin mesh (4), polyglycolic acid mesh (2), polypropylene 
mesh (2), polyurethane foam (1), other plastic (2)
Internal sealing
All 27 Casein prosthesis (1), collagen (2), decalcified bone tube (2), fibrin 
glue (2), latex tube (5), polychlorovinyl (1), polyethylene glycol-
based (2), polyester stent (1), polyglycolic acid (2), polyurethane 
(1), porcine submucosa (1), silicone (3), sucrose (1), vinyl (1), 
other degradable stents (8)
Surgical approach
Laparoscopy 22 Laparoscopic feasibility studies (22)
NOTES 24 Transanal (20), transgastric (6), transvaginal (1) (includes pure 
NOTES or combined with laparoscopy)
Other 7 Single-incision laparoscopic surgery (5), single-incision robotic 
surgery (1), other robotic surgery (2)
Other
Feeding regimens 19 Early postoperative enteral feeding (7), fasting (1) , liquid diet (2), 
parenteral (versus enteral) feeding regimens (9), other (1)
Ostomies 12 Diverting colostomy (12)
Viability 
assessment before 
anastomosis
10 Bioimpedance measurement (1), Doppler ultrasonography (3), 
electromyography (3), fluorometry (2), intramural pH (1), pulse 
oximetry (1), visible light spectroscopy (1)
Perioperative fluid 
management
8 e.g. colloids versus crystalloids (2), autologous blood (1), human 
albumin (1), hydroxyethyl starch (4), hypertonic saline (1), lactated 
Ringer's solution (1), volumes (2)
Other 8 Bowel acidification (1), externalization of anastomosis (1), 
mechanical bowel preparation (4), splenectomy (1), subcutaneous 
anastomosis (1)
CGRP, calcitonin gene-related peptide; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of 
metalloproteinases; RGTA11, regenerating agent 11 (dextran derivative with heparin-like properties); LMWH, low 
molecular weight heparin; EGF, epidermal growth factor; FGF, fibroblast growth factor; G-CSF, granulocyte colony-
stimulating growth factor; GM-CSF;– granulocyte–macrophage colony stimulating growth factor; IGF, insulin-like 
growth factor; KGF, keratinocyte growth factor; PDGF, platelet-derived growth factor; TGF, transforming growth 
factor; VEGF, vascular endothelial growth factor; TNF, tumour necrosis factor; KTP, potassium titanyl phosphate; 
Nd : YAG, neodymium : yttrium–aluminium–garnet; NOTES, natural-orifice transluminal endoscopic surgery.
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Table S3 Specification of research topics of risk factor identification studies 
Risk factor category No. of 
articles
Studied risk factors (no. of studies addressing subject*)
Chemotherapy, 
hormonal therapy and 
other adjuvants
88 5-FU (monotherapy,25; with bleomycin + cisplatin, 5; folinic 
acid, 3; interferon α, 4; irinotecan, 1; levamisole, 1; leucovorin, 
2; mitomycin C, 1; oxaliplatin, 2), angiogenesis inhibitor FR-
118487 (1), angiostatin (2), bevacizumab (2), capecitabine (1), 
carboplatinum (1), cisplatin (6), HIPEC (3), local hyperthermia 
(1), mitomycin/doxorubicin (7), methothrexate (1), MMP 
inhibitor BB-94 (1), mycophenolate mofetil (2), oxaliplatin 
(4), paclitaxel (intravenously, 3; lavage, 1), photodynamic 
therapy (4), propranolol + etodolac (1), sirolimus (1), suramin 
(1), tamoxifen (1), thalidomide (1), tegafur (1), TNP-470 (1)
Radiotherapy 45 Chemoradiation (6), radiotherapy (preop., 34; intraop., 6; 
postop., 1)
Ischaemia 33 Ischaemia/hypoperfusion (18), transient ischaemia/
ischaemia–reperfusion injury (9), hypovolaemia (6)
Antiadhesives 37 Acetylcysteine (2), ancrod (1), bioactive polypeptides (2), 
chitosan and/or dextran (4), gelatine film (1), hyaluronic 
acid and/or carboxymethylcellulose (10), icodextrin (3), 
lornoxicam (1), mitogen-activated protein kinase-activated 
protein kinase 2 inhibitor (1), phosphatidylcholine (1), 
polyvinyl alcohol (2), PXL01 (1), Seprafilm® (Sanofi-
Aventis, Bridgewater, New Jersey, USA) (1), sunitinib (1), 
tetrachlorodecaoxide (1), tissue plasminogen activator (3), 
trasylol (3)
Immuno-
suppressants
32 Adalimumab (1), azathioprine (2), corticosteroids (18), 
everolimus/tacrolimus (9), macrophage inhibitor (1), 
montelukast (1), promethazine (1), thalidomide (1)
Infection 29 Diverticulitis (1), peritonitis or bacterial contamination (22), 
Pseudomonas aeruginosa (with enhanced virulence) (1), 
Staphylococcus aureus contamination (1), sepsis (4)
NSAIDs 18 Carprofen (2), celecoxib (1), diclofenac (6), etofenamate (1), 
flurbiprofen (1), naproxen (1), piroxicam (2), rofecoxib (1), 
tenoxicam (1), valdecoxib (2)
Other analgesics 7 Epidural (5), metamizole (1), paracetamol (1)
Co-morbidity and 
patient factors
26 Colitis (2), diabetes and/or hyperglycaemia (8), ethanol (2), 
hypercholesterolaemia (1), hypertension (1), hypothyroidism 
(2), liver cirrhosis (1), renal failure and/or uraemia (2), old age 
(7)
Prokinetics 17 Bromopride (4), cisapride (1), CPSI-2364 (1), metoclopramide 
(4), neostigmine or pyridostigmine (3), other cholinergic 
drugs (3), sennatin (1)
Nutrition 13 Essential fatty acid deficiency (1), malnutrition/protein 
deficiency (9), mineral/zinc deficiency (2), vitamin A 
deficiency (1)
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Other 70 ACTH suppletion (1), anastomotic location (high/low) 
(1), barium (1), blood presence (2), blood transfusion 
(2), buscopan (1), colostomy (3), colostomy closure (2), 
dehydration (1), extraperitoneal placement (1), faecal 
loading and obstruction (5), foreign material and drains (6), 
haemodilution + crystalloid overload (3), hyperbilirubinaemia 
(4), humidity (1), hypothermia (2), LMWH or prothrombin 
reduction (acenocoumarol) (4), laparoscopy (1), lymphostasis 
(2), malignant cells on anastomotic line (2), mechanical bowel 
preparation (1), microflora disturbance (1), negative-pressure 
therapy (1), octreotide (4), omentectomy (1), pinealectomy 
(1), pneumoperitoneum (9), polyethylene glycol/butyrate 
enema (1), portal triad occlusion (1), postoperative coloscopy 
(1), rectal manipulation (1), repeated laparotomy (1), 
simultaneous liver resection (2), splenectomy (2), statins (1), 
synchronous anastomosis (1), total colectomy (1), trauma (1)
5-FU, 5-fluorouracil; HIPEC, hyperthermic intraperitoneal chemotherapy; MMP, matrix metalloproteinase; 
NSAID, non-steroidal anti-inflammatory drug; ACTH, adrenocorticotrophic hormone; LMWH, low molecular 
weight heparin.
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Abstract
Background 
Nonsteroidal anti-inflammatory drugs have been associated with anastomotic leakage. It 
was studied if diclofenac affects anastomoses differently depending on the location in the 
gut. 
Methods
Ninety-five rats were randomized to 6 groups with an anastomosis in either ileum(IL), 
proximal colon (PC) or distal colon (DC). Groups IL+ (n=10), PC+ (n=30) and DC+ (n=10) 
received diclofenac (3mg/kg/day) from day 0 until sacrifice on day 3. Group PC- (n=15) did 
not receive diclofenac. Groups PC1+ and PC2+ (n=15 each) were given diclofenac from day 
1-4 and from day 2-5. 
Results
Leak rates were 10/10 in group IL+, 22/30 in PC+, 1/10 in DC+ and 1/15 in PC-. Delayed 
administration of diclofenac by one or two days (6/15, p=0.05) resulted in reduced leakage 
rates. Mechanical strength results corresponded with leak rates.
Conclusion
Diclofenac causes leakage of anastomoses in rat ileum and proximal colon, but not in the 
distal colon. This suggests a role for the ileal and proximal colonic content in diclofenac 
induced leakage.
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Introduction
Leakage is the most serious complication of surgeries that include the construction of 
intestinal anastomoses and is associated with a mortality between 6% and 15%. (1) Leakage 
occurs in 3% to 14% of all intestinal anastomoses, a percentage that has not significantly 
changed in the past 2 decades (1-3). Although the highest rates have been reported for the 
most distal rectal anastomoses, ileocolonic anastomoses also may leak in up to 10 percent 
of cases (4). The persistence of high leakage rates is indicative of insufficient understanding 
of leakage etiology and urges for improving knowledge of factors influencing anastomotic 
healing.
In 3 retrospective studies and a recent review of randomized clinical trials the use of 
nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with increased rates of 
anastomotic leakage(4-7). In rat studies, NSAIDs with selectivity for COX-2 (carprofen, 
diclofenac and celecoxib) have repeatedly shown to cause leakage of ileal, but not of distal 
colonic anastomoses(8-10). Despite these data NSAIDs are listed as perioperative analgesia for 
gastrointestinal surgery in present international guidelines and are recommended in fast track 
surgery11. More evidence is necessary to better understand the pathological mechanisms 
involved and, possibly, to adjust postoperative pain treatment recommendations (12, 13).
Two hypotheses for a detrimental effect of NSAIDs have been raised. First is the general 
suppressive effect of COX-2 inhibition on the principal inflammatory and proliferative 
activity in the early phase of wound healing(4, 8). Second is the formation of microthrombi by 
COX-2 inhibition inducing ischemia(5). So far, evidence supporting either hypothesis and at 
the same time explaining the difference between ileum (IL) and distal colon (DC) is lacking. 
In fact, other mechanisms than a direct effect of COX-2 inhibition on wound healing may 
play a role.
Previous studies have shown that COX-2 inhibitors cause leakage of ileal but not distal 
colonic anastomosis in rats(9, 10).  A possible explanation is that the rat DC is thicker and 
stronger than the IL and thus more resistant to leakage. However, IL and DC also differ in 
fecal content with respect to liquidity, microflora and bile acids. A good way to study the 
relevance of the gut content is to investigate the effect of NSAID on anastomotic healing of 
the proximal colon (PC), where gut morphology is more similar to the DC, but intraluminal 
content corresponds to the distal IL. This study investigates the effects of diclofenac on early 
anastomotic healing in the PC of the rat.
Material and methods
Ethics
This experiment was conducted according to the Dutch “Experiments on Animals Act” and 
European Federation of Laboratory Animal Science Associations (FELASA) guidelines and 
was approved by the institutional Animal Ethics Committee of the Radboud University. After 
the start of the experiment, the animals were inspected twice daily for signs of reduced 
wellbeing, including dirty nose, dirty eyes, piloerection, aberrant behavior, distended 
abdomen or diarrhea. Animals were weighed daily. Humane endpoints were defined to 
avoid unnecessary suffering of animals during the study period.
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Animals
Adult male Wistar rats (Harlan, Horst, The Netherlands) were accustomed to laboratory 
conditions for 1 week and weighed 309 (SD±24) g at the start of the experiment. The rats 
were housed 2 per cage at 22-23°C with a 12 hour day cycle and had free access to standard 
rodent chow (Ssniff R/M-H, Bio Services BV, Uden, Netherlands) and acidified tap water. The 
cages were enriched with a shelter and nesting material and were randomly placed on the 
shelves.
Groups
Ninety-five rats were randomly assigned to one of the 6 groups (Figure 1). Rats in group PC- 
(n=15) served as control group and were subjected to a PC anastomosis without receiving 
diclofenac. An anastomosis was made in the IL in group IL+ (positive control; n=10), in the 
DC in group DC+ (negative control; n=10), and in the PC in group PC+ (n=30), all receiving 
diclofenac for 3 days with the first dose given 15 minutes before operation. Rats in groups 
PC1+ (n=15) and PC2+ (n=15) had a PC anastomosis and also received diclofenac for three 
days but with the first dose delayed one or two days after operation, respectively.
Proximal colon + diclofenac 
Ileum + diclofenac
Distal colon + diclofenac
PC + diclofenac from day 1
Proximal colon (no diclofenac)
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5
Surgery Sacrificen=
15
30
10
15
15
10
PC + diclofenac from day 2
Group
PC-
PC+
IL+
PC2+
PC1+
DC+
Figure 1 Experimental setup. PC = proximal colon.
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Intervention and surgical technique
The rats were anesthetized by inhalation of 3% isoflurane (Abbott, Hoofddorp, The 
Netherlands) mixed with pressurized air and oxygen. They were shaved and operated under 
sterile conditions with the aid of an operation microscope at 10x magnification. 
Through a 3 cm midline laparotomy, a 1 cm resection was performed of either the IL (15cm 
proximal to the cecum), the PC (2cm from the ileocecal transition) or the DC (3 cm proximal 
to the peritoneal reflection) and continuity was restored with an inverted single layer 
anastomosis made by 8 interrupted 8-0 Ethilon (Ethicon, Norderstedt, Germany) sutures. 
Precautions were taken preventing leakage of intestinal content into the abdominal cavity. 
During the operation the intestine was covered with gauzes soaked in 0.9%NaCl to minimize 
desiccation. Body temperature was kept at 38°C with a heating pad and lamp. The abdominal 
wall was closed with a running suture (Vircryl 3-0; Ethicon, Norderstedt, Germany) and 
the skin with staples. Immediately postoperatively 10 ml of 0.9% NaCl was administered 
subcutaneously for rehydration. For analgesia buprenorphine (Schering Plough, Houten, 
The Netherlands) 0.02mg/kg was given subcutaneously every 12 hours, starting 15 minutes 
before the operation and ending 48 hours later. Diclofenac sodium (Cayman Chemical 
Company Ann Arbor, MI, USA) was dissolved in 0.1% polysorbate in saline and was given in 
a dose of 3 mg/kg/day (in 2 equal doses) by oral gavage for 3 days. 
Outcome assessment 
On postoperative day 3, animals from groups PC+, PC-, IL+ and DC+ were euthanized by 
CO2 asphyxiation. For groups PC1+ and PC2+ this was on day 4 and 5, respectively. A 
relaparotomy was performed and the anastomosis and abdomen were inspected for signs of 
anastomotic leakage. The inspection was done by 2 researchers (S.Y. and R.L.) independently 
and any differences in scores were solved by consensus. The severity of macroscopic signs 
was scored as “0” for no signs of leakage, “1” for anastomotic abscesses, “2” for free pus or 
large abscesses and “3” for fecal peritonitis or visible dehiscence.
Mechanical strength
Anastomoses of all surviving rats were tested for mechanical strength, except for 3 animals 
from the PC-, PC+, PC1+ and PC2+ groups, which were used for immunohistological analysis. 
The anastomotic bowel parts were carefully resected with 2 cm of bowel on each side and 
any scar tissue or adhesions covering the anastomosis were left in place. These segments 
were infused with water containing methylene blue at 2 mL/min to determine the strength 
of the weakest spot within the anastomosis. The maximum pressure (mmHg) just before 
the sudden loss of pressure in case of failure was recorded as “bursting pressure”. Dehiscent 
anastomoses were scored as “0 mmHg”. 
After bursting pressure measurements the segments were attached to a tensiometer and 
pulled apart at 3 cm/minute to determine the maximal suture holding capacity or breaking 
strength (Newton)14. 
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Immunohistochemistry
Anastomotic segments of approximately 1 cm were opened at the mesenterial side. After 
gentle washing with saline the samples were fixed in 4% buffered formaldehyde.  Samples 
were embedded in paraffin and subsequently cut in 4 µm sections. The samples were dewaxed 
and endogenous peroxidase activity was blocked with 3% H2O2 in phosphate buffered 
saline. Antigens were retrieved by boiling the sections in a citrate-buffered solution (pH=6). 
After preincubation with 20% normal goat serum, the sections were incubated overnight 
with a 1:1,000 dilution of COX-2 antibody (rabbit polyclonal antiserum against murine COX-
2, Cayman Chemical, An Arbor, MI, USA). Subsequently, sections were incubated with a 
1:200 dilution of goat anti-rabbit biotynilated secondary antibody. Following incubation 
with avidin–biotin complex, protein was visualized with diaminobenzidine. Sections were 
counterstained with hematoxylin.
Statistics
The required sample size was determined to detect a difference of 50% in leakage rate, 
compared with expected leakage percentages of 70% in the positive (group IL+) and 10% in 
the negative control group (group DC+)9. Anticipating an analysis with Fisher’s exact test for 
leakage rates and one-way Analysis of variance with post-hoc Tukey’s for strength measures, 
this resulted in 12 animals per group when using an α of 0.025 (Bonferoni correction for 3 
groups) and a β of 0.8.  Because 3 animals of the PC groups were used for histology, total 
numbers for groups PC-, PC1+ and PC2+ were 15 each. Because the PC+ group was used 
to compare in terms of both anastomotic location (with groups IL+ and DC+) and timing of 
administration (with groups PC-, PC1+, PC2+) we chose to double the number of animals 
in this group to 30 to provide sufficient proportional data. Aiming at reducing animals for 
experiments in general we chose to lower the number of animals in groups DC+ and IL+ to 
10, because previous experiments within our department showed very consistent leak rates 
for these anastomoses9. The spread of data is presented as standard errors of the mean. A 
P-value less than 0.05 was considered statistically significant.
Results
Animal welfare and mortality
One animal in the PC- group died on day 2 from an unknown cause, without signs of 
anastomotic leakage. Two animals in the IL+ group died on day 2 from generalized peritonitis 
caused by leakage. These rats were not used for strength testing. Fourteen rats ( IL+: 6, 
PC+: 2, PC1+: 5, PC2+: 1) were sick on day 3 as reflected by a dirty nose, dirty eyes, pillow 
erection, distended abdomen or diarrhea. None of these rats reached the humane endpoint 
necessitating premature removal from the experiment. All other rats recovered well. The 
overall average weight loss on day 3 was 9.3% (± 3.7%) without differences between groups.
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Anastomotic leakage 
One abscess was observed in the PC- group (7%). Macroscopic signs of leakage were 
present in 22 of the 30 (73%) rats with a proximal colonic anastomosis and administration 
of diclofenac from day 0 (PC+). This rate was significantly (p=0.001) higher than the 1/10 
(10%) leak rate in the DC+ group (Figure 2). All 10 anastomoses in the IL+ group leaked. 
This leak rate did not differ from the PC+ group (p=0.165), but the severity of the leak signs 
was significantly higher in the IL+ group (2.8±0.6 versus 1.7±0.5; p=0.004). Delay of the first 
administration of diclofenac by one or two days resulted in a gradual reduction in leak rates, 
10/15 (66 percent) and 6/15 (40 percent) in the PC1+ and PC2+ group, respectively. Also 
the leak severity score declined from 1.7±0.5 to 1.3±0.3 and 0.5±0.2, respectively (Figure 2).
Figure 2  Anastomotic leakage.
Bars represent average leakage rates (A and B) or leak severity score (C and D). Anastomoses 
were constructed in ileum (IL), proximal colon (PC) or distal colon (DC) and animals were 
sacrificed on day 3. Animals in the 1+/2+ groups received diclofenac from day 1 or 2 and 
were sacrificed at day 4 or 5, respectively.  * = p<0.05. ,   ̶  = without diclofenac, + = with 
diclofenac.
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Figure 3 Bursting pressure (A+B) and breaking strength (C+D) per group. Error bars represent 
SEM. *= p<0.05. 1+/2+ = diclofenac from day 1 or 2.  * = p<0.05. ,   ̶  = without diclofenac, + 
= with diclofenac. ns = nonsignificant; SEM = standard error of the mean.
 
Anastomotic strength
In one rat of the PC- group and the PC+ group it was impossible to excise the anastomotic 
segment because of extensive adhesions and peritonitis; neither was used for strength 
assessment. The bursting pressure in the PC+ group was 68±9 mmHg, in the IL+ group 
43±19 mmHg (p=0.356) and in the DC+ group 101±31 mmHg (Figure 3). Only the difference 
between the IL+ and DC+ groups was significant (p=0.023). There was no difference between 
the PC+ and PC- groups. Bursting pressure in group PC1+, sacrificed at day 4 was 113±22 
mmHg (PC+ 68±9 mmHg; p=0.065). Bursting pressure in group PC2+, sacrificed at day 5 was 
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206±11mmHg (compared with PC+: p=0.000). 
In line with the bursting pressures, the breaking strength of the PC+ group (0.50±0.06 
N) was higher than of the IL+ group (0.10±0.05 N; p=0.004), but lower than of the DC+ 
group (1.16±0.11 N; p=0.000) (Figure 3). The breaking strength of the PC+ group was not 
significantly different from the PC- group (0.68±0.08 N; p=0.459). Breaking strength of group 
PC1+  was 0.52±0.09 N (p=0.999) and of group PC2+ 1.47±0.14 (p=0.000). 
Immunohistochemistry for COX-2 
COX-2 immunoreactivity was clearly present at the anastomotic sites in the PC, independent 
of the administration of diclofenac (Figure 4). Because of the many leaking anastomoses in 
group PC+, there were insufficient representative samples to allow quantitative analyses.
Figure 4 Immunohistochemical staining for COX2 presence (dark brown; arrows) at an 
unaffected anastomosis (A; group PC-) and an ulcerative anastomosis with fecal fibers and 
necrotic debris in it (B; group PC+).
Discussion
Diclofenac compromises anastomotic healing of the PC resulting in leakage with a severity 
approximating that observed in the ileal anastomosis. The high leakage rates in the IL and 
the low rates in the DC are comparable with those found previously9, 10. Incidence of leakage 
in the PC and leak severity are lower when administration of diclofenac is delayed. The 
results from this experiment show that, in the large bowel, diclofenac only affects the healing 
of the PC anastomosis, despite the morphological and functional similarities between the 
proximal and distal colon wall. This finding, together with the similar leakage rates observed 
in proximal colonic and ileal anastomoses, suggests that the fecal content in these bowel 
parts is relevant in the mechanism leading to leakage caused by diclofenac. Two hypotheses 
may explain the role of fecal content in diclofenac-associated leakage. First, diclofenac 
affects healing similarly in proximal and distal bowel segments (eg. by COX-2 inhibition), but 
this only leads to leakage in the proximal part because of the fluidity of the fecal content. 
However, the fluidity of feces as a denominator of leakage is not in line with human data 
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where the small bowel is at a lower risk of leakage than large bowel15. Second hypothesis 
is that diclofenac directly alters the composition of the bowel content leading to a more 
hostile intraluminal environment. Two such mechanisms have been described and include 
an increase in bile toxicity and an increase in microbial virulence caused by NSAIDs16, 17. 
Because most bile products are reabsorbed or converted before reaching the DC, the IL 
and PC are exposed to different bile products compared with the DC18. Like many NSAIDs, 
diclofenac is largely excreted through bile19. Both the changed bile salt composition and 
the metabolites of NSAIDs in bile may cause small intestinal damage16, 20-22. Likewise they 
may jeopardize anastomotic healing. The difference in metabolism between celecoxib and 
carprofen on one hand, and naproxen on the other hand supports the hypothesis that altered 
bile affects healing. The first 2 drugs, which cause about 85% leakage of experimental ileal 
anastomoses, are predominantly excreted through bile 23, 24. Naproxen, causing less than 
15% leakage, is for 98% excreted via the urine in both rat and human9, 25, 26. Future studies 
should further elucidate the role of bile in NSAID induced leakage, possibly by using bile 
binding agents or bile exchange techniques.
The terminal IL and PC host a different set of microbes than the DC.27 It has been shown 
that minor changes in microbial composition and virulence may result in leakage.28, 29 
NSAID treatment can affect the gut’s microflora by reducing the number of lactobacilli 
and diclofenac was shown to increase the total number of enteral gram negative bacteria 
resulting in increased mucosal permeability.17, 30 Such alterations may differ along the gut 
and could play a role in the etiology of NSAID-induced leakage31. 
Reduced leakage rates after delayed administration of diclofenac indicate that the 
detrimental effects of NSAIDs become evident already in the early stage of healing, on the 
first and second day after operation, in the inflammatory phase of the repair sequence. 
This finding supports both the hypotheses that healing is affected by COX-2 inhibition and 
that healing is affected by altered intraluminal content, because both COX-2 inhibition and 
change in intraluminal content virulence occur very rapidly after injury17, 19. The increased 
strength of anastomoses in group PC1+ and PC2+ is explained by the later sacrifice on day 
4 and 5 respectively. In time, bursting pressure and breaking strength values increase and 
become stronger than the strengths of the intact bowel, reflected by bursting outside the 
anastomosis at day 5 and thereafter.
We studied diclofenac in a valid and reproducible animal model showing differences in a 
relevant clinical outcome, anastomotic leak. The relevance of mechanical strength tests in 
our study is debatable. Bursting pressure and breaking strength tests are the best available 
proxies for assessing healing alterations in intact anastomoses, but are confounded when 
an anastomosis leaks. Bursting pressures of an anastomosis with a moderate leak can be 
relatively high because of the surrounding adhesion formation as response to the leak. In our 
study mechanical strength data varied substantially and showed fewer differences between 
groups in comparison with the leak rate data. Because the intrinsic strength of intact IL and 
colon is different, a direct comparison of strength between various bowel parts is of limited 
value. Groups with an IL or DC anastomosis without diclofenac were not included. Thus, 
within the current experiment, the data available are insufficient to determine the specific 
quantitative effect of diclofenac on the strength of anastomoses in IL and DC.
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The majority of animal studies on anastomotic healing address healing of the DC. In this 
segment no or only limited effects of NSAIDs were found32. In this study 2 colon locations were 
used for comparison of anastomotic leakage with completely different outcomes. Because 
the choice of the intestinal segment can significantly confound experimental outcomes, 
future experiments investigating the effect of drugs or biomaterials on anastomotic healing 
should preferably encompass both the PC and DC and not automatically focus on the latter 
which is most at risk in the human situation. Moreover, the advantage of the PC is that it 
is easier to induce leakage compared with the DC, where one has to rely on strength tests.
COX-2 immunoreactivity was found in the PC anastomoses irrespective of diclofenac 
administration. In previous experiments we also found COX-2 presence in the ileal and distal 
colonic anastomoses10. This supports a role for COX-2 during healing. COX-2 is a rapidly 
upregulated enzyme that persists for several days after injury and is not downregulated, 
but blocked by diclofenac33. Therefore, it is not possible to determine local differences in 
COX-2 inhibition on the basis of analysis of COX-2 immunoreactivity. Neither can it be used 
to confirm adequate COX-2 inhibition.
Clinical implications
Two large retrospective studies have demonstrated that the use of NSAIDs increases the 
rate of anastomotic leakage4, 5. Subgroup analysis of the data from the study by Gorissen 
et al, involving primary anastomoses in 311 patients after right hemicolectomy and 322 
after left hemicolectomy revealed that NSAID use within the first 5 days increased the 
leak rate of ileocolonic anastomoses after right hemicolectomy (6.9% to 14.8%; odds ratio 
2.3(1.1 to 5.0); p=0.027) but not of colo-colonic anastomosis after left hemicolectomy (8.5% 
to 8.9%; odds ratio 1.0 (0.5 to 2.3); p=0.917)(unpublished data)4. Our findings in PC and 
IL anastomoses support an early detrimental effect of diclofenac. This adds to increasing 
evidence that caution should be taken with diclofenac as early postoperative painkiller in 
gastrointestinal surgery.
In conclusion, it was shown that diclofenac causes evident leakage of anastomoses made 
in the rat ileum and proximal colon, but not in the distal colon. This suggests a role for the 
intestinal content in the pathology of anastomotic leakage caused by diclofenac.
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Abstract
Background 
Anastomotic leakage rates remain unacceptably high, warranting reconsideration of current 
anastomotic technique. Anastomotic healing may improve by abrading the serosal surface 
of bowel ends that are invertedly anastomosed, based on the concept that serosal damage 
evokes inflammatory adherent processes. It is studied if local abrasion leads to stronger 
anastomoses and reduces leakage. 
Methods
Ninety-eight Wistar rats were allocated to six groups. Either a regular anastomosis (RA) or 
abraded anastomosis (AA) was constructed in the proximal colon. Animals were sacrificed 
at day 3 (groups RA3 and AA3, n = 2 x 17) or day 5 (groups RA5 and AA5, n = 2 x 17). Groups 
RA-Dic and AA-Dic (n = 2 x 15) received diclofenac from day 0 until sacrifice on day 3 to 
impair anastomotic healing. Outcomes were leakage, bursting pressure, breaking strength, 
adhesions and histologic appearance.
Results
Both in abraded (AA3 and AA5) and control (RA3 and RA5) groups without diclofenac 
1 of 17 anastomoses leaked (6%). Leak rate was 9 of 15 (60%) in group AA-Dic and 8 of 15 
(53%) in RA-Dic (p=1.0). The bursting pressure in group RA3 (127±44 mm Hg) was higher 
(p = 0,006) compared with group AA3 (82±34 mm Hg), breaking strength was comparable 
(p = 0.331). Mechanical strength was similar between groups RA5 and AA5. Abrasion did 
not increase mechanical strength in the diclofenac groups. Adhesion formation was not 
different between groups. Histology showed dense interserosal scar formation in abraded 
groups, compared with loose connective tissue in control anastomoses. 
Conclusion
Abrasion of serosal edges of large bowel ends invertedly anastomosed does not improve 
anastomotic strength, neither does it reduce leakage in anastomoses compromised by 
diclofenac. 
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Introduction
Despite increased knowledge of anastomotic healing, leakage rates have not declined in the 
past decades and remain between 3 and 14%(1-3). Leakage is a significant cause of increased 
morbidity and mortality after visceral surgery(4). Attempts to reduce leakage by mechanical 
stapling, external sealants (e.g. fibrin glue), biological stimulants (e.g. growth factors), 
internal conduits or various suture techniques have failed(3, 5, 6).
The current standard for constructing an end-to-end or side-to-side handsewn or stapled 
anastomosis is an inverting anastomosis(7). This means that the largest contact area of the 
two bowel parts is formed by the opposing serosal surfaces. However, the physiological 
function of the thin epithelial layer of mesothelial cells covering the serosa, is to provide a 
lubricant surface and not to adhere. Injury of the relatively large sero-serosal contact area 
might provide a way to optimize anastomotic healing. When serosa is damaged, fibrous 
attachments may form between viscera or the abdominal wall because of the inflammatory 
process(8). Serosal abrasion is the most common method to induce adhesion formation in 
experimental adhesion research(9). Also for other mesothelial tissue layers, like the parietal 
and visceral pleura, chemical injury and promotion of the inflammatory process is used to 
achieve proper adherence (e.g. treatment of relapsing pneumothorax). Several methods to 
achieve serosal abrasion and adhesion have been described. It is mostly done by sterile gauze 
rubbing, but dental brushes are also used(10). A study in dogs showed that complete removal 
of the mesothelium before making an inverted anastomosis accelerated and improved 
the healing process without an increased risk of stenosis(11). Based on pathophysiological 
principles of inflammation and wound healing, it is hypothesized that isolated injury to the 
serosal edges of connecting bowel parts may increase anastomotic strength and reduce 
leak rates by stimulating fibrous adhesions between bowel ends. In the first experiment 
of the present study the effect of serosal abrasion on anastomotic strength as the primary 
outcome was assessed. In the second experiment, it was studied if abrasion can reduce 
leakage of anastomoses compromised by diclofenac administration. A rat anastomosis 
model was used because of extensive experience with this model in our laboratory and the 
consistent findings of leak rates and strength over the years(12, 13). Previous research showed 
that the administration of diclofenac provides a reliable model to study leakage of ileal and 
proximal colon anastomoses(13-15). Diclofenac causes 60% to 100% leakage in the ileum and 
proximal colon when given from day 0 until sacrifice on day 3(13, 15).
MATERIAL & METHODS
Ethics
This experiment was conducted according to the Dutch “Experiments on Animals Act” 
and European Federation of Laboratory Animal Science Associations guidelines and was 
approved by the Institutional Animal Ethics Committee of the Central Animal Laboratory 
of the Radboud University Nijmegen (AEC-number 2012-290). Humane end points were 
defined to avoid unnecessary suffering of animals during the study.
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Animals
Adult male Wistar rats (Harlan, Horst, The Netherlands) were accustomed to laboratory 
conditions for 1 wk and weighed 307 grams (standard deviation ± 19) at the start of the 
experiment. The rats were housed two per cage at 22 C – 23 C with a 12 h day cycle and had 
free access to standard rodent chow (Ssniff R/M-H, Bio Services BV, Uden, Netherlands) and 
acidified tap water throughout the experiment. The cages were enriched with a shelter and 
nesting material and were randomly placed on the shelves.
Groups
Ninety-eight male Wistar rats were randomly allocated to one of the six groups. Either a 
regular anastomosis (RA) or an abraded anastomosis (AA) was constructed in the proximal 
colon. 
In experiment 1, animals were sacrificed at day 3 (group RA3, n=17 and group AA3, n=17) 
or at day 5 (group RA5, n=17 and group AA5, n=17). On day 3 anastomotic strength is at its 
lowest and thus most important to improve [22, 24]. Day 5 was chosen as an additional sacrifice 
day to study if the effect of abrasion needs additional time for wound healing. Postponing 
sacrifice to day 7 or longer would not be useful when assessing bursting strength because 
anastomotic strength exceeds that of normal intestine after this period(12, 13). Three animals 
per group were used for histologic analysis and fourteen animals for mechanical strength 
testing. 
In experiment 2, two groups of rats were given diclofenac (3mg/kg/day by oral gavage; 
Cayman Chemical Company Ann Arbor, MI, USA) from day 0 until sacrifice on day 3 to induce 
leakage (group RA-Dic, n=15  and group AA-Dic, n=15)(13, 15). All animals in experiment 2 
were sacrificed at day 3 because diclofenac induced leakage occurs mostly before day 3 
and postponing sacrifice would increase animal discomfort(13, 15). Twelve rats per group were 
used for anastomotic strength measurements and three for histologic analysis. 
Intervention and surgical technique
The rats were anesthetized by inhalation of 3% isoflurane (Abott, Hoofddorp, The Netherlands) 
mixed with pressurized air and oxygen. They were shaved, disinfected and operated under 
sterile conditions using an operation microscope. By a 3 cm midline laparotomy the cecum 
was visualized and carefully placed outside the abdomen in wet gauzes. Two centimeters 
distal from the cecum the place for anastomosis was determined. In the abrasion groups, the 
complete circumference of the colon was abraded over a length of 2 cm with 10 soft strokes 
of a dental brush (Oral-B 1 2 3 Indicator Medium, Kruidvat, Nijmegen, The Netherlands) to 
create a precise and superficial damage of the serosal surface (Figure 1)(10). The middle 10 
mm segment was resected, leaving 5 mm of abraded colon on both sides. In the control 
animals group a 10 mm segment was removed at the same location in the colon without 
abrasion. The end-to-end anastomoses were all constructed under a microscope (Wild M650, 
Heerbrugg, Switzerland, at x10 magnification) by a trained researcher (S.T.K.Y.) using a single 
layer of eight interrupted, inverting sutures (Ethilon 8-0, Ethicon, Norderstedt, Germany). A 
monofilament synthetic suture was chosen because it causes little inflammatory reaction, 
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it is available in 8-0 size, it has produced consistent results in previous experiments and 
rats are sacrificed before absorption is expected to play a role in de healing process(13, 16). 
The abdominal wall was closed with a running suture (Vicryl 3–0; Ethicon, Norderstedt, 
Germany) and the skin was closed with staples. During the operation body temperature 
was kept at 38 C using a heating pad and a lamp. To prevent postoperative dehydration, 
10 mL of 0.9% normal saline was administered subcutaneously. For analgesia in all groups 
buprenorphine (Temgesic, Schering Plough, Houten, the Netherlands), 0.02 mg/kg was 
administered subcutaneously every 12 h, starting at least 15 min before the operation until 
48 h postoperatively. All animals were weighed once daily and inspected twice daily for 
signs of reduced wellbeing, including dirty nose, dirty eyes, piloerection, aberrant behavior, 
distended abdomen, increased respiration activity and diarrhea.
Outcome assessment 
The rats were euthanized by CO2 asphyxiation. A relaparotomy was performed to inspect 
for signs of anastomotic leakage, defined as anastomotic abscess, pus, fecal peritonitis 
or visible dehiscence. The inspection was done by two blinded researchers (S.T.K.Y. and 
R.M.L.M.L.) and only if both agreed on the leakage aspect, this was scored accordingly. The 
leakage severity was scored as “0” for no signs of leakage, “1” for anastomotic abscesses, 
“2” for free pus or large abscesses and “3” for fecal peritonitis or visible dehiscence, as 
previously reported(15). Adhesions between the anastomosis and other viscera were scored 
as “0” if absent, as “1” if detachment was possible by light traction, as “2” if blunt dissection 
was needed or as “3” if sharp dissection was needed to detach the adhesive organ. 
Mechanical strength
Except for the samples used for histologic analysis (n=3 and n=2 per group in experiment 1 
and 2 respectively), all other anastomoses were subjected to mechanical strength testing. 
The anastomotic bowel parts were carefully resected en bloc with 2 cm of bowel on each 
side and any scar tissue or adhesions covering the anastomosis was left in place. To measure 
bursting pressure(BP), the segments were infused (2 mL/min) with water containing 
methylene blue, determining the strength of the weakest spot within the anastomosis(13)
(17). Dehiscent anastomoses were scored as “0 mm Hg”. The site of rupture was noted as 
at the anastomosis or outside the anastomosis. To determine the maximal suture holding 
capacity, the segments were attached to a tensiometer (Aikoh 500, Aikoh Engineering CO. 
LTD. Tokyo, Japan) and pulled apart at 3 cm/min(13, 18). The highest force measured before 
rupture was recorded as breaking strength (BS). 
Histology
The segments of 1 cm of normal bowel, resected at the initial operation, were collected 
to check if proper abrasion was performed. After sacrifice, 1 cm long segments containing 
the anastomosis were collected. All samples were opened at the mesenterial side. After 
gentle washing with saline the samples were fixed in 4% buffered formaldehyde before 
paraffin embedding. From these paraffin embedded samples, 4 µm sections were prepared 
and stained with hematoxylin and eosin. Sections were analyzed using a binocular light 
microscope. 
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Statistics
The required sample size for experiment 1 was determined to detect an absolute reduction 
of 30mm Hg in BP as the primary outcome. With an estimated standard deviation of 25 mm 
Hg, an α of 0.05 and β of 0.80, anticipating analysis of two groups (regular versus abraded) 
with an independent t-test, the group size was determined at 14. Adding three animals 
per group for histologic analysis of the anastomosis, group size in experiment 1 was 17. 
In experiment 2, sample size was calculated with leak rate as primary outcome. With an 
expected leak rate in the positive control between 70% and 80% and anticipating analysis 
with Fisher exact test 15 animals per group were needed to detect a risk reduction to 25%-
35%. As leakage assessment does not interfere with histologic analysis, no extra animals 
were added to these groups.
Fisher exact test was used for analyzing leak percentages and adhesion percentages. The 
two-tailed unpaired T-test was used for analysis of BP, BS, leak severity and adhesion 
severity. One-way analysis of variance was used for comparing weight loss among all groups. 
Results were considered statistically significant at P < 0.05.
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Figure 1 Anastomotic abrasion technique. Serosa is abraded by dental brush. A 10 mm 
segment is resected, leaving approximately 5mm abraded tissue on each side. These 
were then invertedly anastomosed by eight interrupted sutures. (a) schematic drawing, 
(b) intra-operative view.
Abrading
Resection
Inversion
(Lembert)
Anastomosis
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b
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Results
Animal welfare and mortality
All rats showed minor signs of discomfort during the first 2 days after surgery visible by 
a dirty nose, dirty eyes, pillow erection, distended abdomen or diarrhea. One animal in 
the AA5 group died from an unknown cause and one from the same group reached the 
humane end point and was taken out of the experiment showing severe inactivity, low 
body temperature and aberrant shape. No signs of leakage were observed in these two 
animals; they were not used for strength analysis. All rats had weight loss in the first 2 
to 3 days after surgery, but rapidly regained normal weight thereafter. The percentage 
of weight loss in group AA-Dic (6.2±2.9%) was significantly less than in the groups AA3 
(10.4±2.0%; p=0.010), AA5 (10.9±2.4%; p=0.047) and RA5 (9.9±3.5%; p=0.035), probably 
due to diclofenac administration and slight tissue edema. Differences among other groups 
were not significantly different. 
Anastomotic leakage 
In experiment 1, 1 rat in each group of 17 rats without diclofenac administration (AA3, RA3, 
AA5, and RA5) showed macroscopic signs of leakage (6%) (Table 1). In experiment 2, signs 
of leakage were present in 9 of 15 rats (60%) in the AA-Dic group and 8 of 15 rats (53%) in 
the RA-Dic group. The overall leak incidence in experiment 2 (57%) was significantly higher 
than in experiment 1 (6%; p=0.000) (Table 1). The mean leakage severity score was not 
significantly different between the AA-Dic group (1.0±0.9) and the RA-Dic group (1.2±1.2; 
p=0.740(Table 1).
 
Table 1 Anastomic leak, leakage severity and premature death in the six groups.
Outcome Group
RA3 AA3 RA5 AA5 RA-Dic AA-Dic
Rats per Group, n 17 17 17 17 15 15
Anastomotic leak, n(%) 1(6) 1(6) 1(6) 1(6) 8(53) * 9(60)*,**
Leakage severity Score  
0-3 (SEM)
0,1(0,1) 0,1(0,1) 0,1(0,1) 0,1(0,1) 1,2(0,3) 1,1(0,2)
Premature death, n 0 0 0 2 0 0
SEM = standard error of the mean.
Groups: RA3/RA5: regular anastomosis, sacrifice at day 3 or 5. AA3/AA5: abraded anastomosis, sacrifice at day 
3 or 5. RA-Dic/AA-Dic: regular or abraded anastomosis, compromised by diclofenac administration from day 0 
until sacrifice on day 3.
* P < 0.01 compared with groups without diclofenac.
** P > 0.05 compared with RA-Dic.
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Anastomotic strength
The BP in the RA3 group (127±44 mm Hg) was significantly higher (p=0,006) compared to 
the AA3 group (82±34 mm Hg, Figure 2a). There were no differences in BP between the 
groups sacrificed at day 5 (AA5, 207±71 mm Hg; RA5, 205±64 mm Hg; p=0.941). Both in 
group AA5 and RA5 5 out of 14 anastomoses burst outside the anastomotic line, all other 
anastomoses burst within this line. There were no differences in BP between the AA-Dic 
(85±28 mm Hg) and the RA-Dic (83±51 mm Hg) groups (Figure 2a).  
Abrasion did not affect BS (AA3 group, 1.0±0.3 N; RA3 group, 1.1±0.3 N; p=0.331). No 
differences were found between groups sacrificed at day 5 (AA5 group, 1.6±0.4 N; RA5 
group, 1.8±0.4; p=0.157) and between both groups of rats treated with diclofenac (AA-Dic 
group, 0.9±0.3 N; RA-Dic, 0.8±0.3 N; p=0.540) (Figure 2b). 
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Figure 2  Bursting pressure (a), breaking strength (b) and adhesion score (c) per group. Groups: 
RA3 / RA5: regular anastomosis, sacrifice at day 3 or 5. AA3 / AA5: abraded anastomosis, 
sacrifice at day 3 or 5. RA-Dic / AA-Dic: regular or abraded anastomosis, compromised by 
diclofenac administration from day 0 until sacrifice on day 3.
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Adhesions
Adhesion scores were low and not significantly different between groups AA3 and RA3 
(1.1±0.2 and 0.7±0.2; p=0.165), and between groups AA5 and RA5 (1.4±0.3 and 1.1±0.3; 
p=0.532), and groups AA-Dic and RA-Dic (0.7±0.2 and 1.1±0.2; p=0.162, Figure 2c). 
Histology
Because of one technical failure (group AA3), two dehiscent anastomoses (groups RA-Dic and 
AA-Dic) and two premature deaths (group AA5), a reduced number of anastomotic samples 
could be analyzed. Histologic analysis of the bowel pieces resected at the initial operation 
showed a moderate degree of mesothelial damage in all samples of both abraded (n=7) and 
non abraded (n=7) groups (Figure 3a-c). An intact mesothelial segment was only seen in one 
control sample (Figure 3a). The connective tissue layer beneath the mesothelium was more 
frequently injured in the abraded groups, as visible by microscopic hematomas (Figure 3c). 
In 6 out of 7 anastomotic control samples (RA3 n=3, RA5 n=3 and RA-dic n=1) the connection 
of the opposing serosal layers of both bowel parts appeared incomplete (Figure 3d, f, and 
h), whereas dense connective tissue was seen between the serosal layers in 3 out of 4 
anastomoses in the abraded groups (AA3 n=2, AA5 n=1, and AA-Dic n=1) (Figure 3e, g, i).
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a. Control b. Control c. Abraded
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Muscularis
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Control anastomoses Abraded anastomoses
d
f
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e
Resected intestinal segment
Figure 3 (next page) - Hematoxylin and eosin stained samples of resected intestinal 
segments (a-c) and anastomoses (d-i). Examples of intact mesothelium in control group (a), 
damaged mesothelium and serosa in control groups (b) and more severely damaged serosa 
in abrasion groups (c). Examples of incomplete connection of the opposing serosal layers in 
control anastomoses (d, f, h) and dense connective tissue in abraded anastomoses (e, g, i). 
Arrows indicate interserosal area.
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Discussion
The results from the present study show that surgical abrasion of the bowel serosal layer 
does not result in stronger anastomoses and does not reduce leakage rate of compromised 
anastomoses in a rat model despite histologic evidence of more dense interconnective 
tissue. The assumed benefit of serosal abrasion of bowel ends would be an increased 
adhesive and thus fibrous reaction between the two inverted serosal edges resulting in a 
stronger anastomosis. An increased response on abrasion was suggested by analysis of the 
histologic samples, in which loose connective tissue was seen between the two opposing 
serosal layers in most nonabraded anastomoses, compared with marked scar tissue in most 
abraded anastomoses. Apparently such increase in fibrous connections does not lead to 
a stronger anastomosis at two relevant time points in the process of anastomotic wound 
healing of rats(13, 15). 
Possible explanation for the findings is that the healing process of normal intestinal 
anastomoses in the rat is near optimal, and improvement is difficult to achieve and to 
assess with additional interventions. Notably, it is difficult to induce leakage in a normal 
rat anastomosis and even incomplete rat anastomoses can heal well in less than a week(19). 
On the opposite, the impairment of the healing process by administration of diclofenac 
might have been too strong to find a beneficial effect of abrasion on the leak rate in a 
compromised anastomosis. In addition, the relative contribution of scar tissue formation 
because of serosal abrasion might have been low compared with the scar formation by 
the sutures or the strength provided by the repair of the submucosal layer, which is mostly 
responsible for the anastomotic strength(20-22). Abrasion may even have delayed healing as 
indicated by lower bursting pressures after 3 days. An excessive inflammatory response and 
edema formation on injury both negatively interfere with normal healing(23, 24). Histology, 
however, did not show edema whereas fibrosis, as a product of an excessive inflammatory 
response, was present in the specimens of abraded anastomosis already at day 3.
It was expected that adhesions to other surrounding structures and organs would be more 
extensive in the intervention groups, but no difference in adhesion severity was observed. 
Notably, assessment of adhesion formation and severity is typically done after one week or 
even longer, and not after 3 or 5 days(10). Particularly adhesions at day 3 may be fibrinous 
of nature and are still susceptible for fibrinolysis by plasminogen activator in the abdominal 
cavity(25). Day 3 and 5 were chosen in this study because at these times, anastomotic healing 
disturbances are most likely to occur. Comparable adhesion formation further indicates that 
the consequences of abrasion seem limited when considering the healing processes evoked 
by the surgical resection or the suturing. From several animal studies it has been suggested 
that nonsteroidal anti-inflammatory drugs reduce abdominal adhesion formation(26, 27). 
Intraperitoneal administration of cyclooxygenase-2 inhibitors showed anti-adhesive effects 
in several animal studies(28-30). In our study we did not find a reduction of adhesions after 
diclofenac administration in the second experiment. The frequent occurrence of anastomotic 
leakage in these groups is a confounding factor when assessing adhesion formation because 
intraperitoneal infection strongly induces adhesion formation(31, 32). 
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A validated and frequently used animal model with a sufficient number of animals was used 
to assess the effects of abrasion on anastomotic strength and leakage ruling out a type 2 
error. The number of histologic samples however, was not sufficient to allow for conclusive 
interpretation. 
Potential disadvantage of the rat model is the small size of the intestine, which may have 
hampered adequate abrasion. A larger bowel size may be the reason why a beneficial effect 
of abrasion was reported in a dog study(11). Therefore, the negative results of the present 
study do not exclude a beneficial effect in humans. Another disadvantage of the small bowel 
size is the relative damage done by handling the bowel ends while creating the anastomosis. 
Though trying to avoid damage, swabs and forceps may have already induced serosal injury 
comparable with that in abraded groups, as was also observed in some histologic samples 
(Figure 3b). A possible concern regarding outcome assessment involves the diagnosis of 
leakage. The clinical definition often involves the need for reintervention, which is not 
applicable to animals(33). Taking differences in leakage definitions into account, macroscopic 
signs were scored according to severity to allow for a more accurate discrimination of the 
adverse effect on the animal. The severity score was used in a previous study in which 
mean severity scores corresponded with leak rates and strength. However, the score  was 
not statistically validated and thus should be interpreted with caution (15). To minimize 
observer bias, scoring was done by two observers in a blinded fashion. The compromised 
anastomosis model that was used is more appropriate to study healing processes compared 
with models using extensive ischemia or large suture defects, which are unrealistic in the 
clinical situation(19). Leakage was successfully induced by diclofenac administration with rates 
comparable with previously obtained results, making it a consistent model of anastomotic 
leakage(15). The increased leak rate after diclofenac administration in proximal rat colon adds 
to the increasing evidence that nonsteroidal anti-inflammatory drugs impair anastomotic 
healing(34). 
Conclusion
Abrasion of the serosal layers of large bowel ends that are invertedly anastomosed does not 
improve strength and does not reduce leak rate in a rat model of normal and compromised 
anastomotic healing. 
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Abstract
Background 
Diclofenac increases the risk of anastomotic leakage, but the underlying mechanism is 
unknown. As diclofenac is excreted largely as biliary metabolites, the aim of this study was 
to determine the effect of these metabolites on intestinal anastomoses.
Methods
This was a randomized controlled blinded experiment using 210 male Wistar rats to 
assess the effect of ‘diclofenac bile’ on the anastomotic complication score, leak rate and 
anastomotic strength following oral and parenteral administration of diclofenac. Bile duct 
and duodenal catheterization techniques were used for diversion and replacement of bile, 
and biliary diclofenac metabolites were determined.
Results
Replacement of control bile with diclofenac bile resulted in higher anastomotic complication 
scores (P = 0.006) and leakage in five of 18 animals, compared with one of 18 controls (P 
= 0.089). In turn, following oral diclofenac administration, replacement of diclofenac bile 
with control bile reduced anastomotic complications (P = 0.016). Leak rate was seven of 
15 versus 13 of 17 without replacement (P = 0.127). After intramuscular administration 
of diclofenac, the reduction in anastomotic complications was not significant when bile 
was replaced with control bile (P = 0.283), but it was significant when bile was drained 
without replacement (P = 0.025). Diclofenac metabolites in bile peaked within 2 h after 
administration. Administration of diclofenac bile resulted in nearly undetectable plasma 
levels of diclofenac (mean(s.d.) 0.01(0.01) μg/ml) after 120 min. Following oral diclofenac, 
bile replacement with control bile did not affect the plasma concentration of diclofenac 
(0.12(0.08) μg/ml versus 0.10(0.05) μg/ml with diclofenac bile; P = 0.869).
Conclusion
Altered bile composition as a result of diclofenac administration increases the ileal 
anastomotic complication rate in rats.
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Introduction
Anastomotic leakage is the leading cause of morbidity and mortality after intestinal surgery, 
with leak rates varying from 3 to 14 per cent1. Non-steroidal anti-inflammatory drugs 
(NSAIDs) have been related to increased leak rates in both animal and retrospective human 
studies2–4. This is worrisome because NSAIDs are recommended as postoperative analgesics 
in current guidelines5. Clinical evidence is not considered sufficient to ban postoperative 
use of NSAIDs, as some studies do not report adverse effects5,6. Further research is required 
to delineate the role of NSAIDs in clinical anastomotic leakage4,7.
The main mechanism by which NSAIDs are believed to jeopardize anastomotic healing is the 
cyclo-oxygenase (COX) 2 inhibitory action, which may cause suppression of inflammatory, 
proliferative or proangiogenic pathways relevant for normal wound healing2,8. An alternative 
explanation could be direct toxicity of intraluminal factors resulting from NSAID treatment 
(such as drug metabolites and bile products). This is based on a similar relationship found 
between NSAIDs and small intestinal mucosal damage9–11.
It is hypothesized that the NSAID diclofenac may display its detrimental effect on bowel 
anastomoses through altered and toxic bile composition. At least three observations support 
this hypothesis. First, NSAID-induced intestinal mucosal damage has been attributed to 
increased bile toxicity12–15. Biliary excretion of toxic drug metabolites and reduced availability 
of protective phosphatidylcholine in bile due to competitive binding by NSAID metabolites 
appear to be responsible for the bile toxicity9,12,13,16. Second, diclofenac causes leakage of 
anastomoses in the ileum and proximal colon, but not in the distal colon of the rat, which 
can be explained by the fact that most bile components are reabsorbed or converted to non-
toxic substances before reaching the distal colon17. Third, NSAIDs that are predominantly 
excreted through bile (such as diclofenac, celecoxib and carprofen) cause 80–100 per cent 
leakage of experimental ileal anastomoses, whereas naproxen, which is excreted almost 
entirely through urine in the rat and human, results in less than 15 per cent leakage18–20. In 
clinical practice, bile toxicity could pose a threat to a large number of patients, as it could 
be harmful for both small and large bowel anastomoses, considering the altered physiology 
following partial colectomy.
The aim of this study was to investigate the effect of altered bile composition induced 
by diclofenac on small bowel anastomotic healing in rats using bile drainage and bile 
replacement techniques.
Methods
The study was carried out according to the ARRIVE guidelines21. It was approved by the 
Animal Ethics Committee (AEC number 2013-171) and performed in the Central Animal 
Laboratory of Radboud University.
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Animals
In total, 210 adult male Wistar rats (mean(s.d.) weight 313(25) g; Harlan, Horst, The Neth-
erlands) were used (138 to assess anastomotic healing and 72 to donate bile). The animals 
were acclimatized to laboratory conditions and initially housed, two per cage, at 22–23°C 
with a 12-h day cycle, and free access to standard rodent chow (Ssniff® R/M-H; Bio Services, 
Uden, The Netherlands) and acidified tap water throughout the experiment. The cages were 
enriched with a rat retreat and nesting material, and were placed randomly on the shelves. 
All animals were checked at least twice daily. Humane endpoints were defined; animals 
were killed if they showed signs of severe discomfort (such as weight loss greater than 20 
per cent, distended abdomen or severely reduced activity).
Materials
Diclofenac sodium (DCF) (Cayman Chemical, Ann Arbor, Michigan, USA) dissolved in 0.1 per 
cent polysorbate in saline (sodium chloride 0.9 per cent) was used for administration by 
oral gavage, and as a standard for high-performance liquid chromatography (HPLC) and liq-
uid chromatography–mass spectrometry (LC–MS) analyses. DCF injection fluid (25 mg/ml; 
Centrafarm, Etten-Leur, The Netherlands) diluted with saline to 3.33 mg/ml was used for in-
tramuscular injections. 4-Hydroxydiclofenac (4OH-DCF) and 5-hydroxydiclofenac (5OH-DCF) 
(Toronto Research Chemicals, Toronto, Ontario, Canada), and diclofenac acyl-β-glucuronide 
(DAG) (LGC Standards, Wesel, Germany) were used as standards for LC–MS analyses, and 
diclofenac-d
4
 (phenyl-d
4
-acetic) (J. H. Ritmeester, Nieuwegein, The Netherlands) was used 
as an internal standard for bile and plasma.
Study design
The study consisted of three experiments (Table 1). A distal ileum anastomosis model was 
used in all experiments and rats had surgery on day 0; anastomotic healing was assessed 
after killing on day 317. This interval was used because most diclofenac-induced leakage 
occurs before day 3, when the anastomosis is at its weakest, and postponing killing would 
increase suffering20. Rats received 1.5 mg/kg diclofenac twice daily either orally (O+) or 
intramuscularly (IM+), or they received no oral or intramuscular diclofenac (O− or IM−). 
Cannulation of the common bile duct (CBD) and the duodenum was performed to drain and 
infuse bile respectively (Fig. 1). Allocation to groups was done randomly by using the online 
tool at www.randomization.com.
In experiment 1, 72 rats were allocated to four groups of 18 each, and 72 rats were used as 
matched bile donors. In group O−B−, no diclofenac was administered and bile was drained 
and replaced by control bile from matched donor rats. In group O−B+ rats, the bile was 
replaced by ‘diclofenac bile’ from donor rats that had also received 1.5 mg/kg diclofenac 
orally twice daily for 3 days. Rats in group O+B− were administered diclofenac orally, and 
their bile was replaced with control bile17. Rats in group O+B+ were given diclofenac orally 
and received diclofenac bile from donors.
In experiments 2 and 3, a parenteral route of diclofenac administration was used to explore 
the effect of avoiding exposure of the gut to drug molecules as a direct result of oral admin-
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istration13,14. In experiment 2, 42 rats were allocated to three groups. Rats in group IM+B= (n 
= 18) received diclofenac intramuscularly, and no cannulations of the bile duct or duodenum 
were done. In groups IM+B0 and IM−B0 (n = 12 animals each), bile was drained completely 
without replacing it to prevent diclofenac metabolites and bile salts from entering the gut. 
In experiment 3, rats were given diclofenac intramuscularly and either received their own 
diclofenac bile (group IM+B+; n = 12) or bile was replaced with control bile from donor rats 
(group IM+B−; n = 12).
Table 1 Experimental setup and groups
Group name
No. in 
group*
Diclofenac 
administration Bile drainage and replacement
Experiment 1
O−B− 18 None Bile drained and replaced by ‘control bile’ from donor rats
O−B+ 18 None Bile drained and replaced by ‘diclofenac bile’ from donor rats
O+B− 151,2,3 Oral Bile drained and replaced by ‘control bile’ from donor rats
O+B+ 173 Oral Bile drained and replaced by ‘diclofenac bile’ from donor rats
Experiment 2
IM+B= 18 Intramuscular No bile drainage or reinfusion
IM+B0 12 Intramuscular Bile drained; no bile reinfused
IM−B0 114 None Bile drained; no bile reinfused
Experiment 3
IM+B+ 12 Intramuscular Bile drained and reinfused instantly (rat receives its own bile)
IM+B− 104,5 Intramuscular Bile replaced with ‘control bile’ from donors
*Each superscript number denotes an animal that died during or just after operation. These were not included 
in the statistical analysis. Causes of death were:  intraoperative bleeding of portal vein; 2anaesthetic overdose; 
3catheter displacement; 4unknown cause; 5failure of bile duct cannulation. O, oral; IM, intramuscular; +, with 
diclofenac; −, without diclofenac; 0, bile drained and not returned.
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Figure  1 Schematic illustration of the experimental model used in experiments 1 and 3. 
In experiment 2, in groups IM+B0 and IM−B0, no bile was reinfused. IM, intramuscular; +, 
with diclofenac; −, without diclofenac; B0, bile drained and not returned
Operative procedures
All operations were done by two experienced researchers. For analgesia, 0.02 mg/
kg buprenorphine (Temgesic®; Schering-Plough, Houten, The Netherlands) was given 
subcutaneously every 12 h, starting 1 h before the operation until 48 h afterwards. No 
antibiotics were given and animals were not fasted. Anaesthesia was with isoflurane 
(Abbott, Hoofddrop, The Netherlands), 5 per cent for induction and 2.5–3.5 per cent for 
maintenance, in a 1 : 1 mixture of oxygen and pressurized air. Rats were prepared by 
shaving, skin disinfection with iodine and sterile covers, and then operated on through a 
4–5-cm midline laparotomy using strict aseptic technique under a microscope (Wild M650; 
Wild Heerbrugg, Gais, Switzerland) at 10–16× magnification). Body temperature was kept at 
38°C with a heating pad and lamp.
The procedures started with cannulation of the CBD to drain bile and placement of a 
catheter in the duodenum to readminister bile, if applicable. This was followed by 
construction of the bowel anastomosis. The laparotomy wound was closed with a running 
suture, 3/0 Vicryl® (Ethicon, Amersfoort, The Netherlands) for the fascia and staples for the 
skin.
Bile drainage and infusion techniques
The CBD was ligated with 7/0 silk (Pearsalls, Taunton, UK) just before it enters the tail 
of the pancreas, and a V-shaped hole was made in the duct with iridectomy scissors 
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proximal to the ligation. A custom-made 3-Fr polyurethane cannula (BTPU-040; Instech 
Laboratories, Plymouth Meeting, Pennsylvania, USA), 20 cm in length, and a silicone ring 
(BTSIL-047; Instech Laboratories) at 7 and 50 mm from the sharpened tip, was inserted 
into the bile duct and fixed with 7-0 silk proximal and distal to the silicon ring at 7 mm. A 
similar, but blunt, cannula was inserted through a purse-string suture (6/0 Vicryl®; Ethicon, 
Norderstedt, Germany) in the duodenum. Cannulas were fixed to the abdominal wall 
(6/0 Vicryl®), tunnelled through the rectus muscle and subcutaneously towards the back 
between the scapulas, and then connected to a harness (VAHD95AB or VAHD115AB; Instech 
Laboratories). In turn, the harness was connected to a tether and swivel system 
(VAH95T+375/22PS or VAHD115T+375/D/22 with BTCOEX-22 tubing; Instech Laboratories), 
through which the bile was transferred to 50-ml tubes in a cooled (0–10°C) polystyrene box. 
When attached to the swivel, rats were still able to move within the entire cage and use 
nesting material.
In experiment 1, the tube with donor bile was changed twice daily and kept at 4°C until 
reinfusion the next day. Because the donor rats in experiment 1 also provided the control 
bile for experiment 3, and this experiment was conducted later, the bile was kept at −80°C 
until reinfusion. Because it involved control bile, there was no concern for loss of toxicity. 
Bile was infused into the duodenal cannula at room temperature (22–23°C) using a 20-ml 
syringe and an infusion pump (IVAC Medical Systems, San Diego, California, USA) at a rate 
of 0.7–1.0 ml/h.
Intestinal anastomosis
Anastomoses were created as described previously17. Briefly, 1 cm of ileum was resected 
at 15 cm proximal to the caecum. An inverted anastomosis was made with a single layer of 
eight interrupted (Lembert) sutures (8/0 Ethilon®; Ethicon, Norderstedt, Germany). After 
operation, rats were housed individually because they were attached to the swivel system.
Assessment of outcome
Animals were killed by asphyxiation with a mixture of 95 per cent carbon dioxide and 
5 per cent oxygen, and thereafter 100 per cent carbon dioxide (donor rats), or by 
cardiac or inferior vena cava puncture combined with cervical dislocation under general 
anaesthesia with isoflurane (experimental rats). A relaparotomy was done and the 
anastomosis was inspected macroscopically for anastomotic complications by a researcher 
blinded to the group randomization.
Signs were graded according to the anastomotic complication score: 0, no abnormality; 1, 
small (less than 2 mm) anastomotic abscess; 2, free pus or large abscess; 3, faecal peritonitis 
or visible dehiscence17. Grade 2 or 3 was considered an overt anastomotic leak.
Bursting pressure and breaking strength were assessed as described previously17. 
Briefly, bursting pressure (mmHg) was determined by infusing anastomotic segments with blue 
fluid and measuring the maximum pressure sustained before leakage occurred. 
Subsequently, segments were pulled apart with a tensiometer and the highest force 
measured before rupture was recorded as breaking strength (newtons).
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Analysis of diclofenac excretion profile in bile
To determine whether and when diclofenac products are found in bile, bile samples from 
four donor rats were obtained fractionally every hour after a single dose of diclofenac 
1.5 mg/kg orally and analysed by HPLC; for methods used see Appendix S1 (supporting 
information).
Quantitation of diclofenac metabolites in bile and plasma
Bile samples were obtained as described above and analysed by LC–MS/MS to 
determine which diclofenac metabolites were most abundant, and when. Plasma samples were 
collected in experiment 1 to assess whether bile replacement with either diclofenac bile 
or control bile influenced plasma concentrations through the enterohepatic circulation. 
Samples of 1 ml were drawn from the tail vein on postoperative day 2, either at 60, 90 or 120 
min after diclofenac administration. Any change in plasma level was expected to occur after 
60 min, based on biliary excretion time. For a description of methods used, see Appendix S1 
(supporting information).
Statistical analysis
Sample size was determined with expected leak rates of 70–80 per cent in groups 
receiving diclofenac bile and 10–20 per cent in groups receiving control bile or no bile17. 
Anticipating analysis of leak rates with Fisher’s exact test, and anticipating a larger loss to 
follow-up in the first experiment, 18 animals per group were used in experiment 1 and in 
group IM+B= of experiment 2, and 12 animals in other groups. Absolute leak rates, and not 
anastomotic complication scores, were used because this facilitates better sample size 
calculations. Mann–Whitney U test was used to compare complication scores, and an 
independent t test to compare strength. Spread of data is presented as the standard 
deviation. P < 0.050 was considered statistically significant. Statistical analysis was 
with IBM SPSS® Statistics version 22 (IBM, Armonk, New York, USA).
 
Results
Animal mortality and welfare
One rat in group O+B+ and two in IM+B+ were killed before day 3 because of severe 
illness due to peritonitis (humane endpoint). Other rats had a normal postoperative 
recovery or had signs of illness starting on day 3, just before killing. Six rats (3 in group O−B−, 
2 in group O+B−, and 1 in group O+B+) had to be anaesthetized to relieve cannula obstruction by 
manipulating the subcutaneous part of the catheter (leakage occurred in the 2 rats in 
group O+B−). Two rats (1 in group O−B− and 1 donor rat) required a relaparotomy to relieve 
intra-abdominal cannula kinking.
Postoperative weight loss in experiment 1 was comparable between groups (mean(s.d.) 
9.8(2.8) per cent). In experiment 2, weight loss was significantly higher in groups where 
bile was not replaced (IM+B0: 13.7(4.4) per cent; IM-B0: 14.8(3.0) per cent) compared with 
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loss in group IM+B=, where bile was replaced (10.0(2.6) per cent; P = 0.007 and P < 0.001 
respectively). In experiment 3, weight loss was higher in group IM+B− than in group IM+B+ 
(14.6(2.7) versus 8.3(3.0) per cent respectively; P < 0.001).
Anastomotic complication score and leak rate
In experiments 1, 2 and 3, anastomotic complication scores were the highest in ‘diclofenac 
bile’ groups (O−B+ versus O−B−, P = 0.006; O+B+ versus O+B−, P = 0.016; IM+B= versus 
IM+B0, P = 0.025; IM+B+ versus IM+B−, P = 0.283) (Fig. 2a). Grades 2 and 3, which were 
considered leakage, occurred in five of 18 animals (28 per cent) after administration of 
diclofenac bile (O−B+), compared with one of 18 (6 per cent) with control bile (O−B−) (P 
= 0.089). Most leakage occurred in groups receiving oral or intramuscular diclofenac 
combined with diclofenac bile: 13 of 17 animals (76 per cent) in group O+B+ versus seven 
of 15 (47 per cent) in group O+B− (P = 0.127); 12 of 18 (67 per cent) in group IM+B= versus 
three of 12 (25 per cent) in group IM+B0 (P = 0.060); and six of 12 (50 per cent) in group 
IM+B+ versus two of ten (20 per cent) in group IM+B− (P = 0.117) (Fig. 2b). No leakage 
occurred in group IM−B0 (P = 0.122 versus IM+B0; P = 0.001 versus IM+B=).
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Figure 2 Anastomotic healing assessed by: a anastomotic complication scores, b anastomot-
ic leakage, c bursting pressure (n = 5 in group IM+B+, n = 4 in group IM+B−, due to sensor 
failure) and d breaking strength. O, oral; IM, intramuscular; +, with diclofenac; −, without 
diclofenac; 0, bile drained and not returned. *P < 0.050 (Mann–Whitney U test); †P < 0.050 
(independent t test). [Ileum anastomosis without diclofenac administration or bile duct can-
nulation have normal healing without signs of leakage] 
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Anastomotic strength
Bursting pressures corresponded with leak rates; values tended to be lower in groups 
with higher leak rates in experiments 1 and 3 (Fig. 2c). In experiments 1 and 2, breaking 
strength was the highest in groups that received neither oral or intramuscular diclofenac nor 
diclofenac bile, with no significant differences (Fig. 2d). A significant difference was 
observed between group IM+B= and group IM+B0 (mean(s.d.) 0.17(0.09) versus 0.31(0.15) 
N respectively; P = 0.006).
Diclofenac excretion profile in bile
HPLC analysis revealed that diclofenac was detected in bile 1 h after oral administration, 
that levels peaked within 2 h, and that diclofenac remained detectable in bile at least 6 h 
after administration (Fig. 3a).
Bile production and analysis of diclofenac metabolites in bile
In the donor groups, bile production was comparable at a mean(s.d.) rate of 14.9(2.4) ml/
day in control rats and 14.6(2.0) ml/day in diclofenac rats (P = 0.317). DAG was the most 
abundant metabolite in bile pooled over 2–8 h after oral administration (Fig. 3b). Diclofenac 
metabolites were detected almost immediately after intramuscular administration, and 
levels of DAG, DCF and 4OH-DCF peaked around 2 h after administration (Fig. 3c).
Analysis of diclofenac metabolites in plasma
Administration of ‘diclofenac bile’ in group O−B+ resulted in low mean(s.d.) plasma levels of 
DCF (0.01(0.01) μg/ml), 4OH-DCF (0.01(0.01) μg/ml) and 5OH-DCF (0.02(0.02) μg/ml) after 
120 min. 5OH-DCF was the most prominent metabolite found in plasma samples, with levels 
of 0.35(0.05) μg/ml in groups O+B− and O+B+ at 90 min, followed by DCF (0.26(0.02) μg/ml) 
and 4OH-DCF (0.10(0.01) μg/ml). DAG was not detected.
The plasma DCF level in group O+B− at 120 min was comparable to that of group O+B+ 
(0.12(0.08) versus 0.10(0.05) µg/ml respectively; P = 0.869). The total concentration of DCF 
and metabolites combined is displayed in Fig. 3d.
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Figure 3a High-performance liquid chromatogram (HPLC) of hourly bile samples showing 
peak diclofenac levels within 1–2 h after oral administration (AU – arbitrary units): a, control 
bile with  diclofenac sodium (DCF) 0.5mg/ml added; b, mobile phase with DCF 50ug/ml; c, 
0–1 h after administration; d, 1–2 h; e, 2–3 h; f, 3–4 h; g, 4–5 h; h, 5–6 h; i, control. b Liquid 
chromatography–mass spectrometry (LC–MS) or MS analysis of diclofenac metabolites in 
‘diclofenac bile’ pooled over 2–8 h after oral administration (n = 9), showing diclofenac 
acyl-β-glucuronide (DAG) to be most abundant. c Quantitative LC–MS/MS analysis of 
metabolites in bile after intramuscular (i.m.) administration, showing DCF and DAG to be 
most abundant, and concentrations peaking at around 2 h (n = 2–6 per time point). d LC–MS/
MS-detected plasma levels of DCF, 4-hydroxydiclofenac (4OH-DCF) and 5-hydroxydiclofenac 
(5OH-DCF) combined, in samples from groups in experiment 1, showing that administration 
of diclofenac bile results in minimal plasma concentrations in group O−B+ and no discernible 
difference between O+B− and O+B+, with concentrations again dropping after 90 min; DAG 
could not be detected in plasma (n = 1–6)
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Discussion
This study has demonstrated that increased bile toxicity due to diclofenac administration 
results in more anastomotic complications in rats. Replacing normal bile with ‘diclofenac bile’ 
disturbed anastomotic healing and, in turn, replacement of diclofenac bile with control bile 
reduced signs of anastomotic leakage following administration of diclofenac. It is suggested 
that the increase in bile toxicity is caused by biliary excretion of diclofenac metabolites and 
the subsequent increase of enteral drug and metabolite concentrations.
The composition of bile was shown to be altered rapidly by the presence of diclofenac 
metabolites after both oral and intramuscular administration. The metabolites, DAG and 
unconjugated DCF in particular, rapidly enter the gut via biliary excretion, regardless of 
the route of administration. It is hypothesized that these intraluminal molecules disturb 
anastomotic healing. In the present study, this was supported by the slightly higher leak rates 
in oral diclofenac groups compared with those in groups with intramuscular administration.
That altered bile composition and intraluminal drug molecules are detrimental in small 
bowel anastomosis corresponds with earlier findings17, where diclofenac caused leakage 
of anastomosis in the rat ileum and proximal colon, but not in the distal colon. Bile and 
drug concentrations are considerably lower in the distal colon and are known to cause most 
mucosal damage in the terminal ileum13. Furthermore, sustained release forms of diclofenac 
with absorption in more distal intestinal segments appear to divert the mucosal damage 
from the small to the large intestine22. Other studies10,12,13 of NSAID-induced enteropathy 
have also attributed the damage to topical effects of drug molecules. Possible underlying 
mechanisms involve reuptake of active diclofenac molecules, initially causing mitochondrial 
injury and cell death, and, subsequently, initiation of an excessive inflammatory response 
by activation of Toll-like receptor 4 on macrophages11,14,23. Another possibility is that the 
diclofenac molecules suppress secretion of mucus, making the anastomosis more vulnerable 
to leakage, as was recently suggested by Bosmans and colleagues24. Although diclofenac 
is excreted largely as DAG, this metabolite is reactivated by bacterial glucuronidase in the 
terminal ileum, where it can cause mucosal damage12,25. In the present study, the acyl-
glucuronide metabolite (DAG) was also abundant in bile. Reactivation of this metabolite in 
the gut together with biliary excretion of unconjugated forms of diclofenac may lead to high 
enteral accumulation of potentially harmful drug molecules, which may jeopardize healing 
from the luminal side of the anastomosis17,25.
The finding that healing was still disturbed when diclofenac was administered via the 
parenteral route and bile was either diverted or replaced by control bile may suggest a 
systemic role for diclofenac in causing anastomotic leakage. COX-2 inhibition is considered 
the main feature of systemic diclofenac activity, and could affect essential inflammatory 
and proliferative pathways8,26. Administration of ‘diclofenac bile’ had little impact on plasma 
levels of diclofenac through the enterohepatic circulation; thus the effect of diclofenac bile 
could not be explained by more potent systemic activity.
A valid model was used to study comprehensively the effect of diclofenac and bile composition 
on the most clinically relevant outcome: anastomotic complications. Comparison of leak 
severity showed significant differences; comparison of absolute leak rates did not. However, 
leak rate trends pointed in the same direction. Scoring leakage according to severity and 
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clinical consequences is currently advised in literature27. The lack of significance may have 
been the result of a slightly smaller effect size than expected from previous studies; the 
greatest difference was 42 per cent, compared with 50 per cent expected.
The daily amount of bile produced in rats of about 12–16 ml is comparable to the amount 
in humans of 250–1000 ml per day when adjusted for body surface area. Biliary excretion 
of diclofenac is poorly studied in humans and depends on genetic polymorphisms in drug 
metabolism, but is reported to be somewhat lower in humans than in rats28. After oral 
administration (the preferred prescription form of diclofenac) and excretion in bile, total 
diclofenac concentrations could reach comparable levels in the human gut for anastomotic 
injury.
Bile toxicity would have most effect on anastomoses that comprise the terminal ileum, where 
bile is reabsorbed and concentrations are higher, compared with large bowel anastomoses. 
However, considering the physiological changes that occur following partial or subtotal 
colectomy, bile toxicity could be comparably relevant for colorectal anastomoses. Clinical 
cohort studies2–4,8 reporting an increased risk of leakage following NSAID administration 
involved both ileocolic and colorectal anastomoses.
The relevance of the properties of bile and possibly intraluminal drug concentrations 
in relation to anastomotic healing is a novel perspective on leakage pathophysiology, 
and underlying mechanisms should be further elucidated. Current evidence provided by 
retrospective clinical studies and animal models makes it ethically controversial to study 
NSAIDs in a prospective randomized trial29, and experimental studies are suggested to clarify 
further the role of intraluminal diclofenac metabolite concentrations, the influence of bile 
salts, and the role of other drug metabolites, such as those of ketorolac and ibuprofen, in 
leakage pathophysiology.
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Abstract
Background 
The nonsteroidal anti-inflammatory drug diclofenac has been associated with intestinal 
anastomotic leakage, although the underlying pathophysiology is unclear. Previous data 
suggest that reactivation of biliary diclofenac metabolites by microbial β-glucuronidases 
in the gut plays a role in harming the intestinal mucosa, and that microbiome-targeted 
glucuronidase inhibition prevents this damage. Here, the microbial glucuronidase inhibitor 
‘Inh1’ was examined for its ability to reduce diclofenac-induced anastomotic leakage in rats.
Methods
90 male Wistar rats were allocated to five groups. In the two diclofenac groups, group DCF 
received diclofenac (3mg/kg/day) and group DCF-Inh1 additionally received 800ug/kg/d 
of glucuronidase inhibitor Inh1 solution orally. In non-diclofenac groups, animals received 
either Inh1 (800ug/kg/d; group Inh1) solution, the vehicle (methylcellulose; group Veh) or 
no solution (group Ctrl). All solutions were provided from the day of surgery until sacrifice 
on day three. Plasma levels of diclofenac were determined. Outcomes were anastomotic 
leakage, leak severity and anastomotic strength.
Results
Anastomotic leak rates were 89% in group DCF and 44% in group DCF-Inh1 (p=0.006). Leak 
severity was reduced in group DCFic-Inh1 (p=0.029). In non-diclofenac cohorts mostly 
minor leakage signs were observed in 25% in group Ctrl, 39% in group Inh1 (0.477), and 
24% in group Veh (p=1.000). Bursting pressure and breaking strength were not significantly 
different. Plasma levels of diclofenac were not changed by Inh1.
Conclusion
Microbial glucuronidase inhibitor reduces diclofenac-induced anastomotic leakage severity, 
which suggests a harmful effect of diclofenac metabolite reactivation in the gut. This finding 
improves the understanding of the pathogenesis of anastomotic leakage.
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Introduction
The main cause of severe morbidity and increased mortality following intestinal and colorectal 
surgery is leakage of the anastomosis.1 Perioperative use of nonsteroidal anti-inflammatory 
drugs (NSAIDs) has been identified as a risk factor for leakage in multiple preclinical and 
retrospective clinical studies.2-4 Current evidence, however, is considered insufficient or 
too ambiguous to discourage postoperative NSAID use.5-7 To better understand the role 
of NSAIDs and possibly other drugs in surgical outcomes, more fundamental research is 
needed to understand how NSAIDs, such as diclofenac, affect anastomotic healing.6, 8 
Diclofenac is largely excreted through bile and we previously demonstrated that alterations 
in bile composition disturb healing of anastomoses (unpublished data).9 This finding shows 
similarities with results of studies on NSAID induced enteropathy.9-15 A wide range of 
compounds, including NSAIDs such as diclofenac, are detoxified by addition of glucuronic 
acid moieties by liver-resident UDP-glucuronosyltransferase (UGT) enzymes, and excreted 
through bile. In the gut the glucuronic acids are enzymatically cleaved from drug conjugates 
by microbial ß-glucuronidase. These reactivated previously detoxified conjugates damage 
the intestinal epithelium, and, in the case of NSAIDs, results in enteropathy and mucosal 
damage. 16-18 We have previously demonstrated that inhibiting bacterial ß-glucuronidase 
using potent, bacteria-selective, non-lethal inhibitors protects the intestinal mucosa from 
damage resulting from the anticancer drug CPT-11, which is also excreted as a glucuronide.19 
In subsequent studies, we have applied this inhibitor, termed Inhibitor 1 (Inh1), in a model 
of NSAID-induced enteropathy.18 By co-adminstering Inh1 with an ulcerogenic dose of 
diclofenac, we found that Inh1 reduces the multiplicity and area of small intestinal ulcers, 
reduces epithelial permeability and decreases systemic levels of serum alkaline phosphatase, 
a widely-accepted biomarker of enteropathy.20 Notably, pharmacokinetics of diclofenac 
remained unchanged, indicating the analgesic benefit of the compound is not affected by 
Inh1 treatment. Similar results were observed with ketoprofen and indomethacin.16, 17
We hypothesize that toxic aglycones released by reactivation of drug conjugates, such 
as diclofenac-acyl-glucuronide in the gut, impairs anastomotic integrity (Figure 1). In the 
present study this is investigated by inhibiting β-glucuronidase in a validated rat model for 
diclofenac-induced anastomotic leakage (AL).10
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Figure 1 Following glucuronidation of DCF in the liver, DAG enters the gut through biliary 
excretion. In the gut (terminal ileum) DAG is either cleaved by bacterial glucuronidase, 
resulting in reactivation of the metabolite which is thought to injure the bowel wall and 
anastomosis (arrow 1). Or, inhibition of enzymatic hydrolysis by Inh-1 preserves the DAG 
metabolite which can be safely excreted through the feces (arrow 2). DCF, diclofenac; DAG, 
diclofenac-acyl-glucuronide; UGT2B7, uridine diphosphate glucuronosyltransferase 2B7; 
AG, acyl-glucuronide (UDPGA, uridine diphosphate glucuronic acid); Inh1, inhibitor 1.
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Methods
Ethics
This experiment was done according to the EU Directive 2010/63/EU and European 
Federation of Laboratory Animal Science Associations guidelines, and was approved by the 
Animal Ethics Committee, and executed in the Central Animal Laboratory, of the Radboud 
university medical center (AEC-number 2013-200).
Animals and perioperative care
Ninety adult male Wistar rats (weight 299 ± 24 gram; Harlan, Horst, Netherlands ) were used. 
The rats were accustomed to laboratory conditions and housed two per cage at 22-23°C 
with a 12-hour day cycle. They had free access to standard rodent chow (Ssniff Bio Services, 
Uden, Netherlands) and water throughout the experiment. The cages were enriched with 
a rat retreat and sizzle nest and were randomly placed on the shelves. All animals were 
checked at least twice daily. Humane endpoints were defined; animals were killed if they 
showed signs of severe discomfort (e.g. weight loss > 20% or severely reduced activity). 
Materials
Diclofenac sodium injection fluid (Centrafarm, Etten-Leur, The Netherlands) dissolved in 
saline to 3.33mg/ml was used for intramuscular injections. The β-glucuronidase-inhibitor 
Inh1 was obtained as previously described.19 It was first dissolved in DMSO (20mg/ml) and 
further in 0.5% methylcellulose (SigmaAldrich, St.Louis, Missouri, USA) in saline to a final 
concentration of 200ug/ml. Inh1 was administered 800ug/kg/d by oral gavage in two doses. 
Solution vehicle was methylcellulose (SigmaAldrich, St.Louis, Missouri, USA). Diclofenac 
sodium (Cayman Chemical Company Ann Arbor, MI, USA) and 4-hydoxydiclofenac and 
5-hydroxydiclofenac (Toronto Research Chemicals, Canada), and diclofenac-acyl-β-
glucuronide (LGC standards GMBH, Wesel, Germany) were used as standards for liquid 
chromatography mass spectrometry (LC-MS/MS) analyses and diclofenac-d
4
 (phenyl-d
4
-
acetic) (JH Ritmeester, Nieuwegein, The Netherlands) was used as an internal standard of 
bile and plasma.
Study design
Animals were randomly allocated to two diclofenac groups and three non-diclofenac groups 
of 18 animals each by using www.randomization.com. Group DCF received diclofenac 
(1.5 mg/kg twice daily) intramuscularly. The dose was based on the recommended daily 
dose in human (3mg/kg/day) and on previous experiments.10 Group DCF-Inh1 additionally 
received Inh1 (800ug/kg/d). In the non-diclofenac groups, animals received only Inh1 
(800ug/kg/d) in group Inh1, vehicle (methylcellulose, 0.5ml orally twice daily) in group 
Veh or no solution in group Ctrl. All solutions were given orally twice daily from the day 
of surgery until sacrifice on day three. This period was used because diclofenac induced 
leakage mostly occurs before day 3, when the anastomosis is at its weakest, and postponing 
sacrifice would increase suffering.10, 21 
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Operative procedures
In random order, all animals were subjected to the following operation, which was done 
by experienced researchers (S.Y. or R.L.) blinded to group allocation. For analgesia 0.02mg/
kg buprenorphine (Temgesic; Schering Plough, Houten, the Netherlands) was given 
subcutaneously every 12 hours, starting approximately 1 hour before the operation until 48 
hours post-operatively. No antibiotics were given and animals were not fasted. Anesthesia 
was 5% (induction) or 2,5-3,5% (maintenance) with isoflurane (Abott, Hoofddrop, The 
Netherlands) in a 1:1 mixture of oxygen and pressurized air. Rats were shaved, iodized, 
draped with sterile covers and then operated through a 4-5 cm midline laparotomy using 
strict aseptic techniques under a microscope (Wild M650; Heerbrugg, Switzerland, at 10-
16x magnification). Body temperature was kept at 38°C with heating pad and lamp. One 
centimeter of ileum was resected at 15cm proximal to the cecum. Subsequently an inverted 
anastomosis was made with a single layer of 8 interrupted inverted (Lembert) Ethilon 8-0 
sutures (Ethilon 8-0; Ethicon, Norderstedt, Germany). The abdominal wall was closed with 
a running suture (Vircryl 3-0; Ethicon, Norderstedt, Germany) and the skin with staples. 
Postoperatively 10ml of 0.9%NaCl at 37°C was administered subcutaneously for rehydration, 
and subsequently rats were housed two per cage. 
Outcome assessment 
Animals were euthanized by cardiac or inferior vena cava puncture combined with cervical 
dislocation under general anesthesia with isoflurane. A relaparotomy was done and the 
anastomosis was inspected macroscopically for signs of leakage by researchers blinded to 
the group randomization. The signs were graded according to an Anastomotic Complication 
Score: ‘0’ for no abnormalities, ‘1’ for small anastomotic abscesses, ‘2’ for free pus or large 
abscesses and ‘3’ for fecal peritonitis or visible dehiscence (Figure 2). AL was defined as 
having a grade 1, 2 or 3 ACS. The final score was confirmed by agreement between the two 
researchers.
Mechanical strength
All anastomoses were carefully resected and any scar tissue or adhesions covering the 
anastomosis were left in place. These segments were infused with 0.9%NaCl containing 
methylene blue at 2ml/min to determine the strength of the weakest spot within the 
anastomoses. The segments were clamped at 2cm from the anastomosis. The maximum 
pressure (mmHg) just before the sudden loss of pressure in case of failure was recorded as 
‘bursting pressure’(BP). 
To determine the maximal suture holding capacity or scar strength, the segments were 
attached to a tensiometer (Single Column Testing Machine with 20N load cell, Zwick/Roell, 
Ulm, Germany) and pulled apart at 3 cm/min. The highest force measured before rupture 
was recorded as breaking strength (BS) and is noted as Newton.
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Figure 2 Anastomotic Complication Score examples. Grade 0 = no abnormalities; 
Grade 1 = minor abscess; Grade 2 = free pus; Grade 3 = generalized peritonitis or visible 
dehiscence.
Analysis of diclofenac plasma levels by LC-MS/MS
After removing proteins of the plasma samples diclofenac concentrations were determined 
with LC-MS/MS, using an Acquity UPLC (Waters, Milford, MA, USA) coupled to a Xevo TQ-S 
(Waters) triple quadrupole mass spectrometer. The compounds were separated on an HSS 
T3 analytical column (1.8 μm; 100 × 2.1 mm, Acquity UPLC®, Waters, Ireland). As internal 
standard we used deuterated diclofenac: Diclofenac-d4 (phenyl-d4-acetic) (JH Ritmeester, 
Nieuwegein, The Netherlands).  The elution gradient was as follows: 0 min, 40% B; 7-10 min, 
80% B; and 11-14 min, 40% B. Solvent A consisted of 0.1% formic acid in H2O and Solvent 
B consisted of 0.1% formic acid in Methanol. The column temperature was set at 40°C, 
and the flow rate was 300µl/min. The effluent from the UPLC was passed directly into the 
electrospray ion source. Positive electrospray ionization was achieved using nitrogen as a 
desolvation gas with ionization voltage at 1000 Volt. The source temperature was set at 
550°C and argon was used as collision gas. Detection of diclofenac and the internal standard 
was based on isolation of the protonated molecular ion, [M + H]+ and subsequent MS/
MS fragmentations and a multi reaction monitoring (MRM) were carried out. The following 
MRM transitions were used: for diclofenac m/z 295.9(parent ion) to m/z 215.0 and 250.0 
(both product ions), for diclofenac-d4  m/z 300.0 (parent ion) to m/z 219.0 and 254.0.
 
Sample size calculation and statistics
Sample size was determined with expected leak rates of 70-80% in the positive control 
group (group DCF) and 0-20% in the control group (group Ctrl).10 Group DCF-Inh1 was com-
pared with group DCF. In the non-diclofenac cohort groups Inh1 and Veh were compared 
with group Ctrl. Anticipating analysis of leak rates with Fisher exact test and detection of an 
absolute difference of 50% in either direction, 18 animals per group were needed. A 
Mann-Whitney U test was used for the graded anastomotic complication score and an 
independent t-test for continuous variables (strength tests). In the non-diclofenac cohort, 
ANOVA and Kruskal-Wallis were used to compare the three groups. The spread of data is 
presented as standard deviation. P-values <0.05 were considered statistically significant.
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Results
Animal welfare and mortality
All animals experienced minor discomfort on the first postoperative day indicated by dirty 
eyes or nose, and reduced activity. One animal in group DCF died on day 2 due to leakage, 
and two animals in group DCF-Inh1 were killed on day 2 because of leakage related illness 
(Table 1). Rats that died prematurely of leakage were included in analysis of leak rates and 
severity, but were not used for strength tests. Four rats (three in group DCF; one in group 
DCF-Inh1) showed considerable signs of illness on day 3. In the non-diclofenac groups three 
animals died prematurely of other causes: one peroperative isoflurane overdose (group 
Ctrl), and two because of ileus and diarrhea without signs of leakage at autopsy (one in 
group Ctrl; one in group Veh). These rats were excluded from statistical analysis and were 
not used for strength tests. Weight loss from day 0 to day 3 was 10.0±2.6 percent in group 
DCF, 9.6±2.6 percent in group DCF-Inh1 (p>0.05), 7.7±2.7 percent in group Veh, 7.7±2.5 
percent in group Inh1 (p>0.05) and 7.4±2.7 percent in group Ctrl (p>0.05).
 
Table 1
Group name Size
Weight loss 
%(SD)
Illness on  
day 3
Non-AL  
mortality, n
AL-related 
mortality n
DCF 18 10.0±2.6 3 - 1
DCF-Inh1 18 9.6±2.6 1 - 2*
Veh 18 7.7±2.7 - - -
Inh-low 18 7.7±2.5 - 1† -
Ctrl 18 7.4±2.7 - 2†,‡ -
Animal welfare and mortality. Weight loss is comparable among groups. AL, anastomotic leakage; ACS, 
Anastomotic Complication Score (score 0, no abnormalities; score 1, minor abscess; score 2, free pus; score 3, 
generalized peritonitis or visible dehiscence); * killed on day 2 because reaching humane endpoint; †died on 
day 2 due to ileus and diarrhea without signs of leakage; ‡ died of peroperative isoflurane overdose
Anastomotic leakage 
Anastomotic leak rates were 89% in group DCF and 44% in group DCF-Inh1 (p=0.006) (Figure 
3A). Leak severity according to anastomotic complication scores was reduced by the inhibitor 
(p=0.029) (Figure 3B). In the non-diclofenac groups leak rates were 25% in group Ctrl, 39% 
in group Inh1 (p=0.477), and 24% in group Veh (p=1.000). Leak severity was comparable for 
the non-diclofenac groups.
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Anastomotic strength
All bursts and breakings occurred at the anastomotic line. Mean burst pressure values and 
breaking strength were not statistically different between diclofenac groups (Figure 3C and 
2D). 
Mean bursting pressure was 32±27 mmHg in group DCF and 42±29 mmHg in group DCF-Inh1 
(p=0.245) (Figure 3C). In the non-diclofenac cohort bursting pressures were slightly high-
er than in the diclofenac groups but without significant difference between groups (52±14 
mmHg in group Veh, 43±21 mmHg in group Inh1, and 48±23 mmHg in group Ctrl; p=0.329)). 
Breaking strength (Figure 3D) was .17±.09 N in group DCF, .16±.12 N in group DCF-Inh1 
(p=0.757); .23±.17 N in group Veh, .22±.10 N in group Inh1, and .25±.12 N in group Ctrl 
(p=0.742). 
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Figure 3 Anastomotic healing assessed by: A – anastomotic leakage; B – Anastomotic
complication scores C – Bursting pressure; D – Breaking strength. * = P<0.05.
LCMS/MS analysis of diclofenac levels in plasma
Plasma concentrations of diclofenac dropped 60 minutes after intramuscular administration 
in all diclofenac groups (Figure 4). There was no significant difference between groups at 
any timepoint.
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Figure 4 LCMS analysis showing no significant difference in plasma levels of diclofenac two
hours after intramuscular administration.
Discussion
Oral administration of Inh1 significantly reduced anastomotic leak rate and severity in 
diclofenac treated rats. In groups receiving Inh1 or vehicle, minor signs of anastomotic 
healing disturbance were seen. 
The finding that administration of a glucuronidase inhibitor reduces signs of leakage 
suggests that, without inhibition, cleavage of diclofenac-acyl-glucuronide metabolites to 
diclofenac aglycones disturbs ileal anastomotic healing. To assess if administration of Inh1 
could lead to weaker systemic action by preventing reuptake of diclofenac molecules, we 
determined plasma levels of diclofenac at different time points. These showed similar pattern as 
without inhibition making a systemic action unlikely.15, 22 The harmful effect of reactivated 
diclofenac metabolites is in line with other studies demonstrating that drug aglycones cause 
mucosal damage in the terminal ileum.18, 19, 23 Findings also corresponds with results of former 
anastomotic healing experiments, in which it was demonstrated that diverting or replacing 
bile, and thereby preventing the entrance of drug metabolites into the gut, reduces severity 
of diclofenac induced leakage (yet unpublished data). 
In the present study, a certain amount of leakage (33%) still occurred despite Inh1 treatment. 
Several explanations are possible. First, diclofenac is excreted through bile in multiple forms, 
including unconjugated diclofenac.24, 25 This means that even if β-glucuronidase is blocked, 
other active diclofenac metabolites might reach and harm anastomotic tissue.26 Second, 
inhibition of β-glucuronidase by Inh1 was insufficient. In contrast to previous studies, in 
which a single high dose of diclofenac was given to mice, in the present study diclofenac 
was administered twice daily for three days.18 This results in a longer exposure to drug 
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metabolites. The amount of inhibitor we administered was increased accordingly, but may 
have been insufficient still. Efforts were made to administer higher doses of Inh1 (4000ug/
kg/d) but preparation of the highly concentrated solution was troublesome and included 
severe clumping. Third, the remaining leak rate in group DCF-Inh1 could theoretically be 
a result of counteraction caused by intrinsic toxicity of Inh1 as a relatively high leak rate 
was observed in the inhibitor-only group. However, it mostly concerned low grade healing 
disturbances without other remarkable signs of toxicity and previous toxicity studies have 
shown no adverse effects.19 Another plausible explanation for remaining leakage in group 
DCF-Inh1 is the pharmacological action of diclofenac, which involves COX1/2 inhibition. 
Whereas pharmacological COX1/2 inhibition is thought to be less relevant in NSAID induced 
enteropathy, the associated inhibition of prostaglandin E synthesis may play a role by 
interfering with inflammatory and proliferative processes in the healing cascade.15, 27, 28
The mechanism of topical damage and healing disturbance by NSAID molecules is thought 
to be a multistage process in which reuptake of diclofenac aglycones initially causes 
mitochondrial injury and cell death.29, 30 Subsequently, activation of TLR4 on macrophages 
initiates an excessive inflammatory response.30-32 This disturbs the macrophage-mediated 
balance of inflammatory and proliferative processes during wound healing. Excessive 
inflammation involves increased collagen breakdown and may thereby cause weak 
anastomotic scar tissue and leakage.33, 34 Alternative mechanisms by which hepatic clearance 
of diclofenac can cause bowel damage are the formation of more toxic bile acid micelles and 
an increase in harmful enteric gram-negative bacteria.14, 15   
 
A valid and reproducible rat model was used to study the influence of Inh1 on clinically 
relevant anastomotic leakage. In contrast to clinic though, animals were not fasted and 
no prophylactic antibiotics were given, in accordance to previous studies with this model. 
Fasting is considered to cause major discomfort to rats and both fasting and antibiotics 
could disturb the mucosa and microbial glucuronidase activity and thereby the objective of 
this study. 
In the control group absolute leak rate was more than twenty percent, but it only concerned 
minor signs of healing disturbance. It is thought that such disturbances would also be found 
in clinic if every anastomosis would be checked and clinical relevance of such disturbances is 
hard to predict. The vehicle methylcellulose can have a laxative effect and thereby influence 
bowel physiology. Though no diarrhea was observed, this may have slightly confounded 
findings as three grade 2 complications were noticed in the vehicle group.  
The mechanical strength results show that bursting pressure only moderately corresponds 
to leakage signs and that much larger sample sizes would be needed to detect differences. In 
accordance to previous studies breaking strength poorly correlated with leakage. As leakage 
is a much more relevant outcome the additional value of strength test is arguable. 
Conform previous Inh1 studies, we attempted to measure mucosal permeability and 
ulceration with immunohistochemistry to have supportive evidence for leak reduction. 
However, quantitative analysis was not possible because destruction by peritonitis and ileus 
did not reveal sufficient  samples. 
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The detrimental effect of reactivated diclofenac metabolites in the gut, as suggested 
in the present study, is thought to be similarly relevant in human. In humans, diclofenac 
metabolism also involves glucuronidation in the liver.24, 35-37 This, however, also depends on 
individual pharmacokinetics, as disposition of drugs that are predominantly eliminated via 
acylglucuronidation can significantly vary among humans.37 Differences in drug metabolism 
may explain why NSAIDs have not been convincingly identified as a cause of leakage. Possibly 
NSAIDs only harm anastomoses in a particular group of patients.38
In the current study an anastomosis of the distal ileum was used to assess the effect of 
Inh1 as previous studies found that both diclofenac-induced enteropathy and diclofenac-
induced leakage are most severe in this particular segment. However, also for colonic and 
colorectal anastomoses this mechanism may be relevant. Altered bowel content and 
physiology following partial or subtotal colectomy may lead to comparably high levels of 
diclofenac metabolites and bile salts, and thus comparably high risk.39 
In the current experiment Inh1 was used to evaluate the relevance of 
diclofenac-acyl-glucuronide reactivation in leakage pathophysiology and not as a 
potential therapeutic agent for preventing leakage in humans. Though this does not exclude its 
therapeutic potential in certain situations, it is simply easier to avoid diclofenac use because 
alternative analgesics are available.40 
The present study suggests that reactivation of diclofenac metabolites in the gut leads to 
anastomotic healing disturbances. Administration of Inh1 to block this process reduces 
signs of leakage, but could not prevent a leak in all cases. In subsequent experiments a 
stronger effect could be aimed for by increasing frequency of Inh1 administration, instead of 
increasing Inh1 concentration. 
In general, the present study contributes to the evidence that intraluminal compounds 
are relevant in leakage pathophysiology.41 This means that, in order to reduce the clinical 
burden of anastomotic leakage, more research should be done beyond the scope of known 
partially non-correctable risk factors and etiologies (e.g. ischemia). It should aim to clarify 
the role of potential harmful intraluminal factors, which may also include specific bacterial 
virulence factors and  some enteral nutrients.41, 42, 23, 
Administration of glucuronidase inhibitor Inh1, aiming at preventing reactivation of 
diclofenac-acyl-glucuronid metabolites in the gut, reduces diclofenac-induced anastomotic 
leakage. 
This suggests a harmful effect of diclofenac metabolite reactivation on anastomotic 
healing. These findings improve our understanding of the pathogenesis of anastomotic 
leakage.
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Abstract
Objective
To explore the influence of anastomotic surgery and NSAID treatment on the microbiome 
composition of different bowel segments and the association with leak rates.  
Summary background data
Growing evidence suggests a central role for the gut microbiome in the pathogenesis of 
anastomotic leakage. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been recently 
identified as perioperative risk factor for AL and may also affect the microbiome.
Methods
50 rats underwent intestinal resection and anastomosis construction in the ileum (IL), 
proximal colon (PC) or distal colon (DC). One PC group did not receive diclofenac, whereas 
all other groups did. Fecal samples collected from the anastomotic site on POD0 and POD3 
were analyzed by 16S rRNA sequencing.
Results
More distally, the relative abundance of the Firmicutes phylum decreased, whereas 
the Bacteroidetes increased. Microbial diversity of the proximal and distal colon was 
significantly decreased on POD3 (p=0.0025 and p=0.007 respectively) compared to POD0. 
Clear differences in relative abundance of several species could be observed between 
preoperative and postoperative samples, in all investigated segments. Surgery was the 
main contributing factor to these observed changes: it explained 75% of the variance in 
microbiota between POD0 and POD3 in the ileum. Furthermore, analyses revealed no 
significant differences in alpha diversity metrics between leakage and non-leakage samples 
in the proximal and distal colon.
Conclusion
Surgical stress prompts a shift in microbial composition in all investigated segments. 
Microbial changes do not explain the increased risk for AL following NSAID treatment in this 
model. 
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Introduction
Anastomotic leak (AL) is the most feared complication following intestinal surgery. It is 
associated with high morbidity and mortality and occurs in 6-12% of patients after colorectal 
resection [1, 2]. Leak rates have failed to decline over the past decades despite intensive 
research in this field, emphasizing the need for a better understanding of leak pathogenesis. 
Several recent studies have reinforced the hypothesis that gut bacteria play a central role 
in the pathogenesis of AL, by demonstrating a protective effect of antibiotics, and oral 
antibiotics in particular, against anastomotic leak[3, 4]. It has been shown that multiple 
surgery-related factors, such as fasting, bowel preparation, antibiotics, surgical trauma 
and analgesics, can influence the microbiome[5], and in turn, that microbial changes and 
increased bacterial virulence can disturb anastomotic healing[6, 7]. 
Since the past decade, nonsteroidal anti-inflammatory drug (NSAID) use has been associated 
with an increased risk of developing AL in both human and experimental studies[8, 9]. 
Although the main hypotheses are that this is caused by COX2-inhibition or topical toxicity 
of drug metabolites, several studies also support a role for the microbiome in NSAID-
induced leakage[10-13]. Ueijima et al. demonstrated that the presence of specific microbes 
is a prerequisite for the induction of small intestinal ulcers in rats treated with NSAIDs[10]. 
Another study provided evidence that NSAIDs also have a direct influence on the microbiota 
composition. Following injection with indomethacin, an overgrowth of E. faecalis was 
observed in the rat small intestine which resulted in the relative diminution of commensal 
microbes such as segmented filamentous bacteria [14]. Interestingly, high collagenase 
producing strains of E. faecalis have also been associated with AL in both experimental and 
clinical studies [15]. We have previously demonstrated that the use of the NSAID diclofenac 
causes leakage of anastomoses in the ileum and proximal colon in rats, but not in the distal 
colon [16]. These observed differences in AL may be explained by differences in microbiota, as 
this is an important discriminating factor between these segments [17, 18].  
The cumulative evidence suggests that the microbiome of the gut may play an important 
role in the pathogenesis of AL, and could also contribute to NSAID-induced intestinal 
complications. The aim of the present study is to capture the changes that occur in the 
composition of the rat microbiota in different intestinal segments as a result of anastomotic 
surgery and the administration of diclofenac, and to explore whether these changes can 
account for differences in diclofenac-induced leakage. 
Materials and methods
Ethics
This experiment was conducted according to the Dutch ‘‘Experiments on Animals Act’’ 
and European Federation of Laboratory Animal Science Associations guidelines and was 
approved by the institutional Animal Ethics Committee of the Radboud University. 
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Animals
Fecal samples were collected from 50 Male Wistar rats (Harlan, Horst, The Netherlands), 
housed under standard laboratory conditions with free access to food and water. Rats were 
accustomed to laboratory conditions for one week prior to the start of the experiment. 
Animals were weighed daily and were inspected for signs of reduced wellbeing twice daily 
during the experiment. Signs that were monitored included red eyes, nose, and/or fur, 
piloerection, aberrant behavior, distended abdomen, and diarrhea. Humane endpoints 
were defined; animals were euthanized if they showed signs of severe discomfort (e.g. 
weight loss > 20%, distended abdomen or severely reduced activity).
Study design 
The experiment was conducted as previously described [16]. 50 rats underwent a 1 cm 
bowel resection followed by the construction of an anastomosis. Depending on the group 
randomization, resection and anastomosis construction occurred either in the ileum (IL), 
proximal colon (PC) or distal colon (DC), under strict aseptic conditions. No antibiotics were 
administered. Groups IL+ (n=10), PC+ (n=15) and DC+ (n= 10) received diclofenac (3mg/
kg/day) until sacrifice on post-operative day 3 (POD3), with the first dose administered 15 
minutes prior to the operation. Rats in group PC- (n=15) did not receive diclofenac. 
On POD3 animals were euthanized by CO2 asphyxiation. After euthanization, a relaparotomy 
was performed and the anastomosis and abdomen were inspected for macroscopic signs of 
anastomotic leakage.  Two investigators independently assessed the presence and extent of 
leak by means of an anastomotic leak severity score. Any differences in scores were resolved 
by consensus. A score of ‘0’ constituted no signs of leakage, a score of ‘1’ constituted 
anastomotic abscesses, a score of ‘2’ represented free pus or large abscesses, and a score of 
‘3’ stood for fecal peritonitis or visible dehiscence[19]. 
Feces sample collection 
Feces samples were collected from the resected segment (i.e. IL or PC or DC) during the 
initial operation on POD 0 (samples ‘D0’) and again after sacrifice on POD 3 (samples ‘D3’). 
Samples were snap frozen in liquid nitrogen and stored at –80⁰C. 
DNA isolation
DNA isolation was performed using a combination of repeated bead-beating and column-
based purification as described previously [20]. Briefly, PSP lysis buffer (Stratec Molecular, 
Berlin, Germany) and approximately 50 mg of frozen stool aliquots were added to a sterile 
vial containing 0.5 g of 0.1 mm zirconia/silica beads and 4 3.0–3.5 mm glass beads (BioSpec, 
Bartlesville, USA). The samples were homogenized in a MagNA Lyser instrument (Roche, 
Basel, Switzerland) in three cycles of 1 minute at a speed of 5500 rpm, interspersed with 
cooling on ice for one minute in between cycles. DNA isolation was continued using the 
PSP Spin Stool Kit (Stratec Molecular, Berlin, Germany) according to the manufacturer’s 
instructions. DNA was finally eluted in 200 μl elution buffer.
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Sequencing
Amplicon libraries and sequencing were performed according to previously published 
protocols [21]. Briefly, the V4 region of the 16S rRNA gene was PCR amplified from each 
DNA sample in triplicate using the 515f/806r primer pair described previously [21]. Pooled 
amplicons from the triplicate reactions were purified using AMPure XP purification 
(Agencourt, Massachusetts, USA) according to the manufacturer’s instructions and eluted 
in 25μl 1× low TE (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0). Quantification of amplicons was 
subsequently performed by the Quant-iT PicoGreen dsDNA reagent kit (Invitrogen, New 
York, USA) using a Victor3 Multilabel Counter (Perkin Elmer, Waltham, USA). Amplicons 
were mixed in equimolar concentrations to ensure equal representation of each sample, 
and sequenced on an Illumina MiSeq instrument.
Data analysis and statistics
Filtering, denoising, removing of chimeric sequences and clustering of sequences in 
Operational Taxonomic Units (OTUs) at 97% similarity was conducted using the LotuS 
pipeline (version 1.39) [22]. First, sequences with an average quality below 27, a read length 
below 170 bases, with one or more ambiguous bases, or containing homopolymer stretches 
of over 8 bases were discarded. Retained sequences were chimera filtered and clustered 
into OTUs using UPARSE[23]. Taxonomic annotation of OTUs was derived from RDP naïve 
Bayes classifier annotations (minimum acceptance confidence set at 0.8). OTUs representing 
less than 0.01% of the total number of observations (sequences) and OTUs that were only 
observed in a single sample were discarded. Downstream analyses were conducted using 
QIIME version 1.8.1 and R version 3.1.3[24]. 
Taxonomy, alpha and beta diversity, microbial core 
Differences in the relative abundance of bacterial phyla and genera were compared between 
day 0 (surgery) and day 3 (sacrifice), between IL, PC and DC, and between groups with and 
without diclofenac (applicable to proximal colon samples) using either the Wilcoxon signed-
rank test (for the paired samples between day 0 and day 3) or the Mann-Whitney-U-test 
(for unpaired comparisons). The following metrics of species richness and diversity within 
communities (alpha-diversity) were determined at a rarefaction depth of 34,150 sequences/
sample: observed OTUs (observed richness), Chao1 index (estimated richness), and Shannon 
index (diversity). Alpha diversity metrics between paired samples from day 0 and day 3 were 
compared by the Wilcoxon signed-rank test, whereas Mann Whitney U tests were used to 
compare alpha diversity metrics of group IL/PC+ with DC+, and group PC- with group PC+. 
The total number of pairs that were included in the analyses were: n=5 for PC-, n=14 for 
PC+ and n=10 for DC+. All p-values were adjusted for multiple comparisons using the False 
Discovery Rate [Benjamini-Hochberg][25].
Beta-diversity, the diversity shared across samples, was determined by the Bray-Curtis 
dissimilarity (BC) at a rarefaction depth of 34,150 sequences/sample. Clustering of samples 
was visualized using Principal Coordinate analysis (PCoA). 
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Enterotyping
Enterotype analyses were performed as described previously by Arummougham and 
colleagues[26]. We used the R[27] package “vegan: Community ecology”, version 2.2-1 by 
Oksanen et al. from 2011 for calculating the Bray-Curtis distance on the genus-level relative 
abundance profiles. To cluster the samples, we used the Partitioning Around Medoids (PAM) 
clustering algorithm in the R[27] package “Cluster analysis basics and extensions”, version 
2.0.1 ed. by Maechler et al. from 2012. The optimal number of clusters was chosen based 
on Calinski-Harabasz (CH) index and validated by the silhouette index (57) using the R[27] 
package ‘clusterSim’. The optimal number of 2 clusters was identified based on the CH index, 
which was confirmed by the silhouette index although clustering was moderate (SI 0.47).
Between-class analysis (BCA) was performed to plot the samples using the R[27] package 
“Analysis of Ecological Data: Exploratory and Euclidean Methods in Environmental Sciences” 
version 1.7.2. by Dray et al. from 2015. The similarity percentage analysis (SIMPER)[28] was 
used to identify taxa contributing to similarity within- and dissimilarity between groups.
Results
Anastomotic leakage
Animal welfare, mortality and anastomotic healing assessment results were published 
previously. In summary, leak rates were 10 out of 10 (100%) in group IL+ and 22 out of 30 
(73%) in group PC+ (22/30; 73%; p=0.166). Compared to group PC+, rates were significantly 
lower in group DC+ (1/10; 10%; p=0.001) and group PC- (0/15; 0%) (p=0.001).  The mean 
leak severity score was significantly higher in the IL+ group compared to the PC+ group 
(2.8±0.6 vs. 1.7±0.5, P 0.004) and significantly lower compared to the DC+ group (0.1±0.3, 
p<0.001). 
Sequencing 
In total 96 fecal samples were collected during the experiment. Because of insufficient 
material 17 samples could not be analyzed. Two samples failed during sequencing and were 
excluded from subsequent analysis. In total 77 samples remained, from which a total of 
4,869,671 V4 reads were retained for downstream analysis after trimming, quality filtering, 
removal of potential chimeric reads and de-multiplexing. The number of sequences per 
sample ranged from 34,198 to 87,981 (median 63,354).  Sequences were then clustered into 
2,182 OTUs. After discarding OTUs that were only observed in a single sample and OTUs with 
a relative abundance of <0.01%, 1,005 OTUs remained. The taxonomic composition of the 
samples on both phylum and genus level can be observed in figures 1A and B, respectively.
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Figure 1A Phylum abundance in different anatomical regions (IL = ileum, PC = proximal 
colon, DC = distal colon), pre- (D0) and post-surgery (D3) and with or without diclofenac  
(+ or – respectively).  
Figure 1B Genus abundance of 21 most abundant genera in different anatomical regions 
(IL = ileum, PC = proximal colon, DC = distal colon), pre- (D0) and postsurgery (D3) and with 
or without diclofenac (+ or – respectively).  
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Baseline microbiota composition and diversity in different segments 
of the intestinal tract Taxonomy
Phylogenetic classification of the microbiota in the different anatomical locations identified 
21 different families belonging to 9 bacterial phyla. The most abundant phyla in the 
fecal samples obtained from the ileum were Firmicutes, followed by Bacteriodetes and 
Actinobacteria. The most abundant genera were Bacteroides, Lactobacillus, Escherichia-
Shigella, Turicibacter and Bifidobacterium (relative abundance of 23.91, 8.92, 7.17, 2.72 and 
2.05% respectively). The genera that formed major constituents of the microbiota in the 
colon were Lactobacillus, Bacteroides, Alloprevotella, Blautia and Alistipes. More distally 
along the intestinal tract, the abundance of Firmicutes decreased, whereas Bacteriodetes 
showed an increase as compared to the ileum (Fig. 2). 
Figure 2 Bubblechart depicting the relative abundance of the ten most common genera in 
the ileum (IL), proximal colon (PC) and distal colon (DC).
Microbial diversity and community structure
Microbial richness and diversity of feces samples collected before anastomosis construction 
was expressed as the number of observed species, Chao1 index and Shannon diversity index 
respectively. The analysis revealed baseline differences in diversity between the various 
segments of the intestine with a gradual increase in diversity from ileum towards the distal 
colon; see figure 3 for a comparison of the different alpha diversity indexes. Preoperative 
fecal samples retrieved from the ileum demonstrated a significantly lower estimated 
microbial richness than samples retrieved from the proximal (PC- and PC+ combined) and 
distal colon (p = 0.002 and p = 0.001 respectively, as calculated from Chao1 data). 
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Figure 3 comparison of alpha diversity indexes of pre-operative samples of the different 
anatomical locations: IL (ileum), PC (proximal colon), and DC (distal colon). 
The microbial community structure, as expressed by the Bray-Curtis (BC) dissimilarity 
was also examined for each intestinal segment. Clustering of all samples based upon BC 
dissimilarities revealed a clear separation between ileal and colonic samples, represented 
by a separation along the first principal coordinate. Proximal and distal colonic samples 
did however not separate neither in this analysis nor when excluding ileal samples in a 
secondary analysis (results not shown). 
The influence of surgery on microbial diversity and community structure
Surgery significantly decreased microbial richness and diversity in proximal (only PC+) and 
distal colon samples (Figure 4). A similar trend could not be observed in ileal samples, likely 
due to the limited number of paired pre- and post-surgery ileal samples.
Figure 4 Microbial richness (Chao 1 and Shannon index) for all groups measured pre- and 
post-surgery. Asterisk indicates significance <0.05. 
To further examine the effect of surgery on the microbial community structure in specific 
intestinal segments, a PCoA plot was created for each segment individually. A clear 
separation between pre- and post-operative proximal colon samples was observed along 
the first principal coordinate in PCoA plot based on the Bray-Curtis distance (Fig. 5B).  This 
separation was partially, but not completely, driven by a reduced microbial richness in post-
operative samples (see supplementary data for a colored PCoA plot according to the Chao1 
index). This surgery-effect was also observed for both ileum and distal colon samples (see 
figure 5A and 5C respectively). In all intestinal segments, the same trend could be observed: 
all pre-operative samples clustered together, while the majority of the post-operative 
samples form a separate cluster with the exception of a few post-operative samples that 
remained clustered with the pre-operative samples.
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Figure 5A Bray-Curtis: the first principal coordinate shows the effect of surgery on ileum 
samples: 75% of the variation could be attributed to PC1.
Figure 5B Bray-Curtis: the first principal coordinate shows the effect of surgery on PC+ 
and PC- proximal colon samples. No obvious effect of diclofenac can be observed in this 
separation.
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Figure 5C Bray-Curtis: the first principal component shows the effect of surgery on distal 
colon samples.
Enterotyping
In order to further elucidate the origin of the clustering observed in the Bray-Curtis 
analyses of proximal colon samples, enterotyping was performed based on Partitioning 
Around Medioids. The Silhouette score yielded the strongest evidence for clustering in 
two groups (SH index = 0.47), one group consisting of the pre-operative samples and one 
group consisting mainly of the post-operative samples. Bacterial taxa that contributed most 
to the observed clustering were the unclassified Lachnospiraceae, as well as Bacteroides 
and Esherichia-Shigella. Post-operatively, a marked decrease in the relative abundance 
of Lachnospiraceae could be observed and a sharp increase in the relative abundance of 
Bacteroides and Escherichia-Shigella.
Subsequently, paired analyses were performed to examine the differences in microbiome 
composition between pre- and post-operative proximal colon (PC+ and PC-) samples at 
phylum and genus levels (figure 6A). These analyses revealed a significantly lower relative 
abundance of the Firmicutes phylum on D3 compared to D0 (p<0,001), whilst the decrease 
in the abundance of Lactobacillus (the most important genus within this phylum) was 
not significant (p=0.26). An overall increase in the phyla Bacteroidetes (p=0.001) and the 
genera Bacteroides (p<0.001) and Alistipes (p<0.014) was observed, as well as an increase 
in the Proteobacteria phylum (p<0.001), which confirmed the findings in the enterotyping 
analyses. The most important genera within the Proteobacteria phylum showed the expected 
postoperative increase (Escherichia-Shigella p<0.001, Bilophila p<0.001 and Parasutterella 
p<0.001). A postoperative decrease in overall relative abundance was found for the phylum 
of Candidatus Saccharibacteria (p=0.001).
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As was the case for the PC samples, paired analysis of the distal colon samples revealed a 
significantly higher abundance of several genera within the Firmicutes phylum, including 
the Blautia (p=0.005) and Clostridium sensu stricto (p=0.022) genera preoperatively, as well 
as a bloom of Proteobacteria genera such as Escherichia-Shigella (p=0.007) and Bilophila 
(p=0.009) post-operatively (Figure 6B).
Figure 6A Cladogram representation of microbiota composition of proximal colon samples 
on different taxonomical levels. Green indicates significant higher relative abundancy in 
pre-operative samples, higher relative abundancy of post-operative samples is depicted in 
red.
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Figure 6B Cladogram representation of microbiota composition of distal colon samples 
on different taxonomical levels. Green indicates significant higher relative abundancy in 
pre-operative samples, higher relative abundancy of post-operative samples is depicted in 
red.
The effect of diclofenac administration on microbial diversity and composition
Alpha diversity
As stated before, in the PC+ group a decrease in alpha diversity was observed in samples 
obtained at postoperative day 3 compared to the postoperative samples (p = 0,001 for 
both alpha diversity measures). In the proximal colon group that did not receive diclofenac, 
microbial richness was also lower post-operatively, but this difference did not reach 
statistical significance (Chao1 index PC-D0: Mdn. 687,59, PC-D3: Mdn. 593,82, z = -1,483 p 
148
Chapter 8
= 0,138, Shannon index PC-D0: Mdn. 6,46, PC-D3: Mdn. 5,75, z = -2,023, p > 0,05 after FDR 
correction). Surprisingly, significant baseline differences in microbial richness were found 
between PC-D0 and PC+D0 samples collected before anastomosis construction (Chao1 
index p = 0,035), but not in microbial diversity, (Shannon index p = 0,292). 
Despite these baseline differences, the diversity in the PC+D3 group and PC-D3 group was 
comparable (Chao 1 index PC+D3: Mdn. 652,97, PC-D3: Mdn. 593, 82, p = 0,694, Shannon 
index PC+D3: Mdn. 5,93, PC-D3: Mdn. 5,75, p = 0,823). The difference in diversity in the PC+ 
group between D0 and D3 was not significantly greater than that in the PC- group (p = 0,123 
and p = 0,956 for Chao1 and Shannon index respectively). See figure 7 for the associations 
between the different time-points for the paired samples. 
Figure 7 Difference in Chao1 index for paired samples on different timepoints between 
groups PC- and PC+.
Beta diversity
To examine whether the microbial community structure within the PC+D3 and PC-D3 
groups was more similar than the microbial community structure between the groups, 
the average within- and between-group Bray Curtis dissimilarity was examined. Samples 
within the PC+D3 group showed the strongest homogeneity, as indicated by significantly 
lower within-group Bray Curtis dissimilarity compared to the PC-D3 group (p = <0.001) 
(Fig. 8). When comparing OTUs between PC+D3 and PC-D3 group, only one out of >1000 
OTU’s was found to be significantly different: the OTU belonging to Anaerostipes from the 
family of Lachnospiraceae (p = 0,046 after FDR correction).  Together with the similar post-
operative decrease in alpha-diversity in the PC+D3 and PC-D3, these results provide little 
evidence for an effect of diclofenac administration on microbiota composition.
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Figure 8 Within-group Bray-Curtis dissimilarity of proximal colon samples. Samples within 
the PC+D3 group showed the strongest homogeneity.
Relation between microbial composition and diversity 
and the occurrence of AL in different intestinal segments
Anastomotic leakage was observed in ileal and proximal colon (PC+) samples, but only 
sporadically in PC- or distal colon samples. For the analysis of the association between AL 
and microbial composition and diversity, only paired samples were taken into account: in 
the PC+ group, 10/14 rats (71,4%) showed signs of AL, whereas only 1 of 10 rats in the distal 
colon (10%) leaked. In order to investigate the relation between the microbial composition 
and the occurrence of leakage in the proximal colon and distal colon samples, we compared 
alpha diversity scores between leakage and non-leakage samples. Alpha diversity indices 
were not significantly different between postoperative leakage and non-leakage samples 
from the proximal colon (Chao1 index: Mdn. 642,40 vs. 682,91 respectively, z=-0.990, 
p=0.37, Shannon index: Mdn. 5,66 vs. 6,07 respectively, z=-1,414, p=0.19), or the distal 
colon (Chao1 index: Mdn. 606,00 vs. 665,53 respectively, z=-1,219, p=0.40, Shannon index: 
Mdn. 6.01 vs. 6.20, respectively, z=-0,522, p=0.80). 
We further examined the relative abundance between the leakage and non-leakage samples 
in the PC+ group, which showed a significant lower relative abundance for the phylum 
Actinobacteria in the preoperative samples (Mdn. 0.0027 vs. 0.0219, Z=-2.121, p=0.035) 
as well as a lower relative abundance of Bacteroidetes in the postoperative samples of the 
leakage group (Mdn. 0.457 vs 0.567, Z=-2.263, p=0.024). The other most abundant genera 
and phyla showed no difference in relative abundance between leakage and non-leakage 
samples.
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 Discussion
In the present study, the effect of anastomotic surgery and perioperative NSAIDs on the 
microbiome of different gut segments was explored. In the proximal and distal colon, a 
clear reduction of microbial diversity was observed three days after surgery. Changes were 
most apparent in the proximal colon and involved a diminution of the relative abundance 
of the Firmicutes (mainly attributed to a decrease in Lachnospiraceae) and an increase in 
the relative abundance of the Bacteroidetes phylum and Proteobacteria genera such as 
Escherichia-Shigella. The species richness did not change as evidently in the ileum as a 
result of the surgical intervention, but this can be explained by the relatively low richness at 
baseline. The PCoA on the other hand revealed a strong influence of surgery in the ileum: 
75% of the variance between D0 and D3 samples could be explained by the intervention.. 
Contrary to our hypothesis and available literature, no significant difference was observed 
in taxonomic composition and diversity following diclofenac treatment.
A possible explanation is that the current study was not able to detect such influence, 
as surgery alone has proven to be a strong factor to alter the microbiota, and may have 
subsequently camouflaged influences exerted by the administration of diclofenac[7]. Other 
studies have shown that NSAID treatment lead to an obvious decrease in the number of 
gram-positive bacteria[13, 29]. Another study found increased numbers of Enterobacteriaceae 
and Acidominococcaceae in the feces of NSAID-users compared to controls[30]. 
The trauma of undergoing surgery alone may suffice in explaining the alteration of the normal 
microbial composition[7]. Lactobacilli and short chain fatty acids, both considered to have a 
cytoprotective effect, decrease by more than 90% within 6 hours after major trauma[31]. 
Our results are also in concordance with a study by Shogan et al. in which a decrease in 
the relative abundance of the Firmicutes phylum and an increase in Proteobacteria genera 
such as Escherichia-Shigella was observed post-operatively[5]. Shogan et al., however, 
found a more dramatic increase in the relative abundance of Enterococcus. Because of 
the short time frame in which this alteration takes place, it is considered to be a result 
from chemosignalling rather than a depletion of nutrients in the gut[32]. Another possible 
explanation is the exposure of the gut lumen to atmospheric air, which will affect the 
obligate anaerobic species[33, 34].
Several features of the luminal content as well as the structure of the intestine have been 
suggested to play a role in the observed segmental differences[17, 18]. The small intestinal 
content is known to have a lower pH, higher oxygen and bile acid levels as compared to the 
colon, which facilitates colonization by facultative anaerobes, mainly Lactobacillaceae and 
Enterobacteriaceae (belonging to the Firmicutes and Proteobacteria phyla respectively). The 
colon on the other hand, characterized by low oxygen levels, slow transit and high nutrient 
levels, is mainly inhabited by Bacteriodetes or Firmicutes phyla. The microbiome changes 
observed in this study were greater in the proximal colon compared to the distal colon. The 
anastomotic leak rate was also higher in the proximal colon. 
It is possible that the microbial shift in the proximal colon increased its susceptibility to 
damage caused by diclofenac. Other studies have shown that certain antibiotics and 
probiotics reduce the severity of NSAID-induced enteropathy, especially when they target 
gram-negative bacteria[35, 36]. Another important clue for the interaction between NSAIDs 
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and bacteria is the finding that NSAID enteropathy does not occur in germ free mice, but, 
when Eubacterium limosum or E. coli is introduced, intestinal ulceration is observed [10, 37].
However, there may be other explanations than an altered microbiota composition for the 
increased leakage rates in the ileum and proximal colon in this study. Inhibition of cyclo-
oxygenase (COX) consequently leads to inhibition of its products: the prostaglandins. By 
inhibiting the prostaglandins E2 (PGE2) and I2 (PGI2), two important inflammatory mediators 
in the gut, several hallmarks of inflammation are reduced as well [38]. As they also play an 
important role as mediators of mucosal defense and repair, NSAID administration leaves the 
gut lining more susceptible to cytotoxic components of the luminal content [39]. 
Another property of this group of drugs that may explain the observed alterations is their 
metabolism. Many NSAIDs (including diclofenac) are excreted through bile after being 
absorbed in the distal intestine and being glucuronidated in the liver. After their excretion 
together with the bile (free or glucuronidated), they exert secondary effects on the intestinal 
wall, contributing to epithelial damage [40]. 
The decrease in the relative abundance of Lachnospiraceae observed in the colonic segments 
may have detrimental consequences for epithelial permeability as many of the intestinal 
butyrate producers belong to the Lachnospiraceae family [41]. Aside from facilitating tight 
junction assembly, butyrate is associated with many other beneficial properties in the colon. 
Butyrate acts as an energy source for intestinal epithelial cells, reduces oxidative stress in 
the mucosa and by extension inflammation, and is an anti-carcinogenic [42]. Interestingly, in 
inflammatory bowel disease the most consistent change that is observed is also a marked 
decrease in the representation of the Firmicutes phylum (including Lachnospiraceae) [43]. 
No clear association between microbial composition and the occurrence of anastomotic 
leakage was found in this study. This could be explained by the relatively low numbers of 
leakage, as well as the strong influence of the surgical intervention on the microbiota. A 
recently conducted clinical study did find a positive correlation between the occurrence 
of CAL and low microbial diversity, as well as with a high abundance of Bacteroidaceae 
and Lachnospiraceae families[44]. It has been further suggested that aside from microbial 
composition and diversity, microbial virulence also plays an important role in leakage 
pathogenesis. Bacteria have been shown to demonstrate an upregulation of virulence 
factors such as collagenase activity, swarming motility and epithelial adhesion in response to 
changes in their direct environment such as phosphate depletion[45], release of inflammatory 
mediators[46], and the release of endogenous opioids[47]. Even symbiotic microbes can 
express virulence as a reaction to cues coming from their host. This increase in bacterial 
virulence can promote the emergence of a pathobiome capable of penetrating the intestinal 
barrier and causing anastomotic leak [48, 32]. In order to investigate this hypothesis, analyses 
cannot remain limited to taxonomic composition and diversity quantification; analysis of the 
functional context of microbial species is vital in order to determine the clinical relevance of 
the presence of specific bacterial species. 
The strength of this study is the simplicity of the model used; results are not tainted by 
the administration of antibiotics, bowel preparation or radiotherapy – interventions that 
are commonly used in other animal experiments and, most importantly, in clinical practice. 
This allowed us to isolate and identify changes on the microbiota composition that were 
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induced by surgery or NSAIDs alone. We included the proximal colon anastomosis in our 
experiments, a type of anastomosis that is often neglected in experimental CAL research, 
despite the fact that right-sided (ileocolic) anastomosis are common and show significant 
leak rates in recent series[49]. The most important limitation of this study is the low leak 
rate of the distal colon anastomoses, which can largely be attributed to the type of model 
used. Several additional interventions can be employed in order to increase the leakage rate 
of distal anastomoses (e.g. ischemia, radiotherapy, morphine), but this would increase the 
complexity of this specific model and would hamper interpretation of single intervention 
effects. 
In summary, surgical stress, and not NSAID treatment, prompts a shift in microbial 
composition and decrease in diversity in a rat model of NSAID induced anastomotic leak. 
The increased risk for AL that is induced by the administration of NSAIDs is therefore likely 
to be attributable to other properties of this drug class. However, as microbial changes have 
been previously described to occur with the use of NSAIDs, more research is needed to 
clarify if these changes make the gut more susceptible to diclofenac-induced leakage and 
anastomotic leak in general.
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9.1 Anastomotic healing (patho)physiology
We showed in our overview of anastomotic healing that studies on the molecular biology 
of anastomotic healing are scarce and many pathways and fundamental elements of the 
healing process remain unknown. To follow healing over time, researchers used animal 
studies in which sacrifice and immunohistochemistry analysis was conducted in different 
animals at consecutive times (1–4). In human research, only surrogate markers of healing 
processes can be determined, via drains in the operative field near the anastomosis or by 
faecal content analyses. In particular, the (disturbance of) cellular and molecular processes 
of healing in time in one individual is difficult to assess in both animals and humans, due to 
a lack of non-invasive techniques.
Several recent techniques used in human cancer and inflammatory bowel disease 
research have the potential to shed light on the dynamic process of anastomotic healing. 
Two promising techniques are confocal endomicroscopy, which provides visualisation of 
mucosal micro-architecture, and endocytoscopy, which uses ultra-high magnification (450x) 
to visualise mucosal cells (5). Both techniques yield on-site tissue information and allow 
researchers to visualise cellular processes within the anastomotic wound in real time (5). 
This is a step forward compared with traditional histology, which has to be done on biopsies 
or resected specimens. Endoscopic microscopy can be used in translational research, but 
also in clinical research. Using endomicroscopy could involve the risk of trauma to the fresh 
anastomosis by the scope. However, intra- and postoperative endoscopy has been proven 
to be safe, and some researchers even suggest that it can lower anastomotic leak rates (6–8).
A technique which holds promise to increase knowledge of the molecular processes of healing 
is mass spectrometry (9). Variants of this technique, such as matrix-assisted laser desorption/
ionisation mass spectrometry and imaging mass spectrometry, can identify specific proteins 
such as collagen in deeper layers of anastomotic tissue. Such analyses could reveal which 
set of proteins (the proteome) in the bowel wall reflects a firm and healthy scar and which 
proteome develops towards a fragile and leaking scar. Similar approaches determining the 
proteome of the bowel wall have been used to predict the progress of inflammatory bowel 
disease (9). Histological collagen analyses have been conducted on anastomotic tissue, but 
modern proteomics have yet to be incorporated into anastomosis research (1, 2).
Real-time non-invasive monitoring of cellular and molecular processes may reveal temporal 
clues for enforcement of healing and prevention or reversal of disturbed healing. Targeted 
therapies may then be developed to modulate inflammatory and proliferative processes in 
a specific direction for each patient and at the right moment (10–12).      
9.2 Review of published animal research in this thesis
In Chapter 3 we concluded that animal research on AL is of poor quality and still increasing 
in magnitude, which is contrary to societal aims regarding the use of animals for research. 
The main points of criticism were the large variety of animal models, the insufficient quality 
of reporting, and the failure to use randomisation, blinding and relevant outcome measures. 
In all studies in this thesis a rat model was used, which is in line with the recommendation 
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of a recent Delphi analysis on anastomosis research in animals. The authors of this analysis 
advised against using rabbits, dogs, guinea pigs and monkeys for this topic, but rather mice, 
rats and pigs, depending on the research question (13). The authors aimed to provide further 
recommendations on the best anastomosis model but were unable to reach a consensus.
The rat experiments in the current thesis have been well validated by previous researchers 
within our department (1, 14, 15). By standardising the rat strain, gender and age, as well as 
the anastomotic technique, perioperative care and strength measurements, the risk of 
confounding was markedly reduced. Randomisation and a proper perioperative analgesic 
regimen were also used in the experiments (16). As discussed, many studies still do not use or 
report these measures, which are important for the internal validity of study results.
In our experiments we improved the operative procedure by introducing a complete 
sterile approach, mimicking the clinical situation, as routine. Prior to this we had used an 
aseptic technique which only involved shaving and disinfecting the rats, as many research 
groups still do. This runs the risk of bacterial contamination in the peritoneal cavity, with 
potential to disturb anastomotic healing processes. Now, rats were also draped with sterile 
covers, instruments were autoclaved in sterile packages, sterilised between procedures 
and prepared on sterile tables, and sterile gloves and gowns were used during surgery (see 
Figure 1).
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Figure 1 Pictures of the surgery, including sterile drapes, instruments, gowns and gloves.
We introduced blinding of the researcher performing the surgery and blinding of the 
outcome assessor to improve validity in all our experiments. This was facilitated by a second 
researcher who randomised the order and covered the tail markings before surgery and 
before sacrifice. Blinding of the surgeon and blinding of the outcome assessor was reported 
only in 5% and 8% of experimental studies on anastomotic healing, respectively (17).
An important insight from the review was that many research groups failed to adequately 
describe and report the occurrence of AL in their studies. We addressed this topic by using 
a detailed scoring system for reporting disturbed anastomotic healing. It was first termed 
the Leak Severity Score and later the Anastomotic Complication Score (ACS). This four-point 
scale distinguishes between no abnormalities, minor abscesses, free pus, or generalised 
peritonitis, which are relevant entities for clinical outcomes (Figure 2). Scoring leakage 
according to severity and ‘clinical’ consequences is more in line with current advice in the 
literature and allows for a better comparison among groups (18, 19). It also matches the leak 
categories of national audits and databases (20).
The ACS is easy to apply and shows good interobserver agreement, but it has not been 
formally validated. One drawback is the need for sacrifice of the animal or the use of an 
invasive technique (laparoscopy or laparotomy). Recently we started a project to frequently 
scope the proximal and distal bowel anastomosis in rats to map the macroscopic healing of 
an anastomosis under normal and compromised conditions from the luminal side. In this 
project we aim to develop an endoscopic healing score which we will compare with the 
ACS. A validated endoscopic healing score in animals holds more promise compared to the 
intraperitoneal ACS for use in clinical studies. 
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Some researchers are attempting to mathematically approach anastomotic healing with 
computer modelling, in the hope of avoiding animal experiments in future. Animal data of 
molecular and cellular processes can fuel these models (21). Although some processes, for 
example collagen formation, might be modelled accurately, we believe that experimental 
animals are still needed to unravel the complex healing processes of an anastomosis. 
However, the number of animals can certainly be reduced in the coming years by rigorously 
following the guidelines for animal research, sharing study designs and methodologies more 
freely among research groups and reporting negative results. Several collaborative initiatives 
to optimise animal research in general are being undertaken by SYRCLE (SYstematic Review 
Center for Laboratory animal Experimentation) and the CAMARADES group (Collaborative 
Approach to Meta-Analysis and Review of Animal Data from Experimental Studies) (22, 23).
A B
DC
ileum
prox colon
cecum
Figure 2 Anastomotic Complication Score with examples of each score. Signs were scored 
as 0 for uncomplicated anastomoses (A; distal colon), 1 for minor healing disturbances such 
as small abscesses (B; proximal colon), 2 for free pus or large abscesses (C; proximal colon) 
or 3 for dehiscent anastomoses or generalized (fecal) peritonitis (D; ileum). Solid arrows: 
anastomosis. Dotted arrows: small abscesses.
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9.3 Pathophysiology of NSAID-induced anastomotic leakage
The reported risk of leakage following NSAID use varies from 0% in some clinical studies 
to 100% in some rat studies and in the current thesis (24, 25). The risk seems to depend on 
NSAID subtype, but evidence is equivocal as to which NSAIDs are most harmful (15, 26, 27). 
The subtype diclofenac is associated with AL in almost all reported studies (15, 27–32). Risk of 
leakage increases with repeated administration of diclofenac starting at surgery, compared 
with occasional and postponed (repeated) administration (25, 27, 29). The association between 
delay in administration and leak occurrence suggests a detrimental effect during the early 
inflammatory and vulnerable phase of wound healing(25).
Intestinal segment
Clinical cohort studies on NSAID-related leak risk mostly involve colon and rectum surgery (24, 
27, 30). We demonstrated that diclofenac causes leakage in the ileum and the proximal colon 
of rats, and not in the distal colon. The proximal colon leakage model was also adapted 
by the Maastricht group in mice, in which a Muc2-deficiency (Muc2 is a structural mucus 
protein) caused leakage in this segment (33). With ex vivo studies the Maastricht group 
also showed that administration of intraperitoneal prostaglandin E2 (PGE2) increases 
mucous secretion in the small intestine and proximal colon, but not in the distal colon. 
NSAIDs like diclofenac limit the formation of PGE2 by inhibition of cyclooxygenase-2 
(COX-2). This suggests a mucous modulating action of NSAIDs on leakage in the small 
intestine and proximal colon. 
In patients, leak rates of ileocolic anastomosis are often higher than those of colo-colonic 
anastomosis following left hemicolectomies or proximal sigmoid resections (27). The 
differences in leak susceptibility may underlie differences in leak aetiology along the gut 
(27, 34–36). An intestinal-part-dependent leak aetiology has not been described earlier and 
should be further explored clinically because it has important consequences for measures 
to prevent leakage. Available animal data indicate that NSAIDs should not be prescribed 
during or soon after small-bowel and right-colonic surgery.  
Damaging mechanisms
There are several hypotheses for the detrimental effect of NSAIDs. Some concern the 
suppressive effects of COX-2 inhibition on the principal inflammatory and proliferative activity 
in the early phase of wound healing (25, 27, 37). These could include impaired vascularisation, 
reduced host defence, delayed mucosa regeneration and weakened mucosal secretion (33, 
38). Other hypotheses concern NSAID-related enteropathy and direct toxicity from the gut 
lumen. This may imply toxicity of drug molecules, changed bile or an altered microbiome 
(39–46). 
In our study, anastomotic complications seemed the greatest when diclofenac was given 
orally, when bile contained diclofenac metabolites and when reactivation of metabolites 
in the gut was not inhibited. Enteral drug molecules could ‘simply’ cause direct cytotoxic 
damage. This is supported by studies with sustained-release forms of NSAIDs, by case reports 
of colonic perforations caused by unsolved diclofenac pills and by studies on NSAID-induced 
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enteropathy (39–49). Alternatively or additionally, high enteral concentration of active drug 
molecules may exert high pharmacologic activity, e.g. COX-2 inhibition locally at the site of 
the anastomosis, and impair neovascularisation and reduce mucus secretion (33, 38). Such an 
underlying mechanism is supported by studies with COX-2 knockout mice and studies in 
which prostaglandin E2 (PGE2) is used to promote healing. It is difficult to point out which 
action of COX-2 is most relevant, because the enzyme is involved in multiple other cellular 
reactions, such as paracellular closure by tight junction formation and migration of epithelial 
cells (Chapter 2). As previously mentioned, proteomics and microscopic endoscopies could 
shed light on these events in anastomotic healing. 
Microbiota composition
An estimated 1013 bacteria reside in the gut to facilitate tissue homeostasis. It is attractive 
to ascribe leakage to gut bacteria in general and when induced by diclofenac (50, 51). Factors 
such as fasting, bowel preparation, antibiotics, surgical trauma and medication potentially 
disturb the microbiome and are negatively or positively correlated with anastomotic 
healing (52–56). Several studies support a role for the microbiome in NSAID-induced leakage 
by demonstrating that NSAID treatment can alter the microbiome or make the gut more 
vulnerable to specific microbes (40, 57–59). 
We demonstrated that anastomotic surgery drastically altered the microbiome in different 
segments of the gut. A short period of postoperative diclofenac treatment did not lead to 
detectable changes. It is probably that large alterations caused by the surgery itself masked 
a potential diclofenac effect. Although our hypothesis that diclofenac exerts (part of) its 
actions through microbial changes could not be confirmed, significant changes in microbiome 
composition were observed. There is growing evidence from our study and others that 
gut bacteria play an important role in leak pathogenesis. In a recent study the mucosal 
diversity of anastomotic tissue doughnuts of patients who developed AL were compared 
with those who did not develop leakage. The authors found a correlation between AL and 
a low microbial diversity. The authors argued that the reduction in diversity was associated 
with an overabundance of members from the mucin-degrading families Lachnospiraceae 
and Bacteroidaceae (60). Other studies showed a benefit from adding oral antibiotics 
(selective digestive decontamination, SDD) to the standard intravenous prophylactic 
antibiotic regimen to reduce anastomotic leak (56, 61–63). With SDD more-pathogenic gram-
negative bacteria and yeasts are eliminated in favour of less-pathogenic gram-positive 
bacteria. Recent experimental studies performed by a Chicago group in collaboration with 
our group emphasised the detrimental role of changed virulence of the normal microbiome 
by demonstrating that more virulent gram-negative phenotypes are present at the site of a 
leaking anastomosis (64–66). It has been suggested that these bacteria become more virulent 
in a phosphate-depleted environment, and that this status can be reversed by phosphate 
administration (64).
Though evidence on the relation between gut microbes and AL is growing and becoming 
more detailed, this research is still in its infancy. This is understandable because techniques 
to analyse microbiota composition (e.g. 16S rRNA analysis and sequencing) have only 
recently become more efficient, readily available and affordable. We believe that future 
experimental studies addressing anastomotic healing should incorporate microbial 
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analyses and ideally also aim to analyse the gut metabolome. In metabolomics, nuclear 
magnetic resonance spectroscopy or mass spectrometry is used for a more comprehensive 
assessment of all endogenous metabolites within a biological system, such as the gut (67). 
Analyses of intestinal tissue or faeces can provide the complete set of metabolites that is 
present, which involves proteins, fatty acids and bile salt (68, 69). Detection of favourable and 
harmful metabolomes could set the stage for proper measures to prevent leakage.
Interacting intraluminal factors 
In the search for the cause of leakage, emphasis has been placed on the condition of the 
bowel wall, e.g. anastomotic technique and vascularisation. A watertight, well-vascularised 
anastomosis is obviously favourable to maintaining integrity. Recent evidence, however, 
shows that the relevance of ischaemia in causing AL is limited (70). This is in line with some 
animal models in which extensive ischaemia must be induced to cause only a limited amount 
of leakage.
Intraluminal factors have been largely neglected in anastomosis research. The gut is filled with 
many factors that may be relevant for anastomotic integrity, such as bacteria, bile products, 
nutrients, enzymes and metabolites (71). Our research demonstrates that intraluminal 
factors can induce anastomotic complications. In concordance with the literature on drug-
induced enteropathy, we suggest that luminal drug metabolites, biliary products and gut 
bacteria play a role in jeopardising the anastomotic wound. Moreover, we suggest that the 
interaction among these factors induces a more hostile luminal environment (Figure 2). 
By definition, drugs which are hepatically cleared affect the bile composition. Bile salts 
and drug metabolites are changed by gut bacteria. In turn, the supply of bile products and 
the administration of drugs can affect the microbial composition. Drug metabolites, bile 
products and certain bacteria may all be toxic for the intestinal wall, and each factor may 
affect the other (47–49, 72, 73). This interplay of intraluminal factors should be further investigated 
to gain more detailed knowledge of leak pathology. The bile exchange model we developed 
provides a means to study such interactions. Not only bile, but also nutrients, bacteria 
and drugs can be delivered directly into the gut to intervene with intraluminal factors and 
study the effect on anastomotic healing and other bowel diseases. Taking into account the 
elaborate execution of the bile diversion and exchange experiments, concerted action by 
multiple research laboratories might be necessary to obtain results in a timely manner.   
9.4 Clinical use of NSAIDs 
This thesis adds to the cumulative evidence that NSAIDs increase the risk of AL, particularly 
for right-sided anastomoses. The animal findings concur with some clinical studies showing 
higher leak rates in patients using NSAIDs. However, several large cohort studies report no 
significant increase in the risk of leakage (74). Kverneng et al. recently showed a leak rate of 
11% in the NSAID group and 14% in the non-NSAID group (74). Notably, ibuprofen, a non-
selective COX-2 inhibitor, was the most-used NSAID (70%) in this study. When comparing 
leakage between the selective and non-selective COX-2 inhibitor groups there was a trend 
of higher leak rates in the selective COX-2 inhibitor group (17%, compared with 10% in the 
non-selective group). There were also significantly more ileostomies constructed in the 
NSAID group and patients suffered less blood loss, two factors that are known to affect leak 
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rate. Furthermore, leakage which occurred in the first 48 hours was excluded from analysis 
because the authors concluded that technical failure must have been the cause. This shows 
that results of clinical studies should be interpreted with caution and that the type of NSAID 
should be taken into account when claiming an effect or no effect on anastomotic leakage.
A recent review concluded that available data did not permit a formal recommendation 
regarding clinical use of NSAIDs because of heterogeneous patient populations and multiple 
biases (75). The principal conclusion was that the balance of benefit versus risk (i.e. analgesic 
effect versus risk of anastomotic disruption) is acceptable. Hence, the authors advised 
avoiding post-operative NSAID use in the presence of other risk factors for leakage. 
Based on the current thesis and available literature, and because good analgesic alternatives 
are available, we call for a withdrawal of at least diclofenac from current guidelines in 
gastrointestinal surgery (76, 77). If deemed necessary, we advise starting an NSAID no earlier 
than 48 hours after anastomosis and only for a limited time, but not using an NSAID in right-
sided or small-bowel anastomoses. 
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The burden of anastomotic leakage (AL) has been well described in literature and includes 
higher morbidity and mortality, greater recurrence of cancer and increased costs (1, 2). 
This burden has not decreased significantly in the past decades (3, 4). An important reason 
is that leakage aetiology is still poorly understood (3). In this thesis we aimed to increase 
knowledge of (disturbed) healing of small- and large-bowel anastomoses. We investigated 
the detrimental effects of NSAIDs—common painkillers used in gastro-intestinal surgery—
on ileal and right-colonic anastomoses. 
Anastomotic healing physiology: a complex cascade of cellular reactions and inflammatory 
mediators – Chapter 2
 
A literature review was conducted to provide an overview of relevant cellular interactions 
occurring during the anastomotic healing cascade. Knowledge of anastomotic healing was 
combined with knowledge of other types of wound healing (e.g. skin, bone and intestinal 
ulcers) and general cellular physiology.
The healing of multilayer intestinal tissue is highly complex and requires an interplay among 
infiltrating platelets, mast cells, granulocytes, macrophages, dendritic cells, lymphocytes, 
fibroblasts with resident inflammatory cells, mesenchymal stem cells, neurons, endothelial, 
epithelial, mesothelial and smooth muscle cells. It is essential for optimal tissue repair that all 
cell types exert the right action at the right time. Inflammatory activity, involving proteolytic 
processes, is necessary for host defence and tissue reorganisation. The subsequent cessation 
of inflammation and timely transition to proliferation is a physiologically challenging process. 
Biological substances, e.g. bile, bacteria and inflammatory products, and mechanical forces 
such as peristalsis and intraluminal pressure interact with the fresh anastomosis from the 
beginning and greatly challenge the balance and order of cellular reactions. When certain 
drugs or risk factors additionally disturb cellular and tissue processes, the anastomosis 
becomes at risk for leakage. 
Cellular and molecular mechanisms might be potential therapeutic targets, e.g. growth 
factors or hormones, but the complexity and interaction of the different systems impedes 
the development of such therapeutic strategies.
Review of experimental research on anastomotic leakage: reporting and quality of animal 
studies must improve – Chapter 3
Numerous animal studies on intestinal anastomosis have been conducted with regard to 
different aspects of healing and leakage. However, the clinical impact of animal data on 
diagnosis, prevention and treatment of AL is unknown. Therefore, and in view of the current 
societal call to replace, reduce and refine animal experiments, we conducted a systematic 
review to examine the quality of animal research related to anastomotic healing and leakage. 
A total of 1,342 animal studies on AL were identified, with exponential publication rates 
in recent years. Of 350 articles studying experimental therapies, 298 (85%) reported a 
positive effect on anastomotic healing. Given the very small number of these therapies are 
studied or used clinically, the translatability and quality of these studies is questionable. On 
average, 44.7% of relevant study characteristics were not reported, in particular details on 
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anastomotic complications (31.6%), use of antibiotics (75.7%), sterile surgery (83.4%) and 
postoperative analgesia (91.4%). Anastomotic complications were only reported as a binary 
outcome (leak or no leak), despite current advice to grade AL according to severity and 
clinical consequences (3, 5). 
The proportion of studies with randomisation, blinding of surgery and blinding of primary 
outcome assessment has increased in the past two decades but remains insufficient, being 
included in only 62.4%, 4.9% and 8.5% of publications respectively. 
This systematic animal review demonstrates that animal models vary widely in terms of 
species, method to compromise healing, intestinal segment and outcome measure used. 
Animal research on AL is of poor quality and is increasing in volume each year, which 
contradicts societal aims. Both reporting and study quality must improve for better transfer 
of animal data to the clinic.
Diclofenac causes leakage in the ileum and proximal colon, but not in the distal colon of 
rats – Chapter 4
Multiple studies have reported an association between NSAID use and AL, which raises 
questions about the causal role of NSAIDs in leakage (6–11). Important questions include the 
proportion of leak rate attributable to NSAIDs, how relevant the NSAID subtype, dose and 
time of administration are, and which bowel segment is most susceptible for NSAID-induced 
AL.
Clinical cohort studies on NSAID-related leak risk mostly address colorectal surgery (7, 8, 12). Rat 
experiments by our group showed that NSAIDs disturb healing of the ileal, and not the distal, 
colonic anastomosis (6, 13). We were interested in the proximal colon, whose morphology and 
susceptibility to pharmacologic NSAID activity is thought to be more similar to the distal 
colon, but intraluminal content, i.e. liquidity, microflora and bile acids, corresponds more to 
the terminal ileum. 
In Chapter 4 we demonstrated that diclofenac causes leakage in the proximal colon (73%) 
and not in the distal colon of rats. Similar to ileum anastomoses, healing of proximal 
colon anastomoses is most disturbed when diclofenac is administered from the day of 
surgery. Leakage rates were lower if administration was postponed to postoperative day 
1 or day 2. Disturbed healing of the ileal and proximal colonic anastomoses and not the 
distal anastomosis suggests a role for bowel content in diclofenac-induced leakage (14).
Initiation of inflammation and adhesion by serosal edge abrasion before anastomosing 
does not attenuate leakage by diclofenac – Chapter 5
Several studies report that NSAIDs suppress intraperitoneal adhesion formation, a 
phenomenon that theoretically weakens intestinal anastomoses (15–18). We designed a rat 
model of proximal colon anastomosis enhancing the inflammatory response and promoting 
anastomotic scar tissue to study if increased fibrosis can prevent diclofenac-induced leakage. 
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In Chapter 5 we evoked an additional inflammatory and adherent process by surgically 
abrading the serosal edges of the anastomosis before restoring continuity. Explorative 
histologic analysis showed that serosal abrasion leads to dense scar formation at the serosal 
edge, compared to loose connective tissue in control anastomoses. However, this dense scar 
formation did not result in a stronger anastomosis, nor did it reverse diclofenac-induced 
leakage. This finding suggests that anastomotic healing and strength does not depend on 
adhesion formation on the outside of the anastomosis. It seems that the detrimental effect 
of diclofenac on anastomotic healing cannot be reversed by fibrosis-inducing measures, 
possibly due to the magnitude of this effect. 
Biliary excretion of diclofenac affects healing of ileum anastomosis in rats – Chapter 6
NSAIDs that are excreted by the hepatic route (diclofenac, carprofen, celecoxib) cause more 
leakage than those excreted by the renal route (naproxen) (6, 13, 19). NSAID-induced intestinal 
mucosal damage has been attributed to biliary excretion of NSAIDs (20–27). We hypothesised 
that altered bile from NSAIDs is associated with leakage.  
In Chapter 6 the relevance of bile composition in diclofenac-induced leakage was studied 
in 138 rats and 72 rats as bile donors. By cannulating the bile duct and duodenum of 
rats, bile was drained and replaced by bile from donor rats. The leak rate was 28% after 
replacement of bile with ‘diclofenac bile’ from donors, and 6% (p=0.089) after replacement 
with control bile. After oral diclofenac administration, leakage was 76% with ‘diclofenac bile’ 
and 47% (p=0.127) when bile was replaced with control bile. After intramuscular diclofenac 
administration 67% leaked, and 25% (p=0.060) leaked when bile was drained. After 
intramuscular diclofenac, 50% leaked when bile was first diverted and then returned, and 
20% leaked (p=0.117) if bile was replaced with control bile. Taken altogether, leakage was 
significantly more severe in ‘diclofenac bile’ groups. HPLC and LCMS analyses demonstrated 
that diclofenac metabolite levels in bile peak within two hours, indicating that altered bile 
reaches the intestine shortly after diclofenac administration. The results demonstrated 
that altered bile composition by diclofenac administration disturbs the healing of ileal 
anastomoses in rats. It was not determined whether metabolites or diclofenac itself are 
responsible for the effects observed. 
Microbial glucuronidase inhibition, aimed at preventing reactivation of diclofenac 
metabolites in the gut, reduces diclofenac-induced anastomotic complications in rats – 
Chapter 7
In experimental studies on diclofenac-induced small-intestinal mucosal damage it has been 
shown that reactivation of the biliary metabolite diclofenac-acyl-glucuronide by bacterial 
glucuronidase in the gut harms intestinal mucosa. The beta-glucuronidase inhibitor Inh1, 
developed by Wallace et al., prevented this toxic process. We aimed to test the glucuronidase 
inhibiting effect on anastomotic healing. In Chapter 7, 90 rats were used to study whether 
Inh1 reduces AL in diclofenac-treated rats. Administration of Inh1 resulted in a drop in the 
leak rate from 89% to 44% (p=0.094) and significantly reduced leak severity (p=0.029). 
Analysis of plasma levels of diclofenac revealed no changes in groups receiving Inh1. The 
finding that administration of a glucuronidase inhibitor reduces signs of leakage indicates 
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that cleavage of diclofenac-acyl-glucuronide metabolites to diclofenac aglycones disturbs 
ileal anastomotic healing. Next to the human glucuronidase located in the brush border 
of the gut, β-glucuronidase is mainly produced by bacteria. In this way gut microbes are 
involved in the pathology of diclofenac-induced leakage.
Surgical stress causes a marked shift in microbial composition and diversity, though effects 
of diclofenac were not observed – Chapter 8
We wanted to further investigate the gut bacteria in diclofenac-induced AL. For this reason 
we explored the extent to which the operation and diclofenac administration alter the 
microbiome. It appeared that the surgery alone drastically alters the microbiome in different 
segments of the gut. A short period of postoperative diclofenac administration did not lead 
to additional changes. Either diclofenac has no effect on the diversity of the microbiome, 
or the effect was masked by an overwhelming effect of the surgery. In this study we did 
not determine a change in virulence of the microbiome which has been associated with 
AL in other animal models. It was concluded that the microbiota composition significantly 
changes following bowel resection and anastomosis. This study did not further contribute 
to understanding the diclofenac effect on AL, such as mediation via microbiome changes.
Conclusions
This thesis provides an overview of relevant cellular interactions occurring during anastomotic 
healing, illustrating that this process is insufficiently understood. It demonstrates that 
experimental research on AL is of low to moderate quality. In particular there is a need 
for better reporting of study methods and outcomes and for more profound measures to 
reduce bias.
The thesis provides evidence that diclofenac affects anastomotic healing differently along the 
gut, and that biliary excretion of diclofenac is relevant in causing anastomotic complications. 
A luminal intervention targeted at microbial metabolism of diclofenac molecules reduces 
the effect of diclofenac. The finding that such luminal factors impact anastomotic healing is 
novel and provides directions for future research and clues for targeted treatment.
Surgical stress, such as bowel resection and anastomosis, significantly alters the gut 
microbiome. Specific changes in this major luminal factor may make anastomoses more 
susceptible to leakage in general, or specifically when diclofenac is used, although the latter 
suggestion could not be demonstrated in this thesis.
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NEDERLANDSE SAMENVATTING 
Wereldwijd moeten jaarlijks miljoenen mensen een darmoperatie ondergaan vanwege 
darmkanker of andere darmaandoeningen zoals de ziekte van Crohn, colitis ulcerosa 
en diverticulitis. Na het verwijderen van het zieke darmdeel worden de overgebleven 
darmuiteinden vaak weer verbonden middels een darmnaad. Helaas treedt er gemiddeld 
in 6-14% van de gevallen een naadlekkage op. De gevolgen van deze gevreesde complicatie 
zijn enorm voor de patiënt omdat het kan resulteren in abcessen, een buikvliesontsteking 
en zelfs overlijden. Daarnaast is er een grotere kans op terugkeer van de kanker en is de 
kwaliteit van leven op de lange termijn verminderd. De maatschappelijke impact is groot 
door een langer ziekteverzuim en een verdubbeling van de kosten als gevolg van meer 
re-operaties, meer Intensive Care opnames, langere ziekenhuisopnames en een groter 
aantal heropnames (1, 2). De ernstige gevolgen van naadlekkage zijn in de afgelopen decennia 
uitgebreid onderzocht, maar helaas heeft dit nog niet geleid tot een duidelijke afname van 
deze complicatie (3, 4). Een belangrijke reden is dat er nog onvoldoende bekend is over de 
ontstaanswijze van naadlekkage (3). Belangrijk doel van dit proefschrift is om de kennis van 
de normale en verstoorde darmnaadgenezing te vergroten om daarmee de incidentie en 
de gevolgen van naadlekkage te kunnen verminderen. We hebben specifiek gekeken naar 
de schadelijke effecten van een veel gebruikte perioperatieve pijnstiller (i.e. diclofenac) op 
dunne- en dikkedarmnaden. 
Fysiologie van darmnaadgenezing: een complexe cascade van celreacties en 
ontstekings-mediatoren – Hoofdstuk 2
 
Om de relevante celreacties die optreden tijdens een naadgenezing in kaart te brengen 
hebben we een literatuuronderzoek verricht. Hierbij werd geput uit kennis van studies 
over darmnaadgenezing en over andere vormen van wondgenezing zoals huid, bot en 
darmslijmvlies.
De darmwand bestaat uit meerdere lagen en de genezing hiervan, na beschadiging en na 
het maken van een darmanastomose, is complex. Er is een juiste interactie nodig tussen de 
bloedplaatjes, mestcellen, granulocyten, macrophagen, lymphocyten en fibroblasten die het 
weefsel infiltreren, en de cellen die al in het weefsel aanwezig zijn, zoals gladde spiercellen, 
epitheelcellen en mesenchymale stamcellen, maar ook neuronen, endotheelcellen, 
mesotheelcellen en talrijke immunologische cellen. Ontstekingactiviteit en eiwitafbrekende 
processen door deze cellen zijn nodig ter bescherming tegen pathogenen en om de 
weefselstructuur te herorganiseren, maar teveel van deze activiteit kan het weefselherstel 
weer verstoren. Voor een optimale genezing is het dus belangrijk dat de ontstekingsactiviteit 
op het juiste moment wordt afgerond en wordt overgegaan op proliferatieve processen die 
zorgen voor een sterk litteken. Dit is in de darm uitdagend omdat het proces verstoord 
kan worden door biologische factoren (bijvoorbeeld gal, darmenzymen en darmbacteriën) 
en mechanische factoren (bijvoorbeeld darmperistaltiek en hoge intraluminale druk). Als 
bepaalde medicijnen of andere risicofactoren zorgen voor extra verstoring, dan kan dit het 
verschil maken tussen wel of geen naadlekkage. 
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De interacties tussen cellen kunnen aangrijpingspunten zijn voor behandelingen, 
bijvoorbeeld met groeifactoren of hormonen, maar deze interacties en systemen zijn nog 
onvoldoende begrepen om adequate en doelgerichte behandelstrategieën te ontwikkelen.
Review van experimenteel onderzoek op het gebied van naadlekkage: de kwaliteit 
en de rapportage van dierenstudies moet verbeteren – Hoofdstuk 3
Er worden veel dierenstudies uitgevoerd op het gebied van naadlekkage, maar het is niet 
bekend wat de invloed hiervan is op de preventie en behandeling van naadlekkage in de 
kliniek. Omdat we volgens het actuele ‘3V’ principe dierexperimenteel onderzoek waar 
mogelijk willen vervangen, verminderen en verbeteren, hebben we een systematische 
review verricht om de kwaliteit van dierenstudies op het gebied van naadlekkage te 
evalueren. 
Er werden in totaal 1.342 studies gevonden en het aantal publicaties nam vooral in het 
laatste decennium exponentieel toe. Van de 350 artikelen waarin experimentele therapieën 
werden bestudeerd, rapporteerden 298 (85%) een positief effect op de naadgenezing. 
Aangezien er slechts een beperkt aantal van deze therapieën wordt gebruikt of bestudeerd 
bij mensen, lijkt de vertaalbaarheid van uitkomsten van deze studies erg klein. Het viel 
op dat in gemiddeld 44.7% van de studies relevante studiemethoden en studieresultaten 
niet werden gerapporteerd. Het ging hierbij vooral om de beschrijving van de opgetreden 
naadcomplicaties (31.6%), perioperatief antibioticagebruik (75.7%), steriliteit aspecten 
van de operatieve procedure (83.4%) en toegepaste postoperatieve pijnstilling (91.4%). 
Naadlekkage werd alleen gerapporteerd als binaire uitkomstmaat (wel of geen lekkage), 
terwijl in de huidige literatuur wordt geadviseerd om lekkage ook te scoren aan de hand van 
de ernst en klinische consequenties (3, 5). 
Het percentage studies waarin gebruik werd gemaakt van randomisatie, blindering van de 
chirurg en blindering van degene die de uitkomst onderzoekt, is de laatste twee decennia iets 
toegenomen maar is met respectievelijk 62.4%, 4.9% en 8.5% nog altijd ruim onvoldoende. 
Deze systematische review laat zien dat diermodellen voor naadlekkage erg verschillen wat 
betreft diersoort, darmsegment, uitkomstmaat en methode om lekkage te induceren. In 
tegenstelling tot maatschappelijke en politieke doelstellingen neemt het aantal dierstudies 
naar naadlekkage elk jaar toe terwijl de kwaliteit van het gepubliceerde onderzoek matig 
blijft. Zowel de kwaliteit als de rapportage van de studies moet worden verbeterd om de 
impact van het experimentele onderzoek op de kliniek te vergroten.
Diclofenac veroorzaakt lekkage in het ileum en de proximale dikke darm, maar 
niet in de distale dikke darm van de rat – Hoofdstuk 4
Meerdere studies hebben aangetoond dat er een verhoogd risico is op naadlekkage 
wanneer er rondom de operatie non-steroidal anti-inflammatory drugs (NSAIDs) gebruikt 
worden (6-11). Daarbij is het nog onduidelijk in welke mate NSAIDs verantwoordelijk zijn voor 
het ontstaan van lekkage, welke subtypen NSAIDs schadelijk zijn, wat de relevantie is van de 
toegediende dosis en de timing hiervan, en welk darmsegment het meest kwetsbaar is voor 
de effecten van NSAIDs.
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Klinische cohort studies over NSAID-gerelateerde naadlekkage hebben vooral groepen 
patiënten die colorectale chirurgie ondergingen onderzocht (7, 8, 12). Uit eerdere experimenten 
van onze groep bij ratten bleek dat NSAIDs juist lekkage veroorzaken van ileumnaden en niet 
van distale colonnaden (6, 13). Hieruit ontstond de vraag wat het effect zou zijn op naden in 
het proximale colon. In dit darmdeel lijkt de darmwand meer op het distale colon, terwijl de 
darminhoud (vloeibaarheid, darmbacteriën, galzouten) meer op het terminale ileum lijkt. 
In Hoofdstuk 4 hebben we aangetoond dat diclofenac wel lekkage veroorzaakt in het 
proximale colon (73%), maar niet in het distale colon van ratten. Net als bij de ileumnaden 
ontstaan de meeste lekkages als diclofenac wordt toegediend vanaf de dag van operatie en 
neemt dit aantal af als de toediening wordt uitgesteld naar dag 1 en dag 2. De bevinding dat 
de genezing wel wordt verstoord in het ileum en proximale colon en niet in het distale colon 
suggereert dat de darminhoud in de proximale segmenten relevant is bij het ontstaan van 
een diclofenac-gerelateerde naadlekkage (14).
Het oppervlakkig beschadigen van de darmserosa, ten behoeve van het stimuleren 
van inflammatie en adhesievorming, vermindert niet de diclofenac-gerelateerde 
naadlekkage – Hoofdstuk 5
Enkele studies beschrijven dat NSAIDs de vorming van intraperitoneale adhesies 
onderdrukken (15-18). Dit fenomeen zou in theorie ook de darmnaadgenezing kunnen 
verzwakken. We hebben een rattenmodel ontworpen om te bestuderen of het stimuleren 
van de inflammatoire respons en de ontwikkeling van littekenweefsel rondom een proximale 
colonnaad de aan de diclofenac gerelateerde lekkage kan voorkomen. 
In Hoofdstuk 5 hebben we deze inflammatoire en adhesieve processen uitgelokt door 
een mechanische interventie, zoals ook wordt gedaan in experimentele studies naar 
adhesievorming. De interventie bestond uit het oppervlakkig opschuren van de serosa aan 
de randen van de naad, vlak voordat de naad wordt gehecht. Histologische analyse liet zien 
dat dit in veel gevallen leidde tot vast en uitgebreid littekenweefsel, terwijl het weefsel 
losmazig bleef bij controle naden zonder voorbewerking. Dit resulteerde echter niet in een 
sterkere naad en ook niet in vermindering van naadlekkages. Het lijkt alsof de genezing en 
sterkte van de darmnaad dus niet afhangen van de verklevingen aan de serosale zijde van de 
naad. De schadelijke effecten van diclofenac op de naad kunnen niet worden tegengegaan 
door de gebruikte fibrose-inducerende technieken.
De uitscheiding van diclofenac via gal heeft een nadelige invloed op de genezing 
van ileumnaden – Hoofdstuk 6
NSAIDs die worden geklaard door de lever (diclofenac, carprofen, celecoxib) veroorzaken 
meer lekkage dan de NSAIDs die voor het grootste deel worden uitgescheiden door de nieren 
(naproxen) (6, 13, 19). Meerdere studies schrijven ook NSAID-geïnduceerde dunne darmschade, 
die optreedt zonder operatie, toe aan de hepatogene klaring en biliaire uitscheiding van 
NSAIDs (20-27). Op grond hiervan vroegen we ons af of de verandering in de galsamenstelling 
door NSAID gebruik invloed heeft op het ontstaan van naadlekkage. 
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In Hoofdstuk 6 hebben we deze relevantie van de galsamenstelling onderzocht in 138 
ratten en met gebruik van 72 ratten als galdonoren. Door het canuleren van de ductus 
choledochus werd de gal afgetapt en via een canule in het duodenum werd donorgal 
teruggegeven. Het lekkagepercentage was 28% als er ‘diclofenac-gal’ werd gegeven ten 
opzichte van 6% (p=0.089) wanneer er controlegal werd gegeven. Na orale toediening van 
diclofenac was er een 76% lekkage percentage als de ratten hun ‘diclofenac-gal’ terugkregen 
en dit percentage was 47% (p=0.127) als het werd vervangen door controle gal. Na 
intramusculaire toediening van diclofenac lekte 67% van de naden, er lekte 25% (p=0.060) 
als de gal volledig werd afgetapt. Als na intramusculaire toediening van diclofenac de gal 
eerst werd afgetapt en dan teruggeven was er 50% lekkage, en als het gal werd vervangen 
door controlegal dan was er 20% lekkage (p=0.117). Samenvattend was er een significant 
ernstigere lekkage waarneembaar in de groepen die ‘diclofenac-gal’ kregen in vergelijking 
met controle groepen. Met behulp van High Performance Liquid Chromatography en Liquid 
Chromatography Mass Spectrometry (LCMS) analyses toonden we aan dat de spiegels van 
diclofenac metabolieten in gal binnen twee uur na toediening pieken. Hieruit blijkt dat de 
veranderde galsamenstelling al kort na de diclofenac toediening de darm bereikt. 
Deze studie laat zien dat een veranderde galsamenstelling door diclofenac toediening 
de genezing van ileumnaden bij ratten verstoort. Er kon niet worden vastgesteld of deze 
verstoring komt door een veranderde galzoutsamenstelling, door de gemetaboliseerde 
vorm van diclofenac, of door de niet omgezette diclofenac in de darm. 
Remming van microbiële glucuronidase activiteit in de darm, om reactivatie 
van diclofenac metabolieten in de darm te voorkomen, vermindert diclofenac-
geïnduceerde naadcomplicaties bij ratten – Hoofdstuk 7
Uit experimentele studies blijkt dat reactivatie van de biliaire metaboliet diclofenac-acyl-
glucuronide door bacteriële glucuronidase activiteit in de darm leidt tot schade aan de 
dunne darmmucosa. De door Wallace et al. ontwikkelde Inh1, die glucuronidase activiteit 
blokkeert, voorkomt het ontstaan van de mucosale schade en ulcera (23, 28). In Hoofdstuk 7 
hebben we in 90 ratten onderzocht of Inh1 ook naadlekkage kan voorkomen na toediening 
van diclofenac. Toediening van Inh1 kon lekkage niet voorkomen, resulteerde in een niet 
significante daling van 89% naar 44% (p=0.094) maar verminderde wel significant de ernst 
van de lekkages (p=0.029). Uit de LCMS analyse bleek dat de plasmaspiegels van diclofenac 
onveranderd waren bij toediening van Inh1. De bevinding dat een glucuronidase remmer 
naadcomplicaties vermindert, suggereert dat reactivatie van diclofenac-acyl-glucuronide 
in de darm schadelijk is voor de genezing van ileumnaden. Bij mensen is er humaan 
glucuronidase aanwezig tussen de darmvilli, maar wordt het grootste deel van dit enzym 
geproduceerd door darmbacteriën. Dit suggereert een additionele rol van de darmflora in 
de pathophysiologie van naadlekkage door diclofenac. 
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Darmchirurgie veroorzaakt een duidelijke verandering in de samenstelling en 
diversiteit van het microbioom, terwijl toediening van diclofenac hier geen 
duidelijk effect op heeft – Hoofdstuk 8
Om de rol van de darmflora bij diclofenac-geïnduceerde naadlekkage verder te onderzoeken, 
hebben we in verschillende darmsegmenten onderzocht of en hoe het microbioom 
verandert door de operatie en door de toediening van diclofenac. Het blijkt dat alleen al de 
operatie zorgt voor significante veranderingen in het microbioom, zowel in het ileum, het 
proximale colon als het distale colon. Een korte kuur van diclofenac na de operatie leidde 
niet tot verdere veranderingen. In deze explorerende studie konden we geen effect van 
diclofenac aantonen op de samenstelling van de darmflora. Mogelijk maskeerde het grote 
effect van de operatie dat van de diclofenac. We hebben in deze studie niet onderzocht wat 
het effect is van diclofenac op de virulentie van darmbacteriën. Bacteriële virulentie is een 
factor die in andere onderzoeken is gerelateerd aan naadlekkage. Uit de studie in hoofdstuk 
8 kan worden geconcludeerd dat de samenstelling van het microbioom significant verandert 
als gevolg van een darmresectie en het aanleggen van een darmnaad. 
Conclusie
Dit proefschrift bevat een overzicht van de verschillende cellulaire interacties die relevant 
zijn tijdens darmnaadgenezing en beschrijft waarom het proces van naadgenezing nog 
onvoldoende begrepen wordt. Er wordt beschreven dat de kwaliteit van experimenteel 
onderzoek naar darmnaadgenezing matig is en dat er vooral behoefte is aan betere 
rapportage en gebruik van betere methodes om bias te voorkomen. 
In dit proefschrift wordt aangetoond dat de invloed van diclofenac op darmnaadgenezing 
verschilt per locatie in de darm en dat de uitscheiding van diclofenac via gal relevant is 
bij het ontstaan van naadcomplicaties in de rat. Een enterale interventie, gericht op het 
metabolisme van diclofenac moleculen door darmbacteriën, vermindert de effecten van 
diclofenac.
Deze nieuwe bevindingen dat luminale factoren en bijpassende interventies invloed hebben 
op de experimentele naadgenezing opent de weg naar toekomstig naadlekkage onderzoek 
gericht op luminale factoren. Een luminale factor van omvang is het microbioom en in dit 
proefschrift wordt in detail beschreven dat darmchirurgie hierin significante veranderingen 
teweeg brengt. Een specifieke samenstelling van de darmflora, of veranderingen hierin, 
kunnen de darmnaad kwetsbaarder maken voor lekkage in het algemeen, of specifiek bij 
gebruik van diclofenac, hoewel dit laatste niet door ons kon worden aangetoond. 
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